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Background   Cardiovascular disease continues to remain a leading cause of 
morbidity and mortality in both developing and developed worlds. The sirtuin and 
urocortin systems are novel hormone systems in humans with an emerging role in 
cardiovascular physiology and pathophysiology. Through a series of studies, this 
thesis examines the cardiovascular effects of SRT2104 (a novel small molecule 
SIRT1 activator) in otherwise healthy cigarette smokers and in patients with type 2 
diabetes mellitus, and of urocortins 2 and 3 in healthy volunteers and in patients with 
heart failure. 
 
Methods   Twenty-four otherwise healthy cigarette smokers and 15 subjects with 
stable type 2 diabetes participated in a randomised, double blind, placebo controlled, 
crossover trial and received 28 days of oral SRT2104 (2.0 g/day) or matched 
placebo. Plasma SRT2104 concentrations, serum lipid profile, plasma fibrinolytic 
factors, markers of platelet and monocyte activation and pulse wave analysis and 
velocity were measured at baseline and the end of each treatment period together 
with an assessment of forearm blood flow during intra-arterial bradykinin, 
acetylcholine and sodium nitroprusside infusions. The pharmacodynamic profile of 
urocortins 2 and 3 were assessed in 18 healthy male volunteers recruited into a series 
of randomised, double blind, placebo controlled, crossover studies. Bilateral forearm 
venous occlusion plethysmography was performed during incremental intra-arterial 
infusions of urocortin 2 (3.6-120 pmol/min), urocortin 3 (1.2-36 nmol/min) and 
substance P (2-8 pmol/min) in the presence or absence of inhibitors of 
cyclooxygenase (aspirin), cytochrome P450 metabolites of arachidonic acid 
(fluconazole) and nitric oxide synthase (L-NG-monomethyl-arginine (L-NMMA)). 
Finally, 12 patients with stable heart failure (New York Heart Association 
(NYHA) II-IV) and 10 age- and sex-matched healthy volunteers were recruited to 
attend once each. Bilateral forearm arterial blood flow was measured using forearm 
venous occlusion plethysmography during incremental intra-arterial infusions of 
urocortin 2 (3.6-36 pmol/min), urocortin 3 (360-3600 pmol/min) and substance P    
(2-8 pmol/min).  
 
Results   SRT2104 was safe and well tolerated in otherwise healthy cigarette 
smokers and subjects with type 2 diabetes mellitus. There were no significant 
differences in fibrinolytic or blood flow parameters between placebo and SRT2014. 
Treatment with SRT2104 was associated with a significant reduction in 
augmentation pressure (P=0.0273) and a trend towards improvement in the 
augmentation index (AIx) and corrected augmentation index (0.10>P>0.05 for both)  
without significant changes in pulse wave velocity (PWV) and 
time to wave reflection (Tr) (P>0.05). Administration of SRT2104 had a favourable 
effect on lipid profile in otherwise healthy cigarette smokers in comparison to 
placebo. Urocortins 2 and 3 evoked arterial vasodilatation (P<0.0001) without 
tachyphylaxis but with a slow onset and offset of action. Inhibition of nitric oxide 
synthase with L-NMMA reduced vasodilatation to substance P and urocortin 2 
(P≤0.001 for both) but had little effect on urocortin 3 (P>0.05). Neither aspirin nor 
fluconazole affected vasodilatation induced by any of the infusions (P>0.05 for all). 
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In the presence of all three inhibitors, urocortin 2- and urocortin 3-induced 
vasodilatation were attenuated (P<0.001 for all) to a greater extent than with             
L-NMMA alone (P≤0.005). The vasodilatory effects of urocortins 2 and 3 were 
preserved in patients with heart failure. 
 
Conclusion   Activation of SIRT1 through SRT2104 improved lipid profile but did 
not produce demonstrable differences in vascular or platelet function with some 
effect on measures of arterial stiffness. Urocortins 2 and 3 appear to be potent arterial 
vasodilators whose vasomotor responses remained preserved in patients with heart 
failure and were at least partly mediated via the endothelium. Both hormone systems 
hold potential in their role in cardiovascular disease in man but require further 
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Background: The sirtuin and urocortin systems are novel hormone systems in humans with 
an emerging role in the functioning of the heart in health and in disease states. Through a 
series of studies, this thesis examines the effects of SRT2104 (a novel small molecule 
SIRT1 activator) in otherwise healthy cigarette smokers and in patients with type 2 diabetes 
mellitus, and of urocortins 2 and 3 in healthy volunteers and in patients with heart failure. 
 
Methods: Twenty-four otherwise healthy cigarette smokers and 15 subjects with stable 
type 2 diabetes participated in a series of studies and received 28 days of oral SRT2104 (2.0 
g/day) or matched placebo. Through a range of tests, we measured blood levels of SRT2104 
and assessed it’s effects on blood cholesterol, stiffness of blood vessels, blood clotting 
parameters and on blood flow in the forearm at baseline and at the end of each treatment 
period. The profile of urocortins 2 and 3 were assessed in eighteen healthy male volunteers 
recruited in a series studies during the infusion of urocortin 2, urocortin 3 and substance P 
in the presence or absence of specific chemicals (using aspirin, L-NMMA and fluconazole) 
which block receptors found in the lining of blood vessels. Finally, twelve patients with 
stable heart failure and ten age and sex-matched healthy volunteers had forearm blood flow 
measured during incremental infusions of Ucn 2, Ucn 3 and Substance P.  
 
Results: SRT2104 was safe and well tolerated in otherwise healthy cigarette smokers and 
subjects with type 2 diabetes mellitus. There were no significant differences in blood 
clotting or blood flow variables between placebo and SRT2014. Treatment with SRT2104 
was associated with an improvement in some measures of blood vessel elasticity. 
Administration of SRT2104 had a favourable effect on lipid profile in otherwise healthy 
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forearm without a decrease in effect on repeated administration but with a slow onset and 
offset of action. There was no effect on the increase in blood flow to urocortins 2 and 3 in 
the presence or absence of aspirin or fluconazole. In the presence of all three inhibitors, 
urocortin 2 and urocortin 3 induced increases in forearm blood flow were attenuated to a 
greater extent than with L-NMMA alone. The blood flow increasing effects of urocortins 2 
and 3 were preserved in patients with heart failure.  
 
Conclusion: Activation of SIRT1 through SRT2104 improved lipid profile but did not 
produce demonstrable differences in blood vessel or platelet function with some effect on 
measures of blood vessel stiffness. Urocortins 2 and 3 appear to be potent hormones that 
increase blood flow whose responses remained preserved in patients with heart failure and 
whose effects were at least partly mediated via the lining of the blood vessels. Both 
hormone systems hold potential in their role in cardiovascular disease in man but require 
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Cardiovascular disease continues to remain a leading cause of mortality and 
morbidity in both the developed and developing worlds. This presents an ever 
increasing need to understand the underlying mechanism of the pathological 
processes involved in order to aid the development of novel treatment targets. The 
sirtuin and urocortin systems are novel hormone systems in humans with an 
emerging role in cardiovascular physiology and pathophysiology. This thesis will 
focus on the cardiovascular effects of activation of the sirtuin and urocortin systems 
in health and in disease. 
 
Endothelial dysfunction is a recognised pathological process associated with aging 
and in disease processes such as diabetes mellitus and heart failure. Both hormone 
systems appear to play a crucial role in maintaining endothelial homeostasis and 
have therefore generated immense interest in their contribution to cardiovascular 
health. Through a series of studies in healthy volunteers, cigarette smokers, patients 
with type 2 diabetes and patients with heart failure, this thesis will focus on the 
cardiovascular effects of activation of the sirtuin and urocortin systems.  
 








Sirtuins represent a class of highly conserved nicotinamide adenine dinucleotide 
(NAD+)-dependent deacetylases with seven identified members in mammals         
[Frye 1999; Frye 2000]. The members are designated silent information regulator 
two (SIRT) 1 to 7 and have distinct tissue and subcellular distributions [Borradaile 
and Pickering 2009]. The role of sirtuins in metabolism, cardiovascular health and 
particularly in diseases of ageing has been of increasing interest in recent years.  
 
1.2.1   BIOLOGY OF SIRTUINS 
1.2.1.1  Molecular structure and tissue distribution 
Sirtuins are characterised by a conserved 275 amino acid catalytic core and unique 
additional amino (N)-terminal and carboxyl (C)-terminal sequences of variable 
length [Maiese et al 2011] (Figure 1.1). They differ in their cellular localisation, 
tissue distribution and target substrates in mammals. SIRT1, SIRT6 and SIRT7 
localise primarily to the nucleus; SIRT3, SIRT4 and SIRT5 localise to mitochondria; 
and SIRT2 localises to the cytosol [Hubbard and Sinclair 2014]. SIRT1 is currently 
the best-known member of this class and has been shown to play a critical role in all 


















Figure 1.1.  Human sirtuin proteins and their domain structure. The protein sequences and 
annotations are based on the NCBI Gene data set [Dong et al 2012]. 
SIRT - silent information regulator two; NCBI - National Centre for Biotechnology Information. 
 
 
SIRT1 is highly expressed in the vascular endothelium [Edirisinghe and Rahman 
2010] as well as in the brain, heart, liver, pancreas, skeletal muscle, spleen and 
adipose tissues [Maise et al 2011; Stein and Matter 2011; Sundaresan et al 2011;  
Chong et al 2012]. SIRT3 and SIRT4 are predominantly mitochondrial proteins and 
are thus highly expressed in tissues rich in mitochondria, including brown adipose 
tissue, liver, heart and brain. SIRT4 is also highly expressed in pancreatic beta       
(β)-cells and has been demonstrated to play key roles in the regulation of insulin 
secretion [Haigis et al 2006; Ahuja et al 2007]. Table 1.1 illustrates the differential 









Br - brain; Te - testis; He - heart; Ki - kidney;  Sk - skeletal muscle; Li - liver; Lu - lung; Sp - spleen;  Ov - ovary;  Ut  - uterus; 
BM - bone marrow; Th - thyroid; NFkB - nuclear factor kappa B; PGC-1α - coactivator-1 alpha; PPARγ - peroxisome 
proliferators-activated receptor gamma; AceCS1 - acetyl coenzyme A synthetase; Pol 1 - RNA polymerase 1;                      
RNA - Ribonucleic acid. 
 
[Dali-Youcef et al 2007] 
 
 
1.2.1.2  Enzymatic activity of sirtuins 
Sirtuins are class III histone deacetylases (HDACs) that are largely regulated by 
cellular NAD+ availability and preferentially target non-histone proteins [Carafa et al 
2012]. Deacetylation and adenosine diphosphate (ADP)-ribosylation are the two 
main chemical reactions catalysed by sirtuins. SIRT1, which is the closest 
homologue of the yeast Sir2, deacetylates both histone and non-histone proteins 
resulting in a wide range of physiological and metabolic effects [Carafa et al 2012].   
Target proteins for SIRT1 include peroxisome proliferators-activated receptor 
gamma (PPAR-γ) and it’s coactivator-1 alpha (PGC-1α), forkhead transcriptional 
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factors, serine threonine liver kinase B1 (LKB1), nuclear factor-kappa beta (NF-kβ) 
and protein tyrosine phosphatase (PTP) [Chong et al 2012]. SIRT2 is a ubiquitous, 
nuclear and cytoplasmic protein deacetylase that inhibits adipocyte differentiation by 
regulating forkhead box transcription factor (Fox01) acetylation [Borradaile and 
Pickering 2009]. 
 
1.2.2   PHYSIOLOGY OF SIRTUINS 
There is an abundance of data demonstrating the role of mammalian sirtuins in 
metabolic processes such as gluconeogenesis [Sun et al 2007; Chen et al 2010; Li et 
al 2011], lipid metabolism, oxidative stress as well as on the benefits of calorie 
restriction.!SIRT1 is found to be upregulated in tissues of calorie-restricted animals 
and through it’s interaction with PGC-1α, plays a central role in control of energy 
metabolism and serves as a key mediator of the effects of calorie restriction [Cohen 
et al 2004]. This has led to immense interest in the role of sirtuins in the ageing 
process and diseases associated with ageing. 
 
1.2.2.1  Cardiovascular effects 
The cardiovascular benefits of SIRT1 activation have been well elucidated in several 
studies and appear to arise from its effects on maintaining endothelial homeostasis, 
effects on cardiac cell hypertrophy, direct effects as a vasodilator, antioxidative 
properties and its role in promoting myocardial recovery in the setting of 
ischaemia reperfusion injury. Below is a short summary of the cardiovascular effects 




Data from animal models and in vitro studies suggest that sirtuins, in particular 
SIRT1, play an important role in the development and function of cardiomyocytes.  
A direct role for SIRT1 and SIRT7 in the development of the heart has been 
demonstrated by Cheng et al [2003] and Vakhrusheva et al [2008] in mouse models.  
Cheng et al demonstrated that SIRT1 mutant or deficient mice showed defects in 
cardiac septation [Cheng et al 2003]. Similarly, Vakhrusheva et al [2008] 
demonstrated SIRT7 deficiency associated cardiac hypertrophy and inflammatory 
cardiomyopathy. Shan et al [2012] report participation of SIRT1 in the development 
of congenital heart disease.  
 
SIRT1 appears to play a role in the development of cardiomyocyte hypertrophy in 
mouse models. The anti-hypertrophy effects of SIRT1 may be mediated through 
adenosine monophosphate-activated protein kinase (AMPK) and Akt                   
(also known as protein kinase B) pathways [Chan et al 2008 ]. Through PPAR-γ, 
SIRT1 prevents phenylephrine-induced neonatal cardiomyocyte hypertrophy and 
phenylephrine-induced downregulation of fatty acid oxidation genes               
[Maiese et al 2011]. SIRT3 and SIRT6 negatively regulate cardiac hypertrophy by 
inhibiting insulin-like growth factor-1 (IGF-1)-Akt signalling cascade               
[Giblin et al 2014]. Deletion of SIRT6 in mouse heart results in the development of 
cardiac hypertrophy [Giblin et al 2014]. 
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Although increased expression of SIRT1 is associated with cardioprotective effects, 
Alcendor et al have shown that SIRT1 activation can serve as a double-edged sword 
depending on the degree of activity increase [Alcendor et al 2007]. In transgenic 
mice, mild to moderately increased expression of SIRT1 reduced myocardial 
hypertrophy, interstitial fibrosis and senescence markers. On the other hand, high 
levels of SIRT1 expression resulted in development of cardiomyopathy. 
 
There appears to be an emerging role for sirtuins, especially SIRT1 and SIRT3 in the 
pathophysiology of heart failure. SIRT1 is normally localised to the cytoplasm in 
normal human cardiomyocytes. Tanno et al [2010] demonstrated, that in chronic 
heart failure, there occurs a nuclear translocation of SIRT1. It is felt that this nuclear 
accumulation might be an adaptive mechanism of cardiomyocytes in heart failure, 
given the cell protective effects of nuclear SIRT1. Resveratrol, a naturally occurring 
polyphenolic compound and a potent Sir2 homolog activator, prevents the 
development of concentric cardiac hypertrophy and cardiac dysfunction in 
spontaneously hypertensive rats [Thandapilly et al 2010]. A reduced expression of 
SIRT6 has been demonstrated in failing human and hypertrophic mouse hearts 
[Giblin et al 2014]. 
 
Effects on vascular and endothelial function 
Endothelial dysfunction is considered a strong precursor of cardiovascular disease. 
Recent clinical studies suggest that endothelial dysfunction during ageing is 
associated with oxidative stress in endothelial cells [Donato et al 2007]. SIRT1 plays 
an important role in the oxidative stress response in different cell types. Given that 
 25!
SIRT1 is highly expressed in vascular endothelial cells, it is therefore likely to play a 
key role in controlling endothelial cell function. SIRT1 directly controls 
endothelium-dependent vasodilatation and also regulates endothelial nitric oxide 
synthase (eNOS) expression and production of nitric oxide (NO)           
[Mattagajasingh et al 2007]. Inhibition of SIRT1 expression and activity in human 
umbilical vein endothelial cells (HUVEC) induces premature senescence through 
decreased eNOS expression and increased plasminogen activator inhibitor-1 (PAI-1) 
expression [Ota et al 2007; Csizar et al 2008]. In arteries isolated from humans with 
coronary heart disease, NO-dependent vasorelaxation in response to resveratrol is 
lost [Cruz et al 2006], although some dilatation was still observed from                
NO-independent pathways.  
 
There is direct evidence for the role of SIRT1 expression and activity in                 
age-associated endothelial dysfunction. Donato et al demonstrated reduced 
expression of SIRT1 in the endothelial cells obtained from older humans in 
comparison to younger humans with corresponding differences in age-related 
vascular endothelial function [Donato et al 2001]. In vitro, resveratrol blocks 
adhesion of monocytes and granulocytes to endothelial cells by inhibiting expression 
of vascular cell adhesion molecule-1 (VCAM-1) [Ferrero et al 1998]. 
 
Apart from direct effects on endothelial cell function, SIRT1 may also have a role to 
play in regulating blood pressure through its effects on vascular smooth muscle cells 
(VSMC). Miyazaki identified a direct role of SIRT1 in the control of blood pressure 
via regulation of angiotensin II receptor type 1 (ATR1) expression in VSMC 
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[Miyazaki et al]. Resveratrol has been shown to inhibit VSMC proliferation through 
p53-independent mechanisms [Baur and Sinclair 2006] and through inhibition of 
extracellular receptor kinase (ERK) activation [El-Mowafy et al 2008] in rat 
pulmonary arterial cell lines and human coronary smooth muscle cell lines 
respectively. SIRT1 activation enhances liver X receptor (LXR)-mediated inhibition 
of smooth muscle cell proliferation and foam cell formation in mice models           
[Li et al 2007].  
 
SIRT1, a key regulator of the inflammatory process, also has a role in preventing 
atherosclerosis through different mechanisms. Endothelial cell-specific SIRT1 
transgenic mice (SIRT1-transgenic/apolipoprotein E (Tg/apoE-/-)mice) showed 
improvement in high fat-induced impairment in endothelium-dependent 
vasodilatation and had fewer atherosclerotic lesions [Zang et al 2008]. This was 
mediated by endothelial specific expression of SIRT1, leading to inhibition of 
endothelial apoptosis and improved endothelial function. In these mice models, there 
was no change in blood levels of serum lipids or glucose, suggesting that these 
changes are very much at the level of endothelial cells. Other mechanisms involved 
in the anti-atherosclerotic effects of SIRT1 include regulation of                           
tissue inhibitory metalloproteinase 3 (TIMP3) expression [Stein and Matter 2011], 
calcium/calmodulin-dependent protein kinase beta (CaMKKβ) [Wen et al 2013], 
LXR-adenosine triphosphate (ATP) and nuclear factor kappa beta (NF-κβ) pathways 
[Zeng et al 2013]. 
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Role in myocardial stress and ischaemia 
Research data suggest a significant role of SIRT1 in ischaemia-related myocardial 
injury. Monocytic SIRT1 expression is reduced in patients with stable coronary 
artery disease and acute coronary syndromes [Breitenstein et al 2013]. Treatment 
with resveratrol, a well-known SIRT1 activator, during myocardial           
ischaemia reperfusion in rats, reduces rhythm disturbances, cardiac infarct size 
[Dernek et al 2004] and plasma levels of lactate dehydrogenase (LDH) and 
creatinine kinase (CK) [Hung et al 2004]. In murine models, SIRT1 protects the 
heart from ischaemia reperfusion injury through activation of FoxO1 and decreases 
in oxidative stress [Hsu et al 2010]. The anti-atherosclerotic effects of SIRT1 
activation combined with its effects on angiogenesis [Fukida et al 2006;                          
Guarani and Potente 2010] makes it a potential tool in the management of ischaemic 
heart disease. 
 
1.2.2.2  Effects on lipid metabolism 
The exact mechanism by which SIRT1 activation leads to an improvement in lipid 
metabolism in man has not yet been fully elucidated. However, several potential 
mechanisms have been implicated in animal models and appear promising. SIRT1 
modulates hepatic lipid homeostasis in SIRT1 knockout and transgenic mouse 
models [Purushotham et al 2009; Wang et al 2010]. PPAR-γ plays an important role 
in adipogenesis by increasing free fatty acid uptake and decreased lipolysis. In white 
adipose tissue, SIRT1 mobilises fatty acids and prevents preadipocyte differentiation 
via PPAR-γ [Borradaile and Pickering 2009]. 
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Liver X receptors are nuclear receptors that are involved in cholesterol and lipid 
homeostasis. Li and colleagues have shown that SIRT1 deacetylates and positively 
regulates nuclear LXRs, which could alter cholesterol transport and metabolism      
[Li et al 2007]. SIRT3, SIRT4 and SIRT6 also play a role in regulating fatty acid 
oxidation [Hirschey et al 2010; Kim et al 2010; Nasrin et al 2010;                  
Kendrick et al 2011].  
 
1.2.3   SMALL MOLECULE ACTIVATORS OF SIRT1 ACTIVITY 
Several small molecule SIRT1 activators have been developed given the varied 
effects of SIRT1 activation on different metabolic processes. Initially identified 
SIRT1 activators were all plant polyphenols. Plant derived foods contain reactive 
polyphenols with a role in oxidative stress. Resveratrol is a well-known polyphenolic 
compound found in red wine that is a potent activator of SIRT1 activity            
[Howitz et al 2003]. Isoflavanes and silibinin induce SIRT1 expression in 
cardiomyocytes [Zhou et al 2006] and renal proximal tubular cells [Rasbach and 
Schnellmann 2008]. Since the discovery of resveratrol, several other synthetic small 
molecule activators (SRT1460, SRT2183, SRT1720) have been identified which are 
several-fold more potent than resveratrol [Milne et al 2007]. Data focussing on the 
beneficial effects of these and several other small molecule SIRT1 activators in man 
are limited with varying results and require more work to show consistent and safe 
beneficial effects of SIRT1 activation. With advancing age of the general population, 
there is an increase in the incidence of age-related diseases such as metabolic 
syndromes, diabetes, cardiovascular disease and cancers. Therefore, development of 
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a drug with a potential to address these disease processes remains a focus of great 





1.3 THE UROCORTIN - CORTICOTROPHIN-RELEASING HORMONE 
(CRH) SYSTEM 
!
Urocortins belong to the corticotrophin-releasing hormone (CRH) family which 
includes CRH, fish urotensin I, frog sauvagine, urocortin 1, urocortin 2 and 
urocortin 3 [Boonprasert et al 2008] (Figure 1.2). Corticotrophin-releasing hormone 
is produced in the brain in response to stress, has central effects upon behaviour, and 
exerts a variety of peripheral responses. However, CRH is unlikely to have major 
effects upon cardiac function as it is not expressed locally and its plasma 
concentrations are very low.  
 
In 1995, Vaughan and colleagues observed urotensin-like immunoreactivity in the 
Edinger Westphal nucleus and lateral superior olive regions of the adult rat brain. It 
was named urocortin (now known as urocortin 1) to reflect its similarities of 
structure and biological properties to urotensin (suckerfish urotensin) and rat CRH 
[Vaughan et al 1995]. It is believed to be the second endogenous mammalian ligand 
for CRH receptors (CRH-R) [Skelton et al 2000]. Subsequently, two further 
paralogues of CRH were identified; urocortin 2 and urocortin 3. Human CRH and 
urocortin 1 genes have been localised to chromosomes 8 (8q13) and 2 (2p23-p21) 
respectively. Urocortin 2 and urocortin 3 have prominent cardiovascular roles and 
are expressed in the heart. In contrast to CRH, the urocortins do not increase 
corticosterone secretion and do not appear to have any physiologic role in the 
regulation of the hypothalamic-pituitary-adrenal axis [Davidson et al 2009; Davidson 
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1.3.1   CRH RECEPTORS 
The effect of CRH and urocortins is mediated via CRH receptors. These seven 
transmembrane G protein-coupled receptors are members of the secretin family 
[Hillhouse and Grammatopoulos 2006] and the human CRH receptor gene has been 
localised to chromosomes 17 (17q12-qter) and   7 (7p21-p15) [Vamvakopoulos and 
Sioutopoulou 1994; Meyer et al 1997]. Two subtypes of CRH receptors have been 
identified in mammals and rodents; corticotrophin-releasing hormone 
receptor 1 (CRH-R1) and -R2. Structurally, the two subtypes exhibit considerable 
divergence at the N-terminus, consistent with their distinct pharmacological 
properties. Furthermore, three splice variants of CRH-R2 have been identified. These 
variants differ in the structure of their N-terminal extracellular domain. R2a and R2b 
have been observed in rodents and in man, whilst R2g is specific to humans (isolated 
in the limbic regions of the human brain) [Hillhouse and Grammatopoulos 2006]. It 
is, however, unclear whether the g splice variant has any specific physiological role. 
Low homology of the extracellular domains of CRH-R1 and -R2 account for 
differences in their ligand specificity [Hillhouse and Grammatopoulos 2006]. 
Urocortin 1 and CRH both act at CRH-R1 but the affinity of urocortin 1 for CRH-R2 
is more than 10-fold higher than that of CRH [Skelton et al 2000]. While urocortin 1 
can activate both receptors, urocortins 2 and 3 are potent and specific agonists at 
CRH-R2 [Vaughan et al 1995; Hsu and Hsueh 2001] with little effect at CRH-R1. 
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1.3.2   BIOLOGY OF UROCORTINS 
1.3.2.1  Anatomy (tissue distribution of urocortins and CRH receptors) 
Immunoreactivity to the urocortins and their receptors has been demonstrated in the 
central nervous, digestive, reproductive, cardiovascular, immune and endocrine 
systems, suggesting important roles throughout the body [Oki and Sasano 2004]. In 
the brain, urocortin 1 is most prominent in the Edinger Westphal nucleus and lateral 
superior olive. Urocortin 1 messenger ribonucleic acid (mRNA) or immunoreactivity 
has also been reported in other regions of the brain, such as the cerebellum and 
hypothalamus [Hillhouse and Grammatopoulos 2006], and it appears to be              
co-localised with dopamine in the basal ganglia and hypothalamus. Urocortin 1 
mRNA is also expressed in VSMC and in cardiac myocytes. Urocortin 2 has a 
similar distribution in the central nervous system in mice and rats, but is also seen in 
high concentrations in the peripheral tissues including the heart, adrenals, placenta, 
stomach, ovary, skin, gastrointestinal tract, uterine smooth muscle, skeletal muscle 
and peripheral blood vessels [Hillhouse and Grammatopoulos 2006]. 
 
The distribution of urocortin  is distinct. In the central nervous system, it is 
demonstrable in regions of high CRH-R2 expression, supporting the notion that it is 
an endogenous ligand [Hillhouse and Grammatopoulos 2006]. In humans, 
urocortin 3 is also seen in peripheral tissues such as adrenals, heart and kidney – 
particularly in the distal tubules [Takahashi et al 2004].   
 
Corticotrophin-releasing hormone receptor 1 is predominantly found in the central 
nervous system. In addition to its central nervous system expression,     
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CRH-R2 is found in peripheral tissues such as the gut, heart, lymphocytes and 
adrenals. In humans, urocortin 1 and CRH-R2a have been identified in all four 
chambers of the heart, suggesting that urocortin acts in an autocrine or paracrine 
fashion through CRH receptors [Kimura et al 2002]. In contrast to rats where      
CRH-R2b is the predominant splice variant in the heart and VSMC, humans appear 
to predominantly express CRH-R2a in these tissues. CRH-R2 has also been 
characterised in the human left ventricle and intramyocardial blood vessels       
[Wiley and Davenport 2004]. In humans, both CRH-R1 and -R2 are found in the 
periphery, although their specific role remains to be fully characterised in human 
physiology and pathophysiology. 
Figure 1.3.!The effects of urocortins on multiple organ systems in heart failure.  
Urocortins, through different mechanisms exerts a multitude of beneficial effects on the various organ 
systems as demonstrated by animal and human models. 
ACTH - adrenocorticotrophic hormone; Ucn 1 - urocortin 1; LAP - left atrial pressure; BP - blood 
pressure; PRA - plasma renin activity. 
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1.3.2.2  Biochemistry  
Molecular structure and Pharmacokinetics 
Urocortin is a 40 amino acid-containing neuropeptide, related to urotensin (63% 
sequence identity) and corticotrophin-releasing hormone (45% sequence identity) 
[Vaughan et al 1995]. Rat and human urocortin bear 95% homology to each other. 
The precursor protein contains 122 amino acid residues with an N-terminal 
methionine and consensus signal peptide sequence, whilst the carboxy terminus of 
the precursor contains the C-terminal amidated peptide of urocortin. The CRH 
analogue peptides possess a helical conformation with varying degrees of 
amphipathicity. The amphipathic N-terminal helices could play a crucial role in 
selectivity of the analogues to CRH-R1, whereas it may not be as important for 
CRH-R2 binding [Grace et al 2007]. The parent protein is half the length of 
urotensin and CRH precursors with little sequence similarity to either [Hillhouse and 
Grammatopoulos 2006]. Urocortin 2 shows moderate homology with human and rat 
CRH (34%), urocortin 1 (43%) and urocortin 3 (37-40%). The half-life of urocortin 1 
in healthy humans and those with stable heart failure is approximately 50 minutes 
[Davis et al 2004; Davis et al 2005]. Urocortin 2 has a shorter half-life of 10 minutes 
in healthy humans [Davis et al 2007a]. The exact half-life of urocortin 3 is not yet 
known, but it appears to have a more rapid onset and shorter duration of action in 
animal studies [Rademaker et al 2006]. 
 
CRH Binding Protein 
Corticotrophin-releasing hormone-binding protein (CRH-BP) is a 37-kDa protein 
that was first isolated in human plasma in 1989 [Behan et al 1989] and binds to both 
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CRH and urocortin 1. Given that the expression of CRH-BP overlaps that of both 
CRH and urocortin  in the central nervous system, it has been proposed that the 
CRH-BP plays a role in the modulation of the action of urocortin and CRH at these 
sites. In humans, CRH-BP has been detected in the brain, pituitary, liver and placenta 
[Potter et al 1992; Petraglia et al 1993; Lovejoy et al 1998]. In ovine models of heart 
failure [Rademaker et al 2002] the half-life of urocortin 1 was markedly prolonged 
compared to human models. This has been attributed to the possible role of CRH-BP 
in clearance of urocortin 1 in humans. However, the exact role of these binding 
proteins remains to be fully elucidated in health and disease states.  
 
Intracellular signalling pathways 
The urocortins bind to G protein-coupled CRH (R1 and R2) receptors to induce 
conformational changes in the receptor that activate intracellular signalling pathways 
(Figure 1.4). In most cells, this involves adenylyl cyclase and cyclic adenosine 
monophosphate (cAMP). Indeed, Kageyama and colleagues demonstrated that 
urocortin 2 induces vasorelaxation in VSMC via CRH-R2 in association with 
increased cAMP accumulation via activation of adenylate cyclase [Kageyama et al 
2003a; Kageyama et al 2005]. Mitogen-activated protein kinases (MAPK) are also 
implicated in urocortin-mediated vasodilatation [Kaageyama et al 2003a] as well as 
in the cardioprotective role of urocortin in response to ischaemic or hypoxic injury 
[Brar et al 2000]. However, in some studies, inhibition of the cAMP or protein 
kinase A (PKA) pathway has failed to inhibit the effects of CRH and its related 






Figure 1.4.  Schematic of urocortin intracellular signalling pathway. 
Urocortins bind to CRH receptors to induce conformational changes in the G protein-coupled receptors and 
activate the second messenger systems. CRH-BP has a greater affinity to urocortin 1 and may play a role in its 
metabolism. Urocortin 1 binds to both CRH-R1 and -R2, whereas urocortins 2 and 3 are potent, specific CRH-R2 
agonists. 
CRH-BP - corticotrophin-releasing hormone binding protein; CRH-R - corticotrophin-releasing hormone 
receptor; CNS - central nervous system; ERK 1/2-p42/44 - extracellular signal-related kinases 1/2-p42/44;          
c-AMP - cyclic adenosine monophosphate; PKA - protein kinase A; c-GMP - cyclic guanosine monophosphate; 
NO - nitric oxide; MAPK - mitogen-activated protein kinase. 
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Corticotrophin-releasing hormone and related agonists can evoke the endothelial 
release of nitric oxide via nitric oxide synthase with subsequent accumulation of 
cyclic guanosine monophosphate (cGMP). This endothelium-dependent mechanism 
is important in CRH or urocortin-induced relaxation in placental vasculature    
[Clifton et al 1995] and peripheral arteries, and has been studied in isolated arterial 
segments such as the human internal mammary artery graft [Chen et al 2005] and in 
rat coronary artery [Huang et al 2002]. The nitric oxide and cGMP-dependent 
component of this vasodilator effect is mediated via activation of calcium-activated 
potassium channels in underlying vascular smooth muscle. Indeed, the vasorelaxant 
effect of urocortin is blunted in the presence of NG-nitro-L-arginine methyl ester     
(L-NAME) a nitric oxide synthase inhibitor and ODQ (1H-[1,2,4] oxadiazolo [4,2-a] 
quinoxalin-1-one; inhibitor of guanylyl cyclase) [Chen et al 2005]. There is 
increasing evidence that urocortin and CRH-related peptides play an important role 
in cell survival mechanisms in a number of systems. Similar to CRH, urocortin 1 
activates the MAPK extracellular signal-related kinases (ERK) 1/2-p42/44 signalling 
cascade in in vitro cultures of isolated rat cardiac myocytes, which is inhibited by 
blockade of MEK 1/2. This signalling cascade mediates the cardioprotective function 
of urocortin in stimulated hypoxia or ischaemia [Brar et al 2000]. Urocortins also 
possess anti-inflammatory properties that appear to be mediated via pro-apoptotic 
effects on macrophages via a direct effect on pro-apoptotic Bcl-2 related proteins 
[Tsatsanis et al 2005]. 
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1.3.2.3  Physiology of urocortins 
Cardiovascular actions 
The important roles of urocortins in the regulation of normal cardiovascular 
physiology are being increasingly recognised. Genetically engineered mice lacking 
CRH-R2 are resistant to otherwise marked urocortin-evoked changes in cardiac 
performance and blood pressure [Coste et al 2000]. Studies, which are largely 
preclinical, have so far demonstrated a favourable effect of urocortins on 
haemodynamic and neurohumoral regulation. Urocortins 1, 2 and 3 produce positive 
inotropic and lusitropic effects, reduction in the mean arterial pressure due to 
decreased peripheral vascular resistance, and increased coronary perfusion in rodent 
and ovine studies.  
 
Vascular effects 
Central administration of CRH in rats produces a pressor response, which appears to 
be mediated through CRH-R1 receptors [Briscoe et al 2000]. Peripheral 
administration of CRH produces a depressor response, which is blocked by a helical 
CRH (a non-selective CRH antagonist), and not by antalarmin (selective CRH-R1 
antagonist). As a peptide, CRH has limited access to the central nervous system. This 
suggests that the hypotensive effect is mediated via peripheral CRH-R2 receptors. 
CRH-R2 may have a more prominent role in changes in arterial pressure in 
comparison to CRH-R1. CRH-R2 may contribute to the maintenance of basal 
vascular tone in mice. Indeed, mice deficient in CRH-R2 receptors are hypertensive 
with no fall in the mean arterial pressure in response to exogenously administered 
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urocortin [Coste et al 2002]. It remains unknown whether urocortins and 
CRH receptors have a similar role in the maintenance of basal vascular tone in 
humans.  
 
Intravenous administration of CRH produces vasodilatation in rats and a consequent 
fall in blood pressure with a reflex increase in heart rate, although this is not 
observed in sheep and is seen only with relatively high doses in higher primates like 
monkeys and humans. In anaesthetised rats, intravenous injection of human 
urocortin 2 reduced basal systemic blood pressure in a dose-dependent fashion    
[Chen et al 2003]. As demonstrated by Vaughan and colleagues [1995], urocortin 1 
also possesses a potent and long lasting hypotensive action. Decrease in mean 
arterial pressure of 18±1 mmHg was observed with urocortin 1 in rats and lasted for 
almost 2 hours. Thomas Dieterle’s group [Dieterle et al 2009] studied the effects of 
urocortin 2 injection in control and hypertensive rats. They showed an immediate 
and sustained lowering of blood pressure in hypertensive rats with no rise in heart 
rate. This effect on the blood pressure was seen for up to 12 hours after 
intraperitoneal injection of urocortin 2.  
 
Several mechanisms have been postulated for the blood pressure lowering effects of 
urocortins. These may include a direct smooth muscle relaxant effect in combination 
with an associated reduction in plasma concentrations of vasoconstrictor hormones, 
such as endothelin 1, angiotensin II and arginine vasopressin (AVP), as seen in 
animal models of heart failure (see section 1.3.3.3 on Neurohormonal effects).          
Ex vivo studies in the human internal mammary artery [Chen et al 2005] and in the 
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rat coronary artery [Huang et al 2002] suggest both endothelium-dependent and        
-independent components for vasorelaxation. In isolated rat coronary artery                               
[Huang et al 20002], potent vasorelaxant effect of urocortin 1 was observed with an 
IC50 of 2.24 nM, in the presence of an intact endothelium. The                   
endothelium-dependent component appears to be, at least in part, mediated by nitric 
oxide via cGMP, as outlined above. Huang and colleagues [2002] have also shown 
the role of activation of barium chloride (BaC12) potassium channels in arterial 
smooth muscle cells, mediating the endothelial component of urocortin-induced 
coronary relaxation. Indeed, these studies also demonstrate a blunted, but not 
abolished, vasorelaxant response to urocortin in endothelium-denuded arterial 
segments, further suggesting the role of additional endothelium-independent 
mediators. Endothelium-independent regulation of vascular tone appears to involve 
calcium (Ca2+)-independent phospholipase A1 and store operated Ca2+ entry 
modulation [Smani et al 2007]. Other mechanisms demonstrated in mediating 
urocortin-induced vasorelaxation include the MAPK and protein kinase!A pathway 
[Kageyama et al 2003a].  
 
Cardiac effects 
It is not entirely clear whether urocortins mediate their protective effects upon 
cardiac contractility via a direct effect on cardiac myocytes or via sympathetic 
stimulation in response to reduced peripheral resistance. Brar and colleagues [2000]  
have demonstrated the presence of a 22 kDa urocortin 1 precursor protein in neonatal 
rat cardiac myocytes and release of urocortin into the supernatant of cardiac 
myocytes exposed to stimulated ischaemia or hypoxia, suggesting endogenous 
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release of urocortin from ischaemic cardiac myocytes. This may suggest potential 
direct and local action of urocortins on cardiac myocytes, mediated via                 
CRH receptors. 
 
To determine whether urocortin induced direct effects on contractility of cardiac 
myocytes, Yang and colleagues [2006] observed the effects of application of 
100 nmol/L of urocortin 2 to isolated adult rabbit ventricular cardiomyocytes. They 
showed a progressive enhancement in myocyte contractility with reduction in 
diastolic length and concluded that urocortins exert direct positive inotropic as well 
as lusitropic effects. These effects were mediated via activation of CRH-R2 and 
subsequent stimulation of protein kinase A activity, leading to augmentation of        
L-type calcium channel (ICa), and sarcoplasmic and endoplasmic reticulum Ca2+ 
ATPase (SERCA)-mediated Ca2+ uptake into the sarcoplasmic reticulum. 
 
Immediate improvement of left ventricular fractional shortening and circumferential 
fibre shortening velocity were noted following acute injection of urocortin 2 in rats 
[Dieterle et al 2009]. These beneficial effects were preserved even at 5 weeks after 
treatment. In ovine models, intravenous injection of urocortin 1 causes a marked 
dose-dependent increase in cardiac output and contractility, which is sustained at 
24 hours post injection [Parkes et al 2001].  
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Effects in humans 
A small number of clinical studies have carried forward data obtained from animal 
studies, to look at the effects of exogenous administration of urocortins on 
cardiovascular and neurohormonal responses.  
 
In contrast to the favourable haemodynamic responses seen in normal sheep, infusion 
of urocortin 1 in healthy humans caused no change in haemodynamic variables, nor 
did it affect the plasma concentrations of humoral factors, such as aldosterone or 
arginine vasopressin. The pharmacokinetics of urocortin 1 were similar in normal 
humans and in subjects with heart failure: plasma urocortin 1 half-life of 52±3 
minutes in healthy volunteers and 54±3 minutes in those with heart failure [Davis et 
al 2005]. Pemberton and colleagues [Davis et al 2005] did not observe any increase 
in urinary urocortin 1 following its infusion suggesting that urocortin 1 is not 
excreted in the kidneys. Consistent with its predicted cardiovascular profile, 
urocortin 2 infusion caused a dose-dependent increase in cardiac output with a 
decrease in mean arterial and diastolic blood pressure, and systemic vascular 
resistance [Davis, Pemberton et al 2007a]. The effects of systemic urocortin 3 in 
humans are yet to be explored, although recently, Gheorghiade et al [2013] have 
examined the effects of intravenous human stresscopin (a 40 amino acid peptide, 
derived from the same gene as urocortin!3 in patients with heart failure. Wiley and 
Davenport [2004] have demonstrated that urocortin 3, like urocortin 2, causes 
vasodilatation in isolated human internal mammary artery segments and that this 
effect is mediated via the direct effect of urocortin 3 on the VSMC. Although not yet 
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assessed in man, urocortin 3 is likely to exert cardiovascular effects similar to those 
evoked by urocortin 2. 
 
Cardioprotective effects - role in ischaemia reperfusion injury  
Urocortins appear to have a cardioprotective role and indeed, urocortin expression 
and peptide release is increased by ischaemia [Brar et al 1999]. 
 
Urocortin 1 reduces myocyte cell death caused by ischaemia reperfusion injury. This 
appears to be mediated via several mechanisms including upregulation of 
cardiotrophin 1 expression [Talwar et al 2000], stimulation of heat shock protein 
[Brar et al 2002] and natriuretic peptides, and attenuation of calcium insensitive 
phospholipase A2 gene expression [Lawrence et al 2003]. In vitro secretion of 
urocortin is also enhanced by inflammatory cytokines such as interleukin-6, 
interleukin-1 and tumour necrosis factor alpha: factors that are elevated in patients 
with heart failure and acute coronary syndromes. 
 
Urocortins 2 and 3 protect neonatal rat cardiac myocytes in vitro when administered 
before hypoxia or at the point of reoxygenation. Urocortins 2 and 3 also protect the 
adult rat heart ex vivo and acts via the MAPK pathway to reduce the infarct size of a 
perfused intact rat heart exposed to regional ischaemia [Brar et al 2004]. Brar and 
colleagues have demonstrated that urocortin induces ERK 1/2-p42/44 
phosphorylation in neonatal rat cardiac myocytes and that inhibition of MEK 1/2 
inhibits its cardioprotective effects [Brar  et al 2004]. 
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Nitric oxide is recognised as a key determinant of vascular health. It acts as a potent 
vasodilator, inhibits expression of several proinflammatory cytokines and 
chemokines, and plays a key role in vascular smooth muscle proliferation, platelet 
aggregation and endogenous fibrinolysis [Behrendt and Ganz 2002;                      
Ganz and Vita 2003; Yang et al 2008]. Whilst urocortin may act via nitric oxide to 
mediate cardiovascular protective effects [Yang et al 2008], studies to date have not 
yet completely elucidated the effect of urocortins on the endothelium or nitric oxide. 
 
1.3.3   UROCORTINS AND HEART FAILURE 
Given the potent vasorelaxant and inotropic effects of the urocortins, interest has 
grown in their role in the pathophysiology and potential therapeutic utility in the 
treatment of heart failure. A number of studies have demonstrated increased 
concentrations of urocortin 1 in cardiac tissue [Ikeda et al 1998; Nishikimi et al 
2000] and plasma [Rademaker et al 2002; Ng et al 2004; Charles et al 2006] in 
experimental and clinical heart failure. Nishkimi and colleagues [2000] demonstrated 
upregulation of expression of urocortin 1 mRNA in left ventricular hypertrophy. 
They also demonstrated increased urocortin 1 immunoreactivity in the failing heart. 
This has been cited as possible evidence that urocortins play a role in the 
pathophysiology of cardiac hypertrophy and heart failure. 
 
1.3.3.1  Animal models 
Preclinical studies of heart failure have previously examined the roles of urocortin 1 
and 2 whilst urocortin 3 remains less well characterised. The beneficial 
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cardiovascular and neurohumoral responses of urocortins are preserved, and may be 
augmented in the presence of heart failure.  
 
Intravenous infusion of urocortin 1 in an ovine model of heart failure attenuates the 
haemodynamic deterioration and harmful neurohormonal activation associated with 
heart failure [Rademaker et al 2007]. These hormones include renin, angiotensin II, 
aldosterone, endothelin-1, vasopressin and catecholamines that, along with 
sympathetic nervous system activation, combine to exert the haemodynamic and 
endocrine hallmarks of heart failure. Furthermore, in this model, urocortin 1 also 
protected renal function. The preservation of cardiac output with urocortin 1 infusion 
may be partly due to its inotropic actions, in addition to its coronary arterial 
vasodilator effects and improved cardiac bioenergetics. When infused at the onset of 
left ventricular pacing, urocortin 1 infusion restricts the increase in left atrial pressure 
and attenuates the reduction in cardiac output. It also has lusitropic and venodilating 
effects [Sanz et al 2002]. These results highlight that treatment with urocortin 1 may 
be beneficial in the treatment of heart failure initiated early in the disease. Of note, 
these favourable haemodynamic effects persisted during prolonged (4-day) infusion 
of urocortin 1. 
 
In keeping with a favourable haemodynamic profile of urocortin 1 in ovine heart 
failure, urocortin 2 infusion in muscle specific LIM protein (MLP) deficient mice, a 
model of dilated cardiomyopathy, caused a dramatic improvement in cardiac output 
and left ventricular function, enhanced cardiac contractility and reduced systolic load 
[Bale et al 2004]. The enhancement in ejection fraction by urocortin 2 is partly 
 47!
attributed to reduction in arterial load: this may prove more notable in the failing 
heart where there is an afterload mismatch.  
 
Patients with heart failure are likely to receive any new treatment in conjunction with 
conventional evidence based therapy. Hence it is important to ensure that any 
potential new treatment does not interact with and has benefits in addition to drugs 
such as angiotensin-converting enzyme (ACE) inhibitors and beta (β)-blockers. 
Rademaker and colleagues [Rademaker et al 2008] assessed the combined effects of 
captopril with urocortin 2 in sheep with pacing-induced heart failure. Combined 
treatment of urocortin 2 with captopril augmented the decrease in total peripheral 
resistance by an additional 20% compared with either agent alone. One of the 
potential drawbacks of treatment with ACE inhibitors is its profound hypotensive 
effect, which in the presence of heart failure can compromise blood flow to vital 
organs, such as the kidneys. When used in combination with an ACE inhibitor, 
urocortin 2 evoked an additional decrease in peripheral resistance without further 
reduction in the systolic blood pressure. This makes the combination of these agents 
an attractive tool in the management of heart failure. In addition, combination of 
urocortin 2 with captopril improved cardiac performance, and decreased peripheral 
resistance and ventricular filling pressures in association with reductions in plasma 
aldosterone and endothelin-1 concentrations. In a murine acute heart failure model, 
pretreatment with a beta-adrenergic receptor antagonist, did not affect the inotropic 
or lusitropic actions of urocortin 2 in vivo indicating that its actions are independent 
of beta-adrenergic receptors [Bale et al 2004].  
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The effects of combined treatment with urocortin 2 and furosemide has been studied 
recently [Rademaker et al 2009]. When this combination was administered to sheep 
with pacing-induced heart failure, it caused increased diuresis, natriuresis and 
sustained increase in creatinine excretion and clearance without additional potassium 
elimination. Urocortin 2 alone or in combination increased cardiac output and 
contractility whilst furosemide had no effect. Importantly, the combination of the 
two drugs, produced reversal of furosemide-induced increase in plasma renin activity 
and a greater decrease in plasma aldosterone and vasopressin concentrations. These 
beneficial effects of urocortin 2 may be mediated by an increase in cardiac output 
and consequently improved renal perfusion. Indeed, improvements in glomerular 
filtration rate, urine volume and sodium excretion have been demonstrated in the 
ovine model of heart failure [Rademaker et al 2005b]. In addition to increased 
cardiac output and renal vasodilatation, other postulated mechanisms include a direct 
tubular action of urocortin 2 [Hsu and Hsueh 2001] as well as attenuation of anti-
natriuretic and anti-diuretic factors resulting in increased diuresis and natriuresis 
[Rademaker et al 2009]. 
 
As already noted, the haemodynamic and humoral responses of urocortin 3 in 
experimental heart failure are less well studied than urocortin 1 or 2. In a study of 
sheep with pacing-induced heart failure [Rademaker et al 2006], the haemodynamic 
responses produced by urocortin 3 were similar to that produced by equivalent doses 
of urocortin 1 or 2. Urocortin 3 caused a marked dose-dependent improvement in 
cardiac output and reduction in peripheral resistance and left atrial pressure. This was 
associated with a reduction in mean arterial pressure, beneficial effect on hormonal 
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responses (attenuation of vasoconstrictor peptide systems) and improved renal 
function (dose-dependent increases in urine volume, sodium and creatinine 
excretion). The onset and duration of action was much shorter than that of 
urocortin 1 or 2.  
 
1.3.3.2  Patients with heart failure 
Plasma concentrations of urocortins are elevated in patients with heart failure.         
Ng and colleagues [2004] found higher plasma urocortin 1 concentrations in men 
with heart failure as well as in elderly patients. There appeared to be an inverse 
relationship between plasma urocortin concentrations and New York Heart 
Association (NYHA) class. In more severe heart failure, as reflected by NYHA 
classes III or IV and low left ventricular ejection fraction, plasma urocortin 
concentrations appeared to be suppressed, suggesting that upregulation of the 
urocortin system in early heart failure may be cardioprotective. In keeping with this 
report, more recent work by Wright and colleagues [2009] has demonstrated elevated 
concentrations of plasma urocortin 1 in patients with heart failure with positive 
relationships to other circulating neurohormones such as brain natriuretic peptide, 
adrenomedullin and endothelin-1. However, in contradiction to findings from          
Ng et al [2004], Wright’s group [Wright et al 2009] noted an inverse relationship of 
the level of plasma urocortin 1 to left ventricular ejection fraction, with a linear 
increase in plasma concentration of urocortin 1 with increasing NYHA class. It is 
possible that this difference in results is attributable to differences in the 
immunoassay used or potential effect of CRH-BP on the assay performance. Further 
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research is, however, required to establish the relationship between urocortin 
concentrations and NYHA class. 
 
Systemic intravenous infusions of urocortin 1 and 2 have been administered to a 
small number of patients with heart failure. Urocortin 1 infusion increased 
corticotrophin and cortisol, but produced no changes in haemodynamic, renal or 
neurohormonal parameters [Davis et al 2005]. Infusion of urocortin 2               
[Davis et al 2007a] evoked an increase in cardiac output with peripheral 
vasodilatation and a small increase in heart rate. Consistent with findings from the 
ovine model, systolic blood pressure fell in patients with congestive cardiac failure 
but not in control subjects [Davis et al 2007b]. It has been hypothesised that, in the 
presence of heart failure, the urocortin-induced rise in cardiac output is insufficient 
to compensate for the pronounced decrease in systemic vascular resistance [Davis et 
al 2007b] However, this phenomenon may otherwise be explained by heightened 
peripheral sensitivity to the vasodilator effects of urocortin in the presence of heart 
failure. In agreement with this suggestion, administration of a CRH-R2 antagonist 
increases mean arterial blood pressure in sheep with heart failure but not in those 
without [Rademaker et al 2005c]. When administered in acute decompensated heart 
failure [Wandy Chan et al 2013], urocortin 2 markedly augmented cardiac output 
without significant reflex tachycardia. More recently, intravenous administration of 
human stresscopin (JNJ-39588146) has shown to increase cardiac index and 
reduction in systemic vascular resistance in chronic heart failure and reduced 
ejection fraction [Gheorghiade et al 2013].  
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Apart from the positive influences on cardiovascular parameters when used in 
treatment in heart failure, urocortins may serve as potential biomarkers in 
identification of early heart failure, in combination with other biomarkers such as 
brain natriuretic peptide [Wright et al 2009].  
 
1.3.3.3  Neurohormonal effects of urocortins in heart failure 
As noted above, urocortins cause a pronounced suppression of vasoconstrictor 
hormones in animal models of heart failure, which further supports its potential 
therapeutic role. However, studies of urocortins 1 and 2 in humans have only shown 
modest changes in neurohormonal activity. It is important to note that in man, 
infusion of urocortin 2 in healthy volunteers and in patients with heart failure does 
not alter plasma adrenocorticotrophic hormone or cortisol concentrations. Table 1.2 
summarises the effects of urocortins on neurohormonal activity in ovine and human 
experiments. 
 
1.3.4   FUTURE OF UROCORTINS  
There is increasing evidence that urocortins have several potential uses in 
management of cardiovascular conditions such as hypertension, ischaemic heart 
disease and heart failure. The immediate and sustained blood pressure lowering 
effects by urocortin 2 [Dieterle et al 2009] appears to pose a novel and attractive 
approach for antihypertensive treatment. The favourable effects on haemodynamics, 
renal and neurohumoral mechanisms have generated much interest in the use of 
urocortins in heart failure. In particular, the positive inotropic effect, combined with 
its ability to reduce peripheral arterial resistance, favours use in this group of 
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patients. In humans, studies to date have largely looked at combined systemic effects 
of urocortins. Direct arterial and venous effects of urocortins have not yet been 
described in man. It has not been possible to tease out the relative contribution of 
urocortin-induced changes in haemodynamic variables on the augmentation of 
cardiac output. Further studies are required to look at potential effects of long term 
administration of these peptides. 
 
In the search for novel treatments for heart failure, the focus is on urocortins 2 and 3. 
Indeed, urocortin 1 has no haemodynamic effects in man and also bears the potential 
to induce unwanted side effects by activating CRH-R1 and stimulation of the 
hypothalamus-pituitary axis. However, it may have a role as an early biomarker of 
heart failure. 
 
In conclusion, urocortins are emerging as an important group of peptidic mediators 
with important roles in human physiology and pathophysiology. There are several 
other potential applications of this group of peptides, including roles in appetite 
suppression, in muscle wasting and central nervous system disorders to name a few. 
However, their major effects in the cardiovascular system implicate them as potential 







TABLE  1.2  Neurohormonal effects of urocortins in human and ovine models 
 Humans Sheep 
 Healthy Heart Failure Healthy Heart Failure 


















cAMP = ! = = = =  "1!2 " "" 
cGMP ! !  =       
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Cortisol !! = ! = ! !!  ! ! !! 
GH =          
Ghrelin " = = =       
LH/FSH/Prolactin =          
TSH =          
AVP ! = =  ! !!   "" ! "" 
ANP =  =  " "  " "" "" 
BNP =  =  ! !  "" "" "" 
NT – BNP = = = !    "   
PRA = !! = = = =  " "" "" 
Aldosterone = ! =  " =  " "" "" 
Adrenaline = " = = " "  " "" "" 
Nor adrenaline = !! = = = =  " " " 
Endothelin = = = = = =  "" "" "" 
Adrenomedullin = = = !       
Insulin  = = =       
Angiotensin II  !!         
Glucose   =     =   
 
1 Suppression of cAMP by Ucn 1 in LV pacing induced heart failure in sheep – as an acute effect. 
2 On prolonged exposure to Ucn 1 cAMP levels were substantially increased with a lag between the onset of 
haemodynamic and hormonal effects. Fields left blank - no available data.  
‘!’ - Increase, ‘"’ - Decrease, ‘=’ No change. 
cAMP - cyclic adenosine monophosphate; cGMP - cyclic guanosine monophosphate; ACTH - adrenocorticotrophic hormone; 
GH - growth hormone; LH - leutinising hormone; FSH - follicle stimulating hormone; TSH - thyroid stimulating hormone; 
AVP - arginine vasopressin; ANP - atrial natriuretic peptide; BNP - brain natriuretic peptide; NT - N-terminal; PRA - plasma 








Through a series of studies, the aims of this thesis were to examine the 
cardiovascular effects of 
1. activation of SIRT1 through the use of SRT2104, a novel small molecule 
SIRT1 activator in otherwise healthy cigarette smokers and patients with 
type 2 diabetes mellitus, and of 




In otherwise healthy cigarette smokers we hypothesised that activation of 
SIRT1 would result in (Chapter 3): 
• Reversing of vasomotor and fibrinolytic dysfunction.!
• A reduction in markers of platelet and monocyte activation. 
 
In otherwise healthy cigarette smokers and patients with type 2 diabetes 
mellitus, activation of SIRT1 would result in (Chapter 4): 
• Improvement in measures of arterial compliance. 
 
In healthy male volunteers (Chapter 5) and patients with heart failure (Chapter 
6), we hypothesised that, acting via CRH-R2, urocortins 2 and 3: 
• Cause forearm arterial vasodilatation in a dose-dependent manner that is at        
least in part, determined by the endothelium and nitric oxide release. 



















2.1.1   ETHICAL CONSIDERATION 
All studies were approved by the local Research Ethics Committee (Lothian 
Research Ethics Committee and Berkshire Research Ethics Committee) and carried 
out in accordance with the Declaration of Helsinki. Written informed consent was 
obtained from all participants prior to the study. Studies pertaining to the sirtuin 
system were part of a Phase 1 clinical trial and were given Clinical Trial 
Authorisation by the Medicines and Healthcare products Regulatory Authority 
(MHRA, UK). All studies were carried out at the MHRA Phase 1 accredited 
Wellcome Trust Clinical Research Facility at the Royal Infirmary of Edinburgh. 
 
2.2  STUDY PARTICIPANTS 
!
This thesis was based upon four study groups: the first part of the thesis  evaluates 
the cardiovascular effects of sirtuins in otherwise healthy cigarette smokers and 
patients with type 2 diabetes mellitus. These two seemingly disparate groups would 
be deemed as having endothelial dysfunction, albeit through different mechanisms. 
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The second part of the thesis serves to evaluate the cardiovascular effects of 
urocortins in healthy volunteers and in patients with heart failure.  
 
2.2.1   HEALTHY CIGARETTE SMOKERS AND PARTICIPANTS WITH 
TYPE 2 DIABETES MELLITUS 
Twenty-four otherwise healthy cigarette smokers and 15 participants with stable   
type 2 diabetes, aged between 18 and 70 years, were eligible for the study. Healthy 
cigarette smokers were required to have smoked ≥10 cigarettes daily for at least 
1 year. Participants with type 2 diabetes were non-smokers and were selected on the 
basis of having a diagnosis of type 2 diabetes mellitus for at least 6 months prior to 
inclusion in the study, with no change in medications having been made for at least 
the preceding 3 months, a fasting blood glucose ≤13.9 mmol/L (250 mg/dL) and 
Diabetes Control and Complications Trial  (DCCT)-aligned HbA1c <9%           
(75 mmol/mol) on screening. Exclusion criteria included the presence of significant 
comorbidities, chronic illness, renal or liver impairment, history of gastrointestinal 
diseases or previous surgical procedures that would influence drug absorption, 
history of alcoholism, history of neoplastic disease within the last 5 years, a positive 
urinary test for recreational drugs, pregnancy and participation in other clinical trials 
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or blood donation within the last 3 months. Patients with type 2 diabetes mellitus on 
ACE inhibitors, antiplatelet or anticoagulant therapies were excluded from the study. 
Tests for pregnancy (serum human chorionic gonadotrophin (HCG) concentrations at 
screening and urinary HCG concentrations at study visits) were conducted on all 
female participants of child-bearing potential. 
 
2.2.2   HEALTHY VOLUNTEERS AND PATIENTS WITH HEART FAILURE 
Eighteen healthy non-smoking male volunteers were recruited into a series of 
vascular studies. Participants had no documented previous medical history, were 
taking no regular medication and tested negative in a urinary toxicology screen 
(Nova Test, One step Diagnostic Rapid Test, CA, USA) for recreational drugs.   
 
A further 12 patients with stable heart failure (NYHA class II-IV) and 10 age- and         
sex-matched healthy volunteers were recruited to attend once each. Healthy 
volunteers had no previous documented medical history and were on no regular 
medications. Patients with heart failure were eligible if echocardiography had 
confirmed left ventricular ejection fraction <35%, left ventricular end diastolic 
diameter >5.5 cm and fractional shortening <20% within the preceding 12 months. 
! 59 
Patients were required to have been on maximally tolerated doses of ACE inhibitor 
and beta-blocker for at least 3 months. Participants were excluded if they had a 
systolic blood pressure >190 mmHg or <90 mmHg, or if they were known to have 
untreated ventricular arrhythmias or haemodynamically significant valvular heart 
disease. Patients with other severe or significant comorbidities including bleeding 
diathesis, renal or hepatic failure, anaemia or a recent infective or inflammatory 
condition were also excluded. In addition, women of child-bearing potential were 
excluded from the study.  
 
2.3  STUDY METHODOLOGY 
 
2.3.1   FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY 
Forearm venous occlusion plethysmography as a technique to assess human vascular 
physiology in vivo has been around for more than half a century. It has been well 
described in literature and is considered a ‘gold standard’ in the assessment of 
vascular function in health and disease [Wilkinson and Webb 2001]. It provides an 
accurate, reproducible, minimally invasive method of assessing novel vasoactive 
drugs and hormones in man, allowing for the use of sub-systemic doses. Bilateral 
! 60 
venous occlusion plethysmography is now considered the preferred method of 
assessing response to vasoactive drugs/hormones instead of unilateral 
plethysmography, with the non-infused forearm serving as a contemporaneous 
control.  
 
Basic principles of forearm venous occlusion plethysmography 
Venous occlusion plethysmography works on the principle that if venous return from 
the arm is obstructed and arterial inflow continues uninterrupted, the rate of forearm 
swelling is proportional to the rate of arterial inflow [Benjamin et al 1995]. It 
measures the total forearm blood flow, excluding flow through the hand, where 
blood flow is predominantly through the skin and highly influenced by 
environmental factors. A blood pressure cuff around the wrist inflated to well above 
systolic pressures (usually 200 mmHg), serves to exclude the hand circulation. An 
upper cuff (around the upper part of arm) is intermittently inflated and deflated       
(to 40 mmHg, inflating for 10 seconds followed by a deflation period of 5 seconds) 
allowing intermittent occlusion of venous return, whilst maintaining arterial flow 
[Wilkinson and Webb 2001]. Changes in forearm volume measured by the     
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mercury-in-silastic strain gauges applied across the widest part of the forearm, is 
expressed as mL/100 mL forearm tissue/minute.  
 
This technique has been extensively used in assessing vascular and endothelial 
responses to intra-arterial infusion of vasodilators such as acetylcholine [Kubo et al 
1991; Hirooka et al 1992; Walker et al 2001; Lang et al 2008a, Lang et al 2008b; 
Maclay et al 2009; Japp et al 2010], bradykinin [Mason and Melon 1965; Labinjoh 
et al 2001; Pretorius et al 2002; Witherow et al 2003; Pretorius and Brown 2010; 
Ozkor et al 2011] and substance P [Tagawa et al 1997; Newby et al 1997a;      
Newby et al 1997b; Newby et al 1999a; Newby et al 1999b] and vasoconstrictors 
such as endothelin [Strachan and Webb 2002] in addition to assessing factors 
influencing the maintenance of peripheral vascular tone [Helmy et al 2001; Helmy et 
al 2003]. Several groups have demonstrated within-subject reproducibility and 
reliability of bilateral occlusion plethysmography [Petrie et al 1998; Walker et al 
2001]. Walker et al [2001] and Petrie et al [1998] have demonstrated that changes in 
absolute forearm blood flow is a more reliable way of expressing responses to 
vasodilators whereas percentage changes may be more appropriate to represent 
response to vasoconstrictor agents. Forearm plethysmography is able to detect as 
! 62 
much as a 4 to 8-fold shift in dose-response relationships when comparing        
within-day and between-day responses for vasodilator agents [Newby et al 1997a], 
thus making it a sensitive tool for detecting changes in forearm blood flow.     
Previous work has assessed intra-subject variability and determined the coefficient of 
variation for forearm blood flow across resting conditions and a range of agonists to 
be between 24 to27% [Walker et al 2001].  
 
Study technique 
Forearm plethysmography was performed with the participant lying supine, in a 
quiet, temperature controlled room (22-25oC). Volunteers fasted for 4 hours prior to 
the study and refrained from alcohol and caffeine for 24 hours prior to the study. 
Venous cannulae (17-G) were inserted into large subcutaneous veins in the 
antecubital fossae of both arms at the start of the study to facilitate periodic venous 
sampling as per study protocol. Heart rate and blood pressure were monitored at 
regular intervals throughout the study with a semi-automated oscillometric 
sphygmomanometer (Omron 705IT, Omron Healthcare, UK) (Figure 2.1). 
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Participants underwent brachial artery cannulation of the non-dominant forearm with 
a 27-standard wire gauge steel needle (Coopers Needle Works Ltd, Birmingham, 
UK) and received intra-brachial infusions of vasoactive agents as per protocol. These 
include acetylcholine (Chem. Pharm Fabrik GmbH, Germany),                     
bradykinin (American Peptide Co, CA, USA), sodium nitroprusside (Hospira Inc, 
Lake Forest, IL, USA), urocortin 2 (Neurocrine Biosciences Inc, San Diego, CA, 
USA), urocortin 3 (GenScript, NJ, USA) and substance P (Clinalfa Basic, Bachem 
Distribution Services GmbH, Germany). Each drug dose was infused for a total of 
6 minutes through the brachial artery cannula. Forearm arterial blood flow was 
measured using mercury-in-silastic strain gauges around the widest part of the 
forearm in both infused and non-infused forearms. Measurements were taken after 
the first 3 minutes of infusion, allowing for equilibration of blood flow.                    
A 20 to 30-minute saline washout followed each period of drug administration, 
allowing forearm blood flow to return to baseline. Plethysmography data was 
analysed using LabChart (ADInstruments, Australia, version 7.1). 
 
Forearm venous occlusion plethysmography was used in assessment of vascular 




Figure 2.1.  (A) Participant set-up for forearm venous occlusion plethysmography. (B) 27-G steel 
needle cannulated in left brachial artery with mercury-in-silastic strain gauge wrapped around widest 
part of forearm. (C) Typical LabChart data obtained during plethysmography showing non-infused 
and infused forearm blood flow.  
! 65 
2.3.2   FLOW CYTOMETRY 
Flow cytometric measurements of platelet-monocyte aggregation (PMA), platelet 
surface expression of P-selectin and monocyte Mac-1/CD11b expression were 
performed to assess effect of SRT2104 on markers of platelet and monocyte 
activation in otherwise healthy cigarette smokers (Chapter 3). These assessments 
were carried out at baseline and at the end of each treatment period as described 
previously [Sarma et al 2002; Harding et al 2004a; Harding et al 2004b].  
 
Basic principles of flow cytometry 
Flow cytometry uses the principle of light scatter and fluorescence emitted by 
fluorochrome tagged cells to measure specific properties such as size (represented by 
forward angle light scatter) and internal complexity (represented by right-angled 
scatter) of a large number of individual cells.  
 
Before flow cytometric analysis, cells in suspension are fluorescently labelled, 
typically with fluorescently conjugated monoclonal antibodies. Antibodies 
conjugated to fluorescent dyes can bind specific proteins on cell membranes or inside 
cells. When labelled cells are passed by a light source, the fluorescent molecules are 
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excited to a higher energy state. Upon return to their resting states, fluorochromes 
emit light energy at higher wavelengths. The use of multiple fluorochromes, each 
with similar excitation wavelengths and different emission wavelengths, allows 
several cell properties to be measured simultaneously. In the flow cytometer, the 
suspended cells pass through a flow chamber, and at a rate of 1,000 to 10,000 cells 
per minute, through a focussed beam of laser. After fluorescent activation of the 
fluorophore at the excitation wavelength, a detector processes the emitted 
fluorescence and light scatter properties of each cell. The resulting information is 
displayed in a histogram or two-dimensional dot-plot format (Figure 2.2). 
 
In samples anticoagulated with D-Phenylalanine-L-propyl-L-arginine chloromethyl 
ketone (PPACK, a direct thrombin inhibitor), Harding et al [2007] were able to 
demonstrate a mean coefficient of variation of 7.8% for platelet-monocyte 
aggregates. Similarly, Burdess et al [2012] have also demonstrated good 
reproducibility (both within-day and between-day) of platelet-monocyte aggregates, 
P-selectin and CD40 ligand. Harding et al [2007] also demonstrated that in    
immune-fixed samples stored at 4oC, platelet-monocyte aggregates remained stable 





Figure 2.2.  Typical flow cytometric dot-plot representation of CD14-FITC tagged human peripheral 




Peripheral venous blood was drawn from a large antecubital vein and anticoagulated 
with PPACK (75 µmol, Cambridge Biosciences, UK) and immunolabelled within 
5 minutes of phlebotomy for subsequent flow cytometric analysis.                  
Directly conjugated monoclonal antibodies were obtained from DakoCytomation 
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(Cambridge, UK) and Serotec (Oxford, UK). Samples were stained with the 
following conjugated monoclonal antibodies: phycoerythrin (PE)-conjugated CD14, 
PE-conjugated CD62p, PE-conjugated CD11b, fluorescein isothiocyanate        
(FITC)-conjugated 42a, and FITC-conjugated CD14 and appropriate control 
isotypes. Once stained, samples were incubated for 20 minutes at room temperature 
before being fixed with FACS-Lyse (Becton-Dickinson, Oxford, UK). All samples 
were analysed using a FACS Calibur flow cytometer using CellQuestPro software 
(Becton-Dickinson, Oxford, UK). Platelet-monocyte aggregation, P-selectin and 
Mac-1/CD11b values expressed as a percentage, were directly obtained from the 
FACS Calibur flow cytometer. 
 
2.3.3  PULSE WAVE ANALYSIS AND VELOCITY 
Measurement of arterial stiffness is widely used in both clinical practice and 
research. Arterial stiffness, as a marker of cardiovascular risk, is not a new concept. 
Pulse wave velocity (PWV), measured through peripheral arterial applanation 
tonometry is the current gold standard for determining arterial stiffness. Pulse wave 
analysis (PWA) and velocity provide a non-invasive, reproducible and relatively 
inexpensive method of measuring arterial stiffness. A number of studies have 
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examined the ability of arterial stiffness to predict the risk of future fatal and         
non-fatal cardiovascular events and total mortality [Vlachopoulos et al 2010]. 
 
Pulse wave analysis and velocity were measured in otherwise healthy cigarette 
smokers and patients with type 2 diabetes mellitus before and after administration of 
SRT2104 (Chapter 4).  
 
Basic principles of pulse wave analysis and velocity 
Arterial stiffness partly depends on smooth muscle tone. The shape of the arterial 
waveform provides a measure of systemic arterial stiffness and can be assessed   
non-invasively using pulse wave analysis [Wilkinson et al 2002]. O’Rourke and 
colleagues [O’Rourke and Gallagher 1996] developed the technique of pulse wave 
analysis to allow non-invasive measurement of central pressure waveforms using 
applanation tonometry. A meta-analyses of 17 original articles measuring aortic 
pulse wave velocity and cardiovascular outcomes by Vlachopoulos et al [2010] has 
shown that aortic pulse wave velocity is a strong predictor of future cardiovascular 
events. Pulse wave analysis has been shown to be a simple way of assessing 
endothelial vasomotor function [Wilkinson et al 2002]. It has also been shown to be 
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a simple and reproducible technique [Wilkinson et al 1998], allowing easy use in 
large scale studies. Wilkinson et al [1998] have reported extremely low standard 
deviation (SD) for measurement differences (both within-observer and between-
observer reproducibility; 5.37% and 3.8% respectively) for pulse wave analysis. 
 
Pulse wave analysis derives an aortic pulse pressure waveform (Figure 2.3) from the 
radial artery wave via a mathematical transfer function. The arterial pressure 
waveform is a composite of the forward pressure wave created by ventricular 
contraction and a reflected wave generated by peripheral vascular resistance 
[Lundback et al 2009]. The augmentation pressure is the pressure difference between 
the second and first systolic peaks. The augmentation index (AIx), augmentation 
pressure as a percentage of the pulse pressure, is a measure of systemic arterial 
stiffness and wave reflection. Corrected augmentation index represents the AIx 
corrected for heart rate [Wilkinson et al 2000]. The time to wave reflection (Tr) 
declines with increasing arterial stiffness, and provides a surrogate measure of aortic 
pulse wave velocity [Mills et al 2008]. Pulse wave velocity was calculated by 





Figure 2.3.  Aortic pulse pressure waveform. Systolic and diastolic pressures are the peak and trough 
of the waveform. Augmentation pressure is the difference between the second and first systolic peaks. 
Augmentation index is the augmentation pressure as a percentage of pulse pressure. Time to reflection 




All studies were performed in a quiet, temperature controlled (22-25°C) room. 
Participants were fasted and asked to refrain from smoking for 10 hours, and abstain 
from caffeine and alcohol for 24 hours prior to assessment. Subjects remained supine 
for at least 30 minutes before any recordings were commenced. Systolic and diastolic 




Pulse wave analysis of the radial artery was performed at the wrist using 
micromanometer applanation tonometry (Millar Instruments, Texas) and the 
SphygmoCor™ system (AtCor Medical, Sydney) in accordance with the 
manufacturer's recommendations. The SphygmoCor pulse wave analysis system uses 
applanation tonometry to record non-invasively a high fidelity peripheral arterial 
blood pressure waveform. From peripheral measurements, the PWA software derives 
central aortic blood pressure waveform and a range of central arterial indices. At 
least three independent waveform analyses were obtained from each subject, with 
measurements only accepted upon meeting SphygmoCor™’s internal quality control 
criteria (Figure 2.4).  
 
As part of the study protocol, the process of data collection of pulse wave analysis 
and velocity was carried out by a trained research nurse at the Wellcome Trust 
Clinical Research Facility at the Royal Infirmary of Edinburgh (otherwise healthy 
cigarette smokers) and Western General Hospital (participants with type 2 diabetes). 
The operator performing the analysis was kept constant for each participant 















Figure 2.4.  Applanation tonometry apparatus. Top panel: Application of the Millar tonometer 
against the radial artery. Bottom panel: The SphygmoCor applanation tonometry apparatus. 
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2.4 BLOOD ANALYTES 
!
2.4.1   HAEMATOLOGICAL AND BIOCHEMICAL ANALYTES 
Venous cannulae (17-G) were placed in the antecubital fossa in both forearms to 
facilitate periodic venous blood sampling throughout the study as per protocol. Blood 
sampling was carried out at baseline and at periodic intervals (as per protocol) for the 
assessment of full blood count, liver and renal function tests, cholesterol and blood 
glucose levels. Analysis was performed by the local clinical biochemistry and 
haematology reference laboratories using an automated haematology analyser      
(XE-2100, Sysmex Corporation (Japan)) and ACL TOP, Instrumentation Laboratory, 
(Bedford, MA, USA), an automated chemistry analyser using colourimetric, kinetic 
and enzymatic ultraviolet and colour assays (AU2700/ AU640 analysers, Beckman 
and Coulter, UK Ltd), ion selective electrodes (sodium, potassium and chloride 
assays) and two-point and multiple point rate assays (Ortho Clinical Vitros 250 





2.4.2   MEASUREMENT OF ENDOGENOUS FIBRINOLYSIS AND MARKERS OF PLATELET 
AND MONOCYTE ACTIVATION 
Bradykinin is an endothelium-dependent vasodilator that also stimulates the release 
of stored tissue-plasminogen activator (t-PA) from the vascular endothelium.      
[Brown et al 1997; Brown et al 2000; Witherow et al 2001; Witherow et al 2003]. 
Paired venous blood samples were obtained from each forearm before and during the 
infusion of intra-arterial bradykinin (Chapter 3). Samples were collected into 
acidified buffered citrate (Stabilyte™, Trinity Biotech plc, Bray, Ireland) and citrate 
(BD Vacutainer, Becton-Dickinson, Oxford, UK) for determination of t-PA and   
PAI-1 concentrations respectively. Samples were placed on ice before centrifuging at 
2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and stored at -80°C 
before further analysis. Venous blood samples were collected into ethylene diamine 
tetraacetic acid (EDTA) at the beginning and end of the vascular study to determine 
haematocrit. 
 
Plasma t-PA antigen and activity (t-PA Combi Actibind t-PA ELISA kit, 
Technoclone, Vienna, Austria) and PAI-1 antigen and activity (Elitest PAI-1 Antigen 
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and Zymutest PAI-1 Activity, Hyphen Biomed, France) concentrations were 
determined by enzyme-linked immunosorbent assays (ELISAs). Intra-assay 
coefficients of variation were 7.0% and 5.5% for t-PA and PAI-1 antigen, 4.0% and 
2.4% for t-PA and PAI-1 activity. Inter-assay coefficients of variability were 4.0%, 
7.3%, 4.0% and 7.6% respectively. The sensitivities of the assays were 0.5 ng/mL, 
0.10 IU/mL, 2.5 ng/mL and 5 IU /mL respectively. 
 
Venous blood was collected into citrate at baseline and after each dosing period of 
SRT2104 to assess plasma soluble CD40 ligand (sCD40 ligand) concentrations. 
Blood was centrifuged at 1500 g for 15 minutes at 4°C, and plasma was decanted 
and stored at -80°C for further analysis by ELISA (Bender Medsystems, UK). 
 
2.4.3   PHARMACOKINETIC ASSAY OF SRT2104 
Venous blood samples were taken into pre-labelled heparinised sodium tubes for 
pharmacokinetic assessment of plasma SRT2104 concentrations (Simbec 
Laboratories Limited, UK). Serial blood samples were collected on days 1, 28 and 56 
immediately prior to (0 min) and 15, 30, 60, 120, 180, 240, 480, 720 and             
1440 min following study medication. Plasma was separated by centrifugation of 
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whole blood at 1500 g at 4°C for 15 minutes, and decanted and stored at -80°C until 
analysed. 
 
Plasma concentrations of SRT2104 were measured using liquid chromatography 
with tandem mass spectrometry detection (LC-MS/MS) in positive ion mode.     
High-pressure liquid chromatography was performed using Betasil silica–100 
columns utilising a Phenomenex C18 guard column [Hoffmann et al 2012].  
 
2.5    DATA ANALYSES AND STATISTICS 
 
Forearm blood flow data were analysed as described previously                        
[Newby et al 1997b]. In Chapter 3, fibrinolysis and forearm blood flow data were 
analysed using linear mixed model repeated measures analysis of covariance. 
Treatment differences were investigated in a model adjusting for period, treatment by 
period, vasodilator dose, treatment by vasodilator dose, and vasodilator dose by 
period using SAS® for UNIX (Version 9.1.3 or higher) (SAS Institute, Cary, North 
Carolina). Values for these parameters are expressed as model adjusted                 
(least square means) and 95% confidence intervals. Between-day reproducibility of 
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forearm venous occlusion plethysmography data was assessed using the Bland-
Altman method and coefficient of reproducibility was determined for 95% 
confidence intervals using the Student’s t-test distribution. All other values are 
expressed as mean±SD.  
 
Estimated net release of t-PA and PAI-1 antigen and activity was measured with 
intra-brachial infusion of bradykinin. It was defined as the product of forearm plasma 
flow (based on blood flow and haematocrit) and the difference in plasma antigen     
(or activity) concentrations between the two forearms.  
 
           Estimated net t-PA release = FBF x (1-Hct) x ([t-PA]inf – [t-PA]non-inf ) 
 
Based on previous power calculations [Labinjoh et al 2001], a sample size of 20 
gives 80% power to detect a change in net t-PA antigen release of 27.0 ng/100 mL of 
tissue/minute, assuming a standard deviation of 40.0 and a two-sided P<0.05                 





For pulse wave analysis and velocity, data was analysed, where appropriate, using 
repeated measures analysis of covariance on the change from baseline for all 
parameters. Initially, analyses were conducted separately on cohorts (otherwise 
healthy cigarette smokers and patients with type 2 diabetes). Because of the small 
sample size and similar trends for the two cohorts, these data were pooled post-hoc. 
Treatment differences were investigated in a model adjusting for baseline, period, 
treatment by period and treatment by cohort using SAS® for UNIX (Version 9.1.3 or 
higher). Unless stated otherwise, values are expressed as mean±SD. Tests for 
treatment effect were two-sided with a significance level of 0.05. 
 
For the studies assessing effect of urocortins in healthy volunteers and patients with 
heart failure (Chapters 5 and 6), data was analysed, where appropriate, by analysis of 
variance (ANOVA) with repeated measures, and paired and unpaired Student’s t-test 
as appropriate (Graph-Pad Prism, GraphPad Software, San Diego, CA, USA). 
Significance was taken at 5%. At a level of significance of 5%, a sample size of 12, 
gives a 80% power of detecting a change in forearm blood flow of         
0.7 mL/100 mL/minute. These power calculations are based on a                     
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standard deviation of 0.53 mL/100 mL/minute [Newby et al 1997a; Lang et al 
2008b; Lang et al 2008c]. All results are expressed as mean±standard error of the 
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CARDIOVASCULAR EFFECTS OF A NOVEL SIRT1 ACTIVATOR,  
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Cardiovascular effects of a novel SIRT1 activator, SRT2104, 
in otherwise healthy cigarette smokers.  








Background   We examined the effect of the oral SIRT1 activator, SRT2104, on 
cardiovascular function in otherwise healthy cigarette smokers. 
Methods  Twenty-four otherwise healthy cigarette smokers participated in a 
randomised, double blind, placebo controlled, crossover trial and received 28 days of 
oral SRT2104 (2.0 g/day) or matched placebo. Plasma SRT2104 concentrations, 
serum lipid profile, plasma fibrinolytic factors and markers of platelet and monocyte 
activation were measured at baseline and the end of each treatment period together 
with an assessment of forearm blood flow during intra-arterial bradykinin, 
acetylcholine and sodium nitroprusside infusions. 
Results  Three hours post-dose, mean plasma SRT2104 concentration was 
1328±748 ng/mL after 28 days of active treatment. In comparison to placebo, serum 
lipid profile improved during SRT2104 administration with reductions in serum total 
cholesterol (-11.6±20 versus +6±21 mg/dL), low-density lipoprotein (LDL)               
(-10±17 versus +3±21 mg/dL) cholesterol, and triglyceride (-39.8±77 versus 
+13.3±57 mg/dL) concentrations (P<0.05 for all). All vasodilators produced a     
dose-dependent increase in blood flow (P<0.0001) that was similar during each 
treatment period (P>0.05 for all). No significant differences in fibrinolytic or blood 
flow parameters were observed between placebo and SRT2014. 
Conclusion  SRT2104 appears to be safe and well tolerated, and associated with an 
improved lipid profile without demonstrable differences in vascular or platelet 




3.2     INTRODUCTION 
 
Originally identified in yeast, sirtuins represent a class of highly conserved         
NAD-dependent histone deacetylases that have seven identified members in 
mammalian species [Frye 1999; Frye 2000]. They have been implicated in the 
beneficial effects of calorie restriction, on longevity in several species, and are 
promising drug targets for a variety of diseases of ageing [Tang 2011]. Sirtuin 1 is 
the best-known member of this class of proteins and is expressed broadly in multiple 
tissues and highly expressed in the vascular endothelium [Edirisinghe and Rahman 
2010]. SIRT1 inhibition is associated with vascular dysfunction and arterial 
thrombosis [Breitenstein et al 2011] as well as alterations in fibrinolysis [Ota et al!
2007]. Conversely, SIRT1 activation is associated with improved endothelial 
function [Mattagajasingh et al 2007], enhanced lipid metabolism [Lomb et al 2010] 
and inhibition of atherogenesis [Stein et al 2010].  
 
Smoking tobacco remains one of the most important and consistent modifiable risk 
factors for coronary heart disease, and is associated with an up to 7-fold increased 
risk of non-fatal myocardial infarction [Teo et al 2006]. It is associated with both 
accelerated atherosclerosis [Ambrose and Barua 2004] and a propensity to acute 
coronary thrombosis [Burke et al 1997; Zieske et al 2005]. This is mediated through 
a variety of mechanisms including alterations in vascular, endothelial, fibrinolytic 
and platelet function [Newby et al 1999b; Newby et al 2001; Harding et al 2004; 
Lang et al 2008b]. The precise cellular mechanism for these effects is as yet 
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unknown but cigarette smoke is associated with oxidative stress, eNOS acetylation, 
and increased endothelial cell senescence that has been attributed to reduced SIRT1 
levels [Edirisinghe and Rahman 2010].  
 
To date, there have been few clinical studies to assess the effect of SIRT1 activation 
in vivo in humans. Therefore, the aim of the present study was to examine the in vivo 
effects of a novel oral SIRT1 activator, SRT2104, on the lipid profile, and vascular, 
endothelial and platelet function in otherwise healthy cigarette smokers. We 
hypothesised that SIRT1 activation could improve the cardiovascular risk profile, 





The study was approved by the Research Ethics Committee, was given Clinical Trial 
Authorisation by the MHRA, UK, and carried out at the MHRA Phase 1 accredited 
Wellcome Trust Clinical Research Facility at the Royal Infirmary of Edinburgh, UK 
between June 2010 and September 2011. Written informed consent was obtained 







3.3.1   STUDY PARTICIPANTS 
Twenty-four otherwise healthy male and female volunteers aged between 18 and 
70 years who smoked ≥10 cigarettes daily for at least 1 year were eligible for the 
study. Exclusion criteria are as described in Chapter 2. Eligibility of participants 
including absence of relevant past medical history was confirmed through a 
standardised proforma completed by the registered General Practitioners after 
informed consent. Tests for pregnancy (serum HCG concentrations at screening and 
urinary HCG concentrations at study visits) were conducted on all female 
participants of child-bearing potential.  
 
3.3.2   STUDY DESIGN 
This was a prospective randomised, double blind, placebo controlled, crossover 
study (1:1, SRT2104:placebo). Subjects were randomised to receive 2.0 g daily of 
oral SRT2104 or matched placebo (Sirtris a GSK Company, Cambridge, MA, USA) 
for a 28-day period, followed by crossover to the alternate study arm for another 
28 days, giving a total dosing duration of 56 days. An end of study visit was 
conducted at Day 70! with a phone call follow up on Day 86. Assessment of drug 
safety, tolerability and efficacy on vascular function was carried out at baseline, 





Figure 3.1.  Schematic representation of study design.  




3.3.3   VASCULAR STUDIES 
Vascular studies were undertaken before and at the end of each 28-day trial period. 
All studies were performed with the patient lying supine in a quiet, 
temperature controlled (22-25°C) room. Participants were fasted and asked to refrain 
from smoking for 10 hours prior to the study and avoid caffeine and alcohol for       
24 hours prior to the study. Venous cannulae (17-G) were inserted into large 
subcutaneous veins in the antecubital fossae of both arms at the start of the study to 
facilitate periodic venous sampling. Supine heart rate and blood pressure were 
monitored at intervals throughout the study using a semi-automated non-invasive 





Forearm venous occlusion plethysmography 
Forearm blood flow was measured in the infused and non-infused forearms using 
forearm venous occlusion plethysmography as described in Chapter 2. After a       
20-minute baseline infusion with 0.9% saline, incremental intra-arterial doses of 
bradykinin at 100, 300 and 1000 pmol/minute (an endothelium-dependent 
vasodilator that evokes t-PA release), acetylcholine at 5, 10 and 20 µg/minute         
(an endothelium-dependent vasodilator that does not evoke t-PA release) and sodium 
nitroprusside at 2, 4 and 8 µg/minute (an endothelium-independent vasodilator that 
does not evoke t-PA release) were infused for 6 minutes at each dose, with a          
30-minute 0.9% saline washout infusion between drugs (Figure 3.2). The order of 
drugs was randomised between subjects but kept constant for each subject across the 
three visits. 
 
Figure 3.2.  Schematic representation of forearm intra-arterial infusion protocol: Incremental intra-
arterial infusion of bradykinin (Bkn) (100, 300, 1000 pmol/min); acetylcholine (Ach) (5, 10,     
20 µg/min) and sodium nitroprusside (SNP) (2, 4, 8 µg/min) in the presence of saline washout 




Paired venous blood samples were obtained from each forearm before and during the 
infusion of intra-arterial bradykinin for estimation of plasma t-PA and PAI-1 antigen 
and antibody as described in Chapter 2.  
 
Platelet and monocyte activation 
Flow cytometric measurements of platelet-monocyte aggregation, platelet surface 
expression of P-selectin and Mac-1/CD11b were performed at baseline and at the end 
of each treatment period as described in Chapter 2. Venous blood was also collected 
at baseline and after each dosing period to assess plasma sCD40 ligand 
concentrations as described in Chapter 2.  
 
3.3.4   SAFETY AND PHARMACOKINETIC ANALYSES 
Venous blood samples were collected at fortnightly intervals to measure 
haematological and biochemical analytes including full blood count, coagulation 
profile, liver and renal function, creatine phosphokinase, lactate dehydrogenase, lipid 
profile and free fatty acids. Analyses were conducted by the regional clinical 
haematology and biochemistry reference laboratories as described in Chapter 2.  
 
Serial venous blood samples were collected following study medication for 
pharmacokinetic assessment of plasma SRT2104 concentrations as described in 




3.3.5   DATA ANALYSIS AND STATISTICS 
Plethysmographic data were analysed as described previously [Newby et al 1997b], 
Estimated net release of t-PA and PAI-1 antigen and activity was defined as the 
product of forearm plasma flow (based on blood flow and haematocrit) and the 
difference in plasma antigen (or activity) concentrations between the two forearms. 
Based on previous power calculations [Labinjoh et al 2001], a sample size of 20 
gives 80% power to detect a change in net t-PA antigen release of 27.0 ng/100 mL of 
tissue/minute, assuming a standard deviation of 40.0 and a two-sided P<0.05 
(Student’s paired t-test). To account for a 20% dropout rate, we recruited 24 subjects. 
 
Fibrinolysis and forearm blood flow data were analysed as described in Chapter 2. 
 
3.4       RESULTS 
 
3.4.1   STUDY PARTICIPANTS 
Volunteers had a mean age of 38±13 years (median 37 years), relatively equal sex 
distribution (58% male) and were normotensive without any significant coexisting 
medical conditions. Volunteers had a body mass index of 25±4 kg/m2 and a mean 
cigarette consumption of 17±6 cigarettes per day over 21±14 years. The mean 
urinary cotinine concentration at screening was 1352±950 ng/mL. All 24 volunteers 
completed all study visits. Prior to drug administration, one subject was withdrawn 
from the study due to problems with venous access and was replaced. 
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3.4.2   PHARMACOKINETICS, TOLERABILITY AND SAFETY 
Three hours post-dose, mean plasma SRT2104 concentration was 1328±748 ng/mL 
after 28 days of active treatment (Figure 3.3). The median plasma SRT2104 
concentration after 28 days of treatment was 366 ng/mL (IQR 940 ng/mL). The 
median time at which the maximum plasma concentration was observed (Tmax) on 
Day 28 of dosing was 3.05 hours, which coincided well with study measurements 
performed on those days (2 to 4 hours post-dose). The geometric mean area under 
the curve (AUC0-τ) was 6412 hr ng/mL. Consistent with previous observations 
[Hoffmann et al 2012] there was substantial inter-subject variability in exposure 
during this study. Plasma SRT2104 concentration was below level of quantification 
(<0.521 ng/ml) after treatment with placebo. 
 
 
Figure 3.3.  Pharmacokinetics: Mean plasma concentration - time curve following oral dosing of 
SRT2104 on Day 1 (closed circles) and Day 28 (open circles). Data presented as Mean±SD. 
Hr - hour; SD - standard deviation. 
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All subjects tolerated study medication well. Commonly reported side effects 
included headache (25%), rhinitis, nasopharyngitis and respiratory tract symptoms 
(17%) (Table 3.1). The reported adverse events were mild in intensity and resolved 
without any intervention or sequelae. There were no meaningful differences in the 
number of events between active treatment and placebo. There was only one reported 
serious adverse event in the study (SRT2104 arm) of traumatic facial bone fracture 
that was considered unrelated to SRT2104. 
 
Blood pressure and heart rate remained unchanged throughout the study (P>0.05). 
There were no effects on cardiac rhythm or the 12-lead electrocardiogram, and 
specifically there were no effects on the corrected or uncorrected QT intervals. There 
were no clinically significant adverse effects involving any of the clinical 
haematological or biochemical analytes. 
 
3.4.3   LIPID PROFILE 
Treatment with SRT2104 had a favourable effect on the lipid profile. A statistically 
significant period effect was observed in the analysis of total and LDL cholesterol 
concentrations. Baseline values were higher in subjects receiving placebo in the first 
period. Regardless of treatment arm, the level of change from baseline was greater in 
treatment period 2 for total and LDL cholesterol, and less in treatment period 2 for 
triglycerides. Adjusted summaries combined over treatment periods are presented in 
Table 3.2. There was a reduction in total and LDL cholesterol as well as triglyceride 
concentrations. There was no effect on high-density lipoprotein (HDL) 
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concentrations and the 7% fall in total cholesterol was attributable to the 11% fall in 




TABLE  3.1   List of adverse and serious adverse events 





Any Event  18 18 
Nervous System Disorders Headache 
Paraesthesia 
Hypoaesthesia 



























Gastrointestinal Disorders Flatulence 
Mouth ulceration 










Reproductive System and 
Breast Disorders 
Dysmenorrhea 3 1 
Musculoskeletal and 
Connective Tissue Disorders 
Back pain 






























General Disorders and 
Administration Site 
Conditions 
Influenza like illness 
Fatigue 
Catheter site pain 
Catheter site rash 
Catheter site related reaction 























Infections and Infestations Nasopharyngitis 
Rhinitis 
Upper respiratory tract 
infection 
Oral Herpes 






























Skin and Subcutaneous 
Tissue 
Rash 1 0 
Metabolism and Nutrition 
Disorders 
Decreased appetite 0 1 
Vascular Disorders Phlebitis 0 1 






Ear and Labyrinthine 
Disorders 
Motion sickness 0 1 
Surgical and Medical 
Procedures 





      TABLE 3.2   Effect of SRT2104 on serum lipid concentrations 
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* = P value <0.05.!!!!!!!!!
SD - standard deviation; HDL - high-density lipoprotein; LDL - low-density lipoprotein. Values 
expressed as mean±SD. 
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3.4.4   VASOMOTOR FUNCTION 
Non-infused forearm blood flow remained unchanged throughout all assessment 
periods, as were the pre-dose measurements of blood flow in the infused arm 
between visits (P>0.05). Baseline blood flow remained unchanged throughout the 
study (P>0.05). There was a dose-dependent increase in the infused forearm blood 
flow with all three agonists (acetylcholine, bradykinin and sodium nitroprusside) in 
the presence of either SRT2104 or placebo (P<0.0001 for all three agonists; Figure 
3.4). There were no significant differences in response to either endothelium-
dependent or -independent vasodilators in the presence of SRT2104 compared to 
placebo (bradykinin, P=0.17; acetylcholine, P=0.17; sodium nitroprusside, P=0.90: 
placebo versus SRT2104). There were no differences in forearm vasodilatation 
between the baseline and placebo visits of the study for all three agonists (P=0.56, 
P=0.40, P=0.29 for bradykinin, acetylcholine and sodium nitroprusside, respectively) 


















































































































































































































































TABLE 3.3   Between-day repeatability of forearm blood flow  
 
 
Between-day reproducibility (Baseline versus Placebo visit) in absolute forearm blood flow for 
Bradykinin (100, 300, 1000 pmol/min), Acetylcholine (5, 10, 20 µg/min) and Sodium Nitroprusside 
(2, 4, 8 µg/min). 
 
Drug Dose Mean of differences in 





Bradykinin 100 -0.3 
 
5 
(pmol/min) 300 0.5 6 
 1000 -0.2 7 
    
Acetylcholine 5 -0.1 
 
8 
(µg/min) 10 -0.5 8 
 20 0.3 7 
    
Sodium 
Nitroprusside 
2 0.2 5 
(µg/min) 4 0.3 6 
 8 0.7 6 
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3.4.5   ENDOGENOUS FIBRINOLYSIS, AND MONOCYTE AND PLATELET ACTIVATION 
There was a dose-dependent increase in bradykinin-evoked net t-PA antigen and 
activity release (P<0.0001 for both) in the infused arm that was unaffected by 
SRT2104 (P=0.37, P=0.13, placebo versus SRT2104, for net t-PA antigen and 
activity, respectively; Table 3.4). Plasma PAI-1 activity decreased with time during 
all study visits (P<0.05) consistent with its circadian variation and t-PA release. 
Plasma PAI-1 antigen and activity concentrations were similar in both treatment 
arms (P=0.89, P=0.66, placebo versus SRT2104, for plasma PAI-antigen and activity 
respectively). SRT2104 had no effect on markers of in vivo platelet or monocyte 
activation (Figure 3.5). 
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+ 95% CI) 
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Bradykinin Dose (pmol/min) Bradykinin Dose (pmol/min) 
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Data presented as LS Mean±95% Confidence Intervals *P>0.05, SRT2104 versus Placebo; §P<0.0001, for dose 
response to agonist. 







Figure 3.5.  Effect of SRT2104 on markers of platelet and monocyte activation. 
PMA - platelet-monocyte aggregate; sCD40L - soluble CD40 ligand; Mac-1 - membrane activated 
complex-1; CD - cluster of differentiation; SD - standard deviation. 







In this randomised, double blind, placebo controlled, crossover trial of otherwise 
healthy cigarette smokers, we have demonstrated that oral SRT2104 is safe and well 
tolerated at a dose of 2.0 g daily. Importantly, we have shown that treatment with 
SRT2104 was associated with an 11% mean reduction in serum LDL cholesterol 
concentrations, but without demonstrable differences in vasomotor function, 
endothelial function, or platelet activation assessments compared to placebo. The 
favourable effects on lipid profile suggest that SIRT1 activation may have a 
beneficial role in patients at risk of developing, or with established, cardiovascular 
disease. 
 
Elevated serum cholesterol is an established risk factor for atherosclerosis and 
coronary heart disease. In general, coronary heart disease risk is reduced by 2 to 3% 
for each 1% decrease in total cholesterol concentrations [Gotto 1999]. We observed a 
7% mean reduction in serum total cholesterol and an 11% mean reduction in LDL 
cholesterol concentrations without affecting serum HDL cholesterol concentrations. 
The mechanism of this lipid-lowering effect is not entirely clear, but is consistent 
with observations associated with SIRT1 activation in animals. Resveratrol      
(3,5,4'-trihydroxy-trans-stilbene), is a naturally occurring polyphenolic compound 
that is believed to confer health benefits through SIRT1 activation [Yu et al 2012]. 
Resveratrol has been found to lower plasma triglycerides and cholesterol 
accumulation in guinea pigs [Zern et al 2003] and to suppress atherogenic lesion 
formation in apoE-/- deficient mice [Do et al 2008]. Indeed, SRT2104 also lowers 
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triglyceride levels in preclinical murine models of dyslipidaemia, diabetes, and 
obesity as well as improving insulin sensitivity and metabolic function in these 
animals [Qi et al 2010]. One mechanism whereby SIRT1 activators, such as 
SRT2104, could improve lipid profiles may involve a positive regulatory effect on 
LXRs, nuclear receptors involved in cholesterol and lipid homeostasis. Nuclear 
receptor LXR is a substrate for SIRT1. Li and colleagues have shown that SIRT1 
deacetylates and positively regulates this receptor, potentially altering cholesterol 
transport and metabolism [Li et al 2007]. Although the exact mechanism of the 
improved lipid profiles seen with SIRT1 activation remains to be determined, our 
findings would suggest that SIRT1 activation could provide a therapeutic adjunct to 
current lipid lowering strategies, leading to improvements in cardiovascular disease 
pathophysiology and thus clinical outcomes. 
 
There are currently no published data directly examining the effects of SIRT1 
activation on vasomotor function or endogenous fibrinolysis in vivo in man. Despite 
the several beneficial effects of SIRT1 activation on endothelial function observed in 
preclinical in vitro studies [Mattagajasingh et al 2007; Ota et al 2007;              
Csiszar et al 2008; Orimo et al 2009; Donato et al 2011], we were unable to 
demonstrate improvements in vascular, endothelial or platelet function in these 
otherwise healthy smokers. Why was this? 
 
Did we use appropriate and sufficiently sensitive techniques? Forearm venous 
occlusion plethysmography is a well established technique that has been used 
extensively over the years to study human vascular physiology and has been 
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considered one of the gold standards in the assessment of vascular function in health 
and disease [Wilkinson and Webb 2001]. Using endothelium-dependent (bradykinin 
and acetylcholine) and -independent (sodium nitroprusside) vasodilators, we 
observed a dose-dependent increase in forearm arterial vasodilatation with all 
three agonists. Our results are comparable with those reported in previously 
published studies [Heitzer et al 1996; Butler et al 2001; Noma et al 2005;           
Lang et al 2008b], in otherwise healthy cigarette smokers including impaired t-PA 
release [Newby et al 2001; Pretorius et al 2002; Takashima et al 2007]. Moreover, 
our data had low variance and were highly reproducible when we compared the 
baseline responses with those obtained during placebo administration. Similarly, 
flow cytometric analysis is considered a sensitive gold standard for measurement of 
in vivo platelet activation. We have previously shown that in patients with peripheral 
arterial disease, measurements of platelet-monocyte aggregates are reproducible and 
consistently reflect other markers of platelet and monocyte activation [Burdess et al 
2012]. In the present study, we again report comparable levels of platelet-monocyte 
aggregation [Harding et al 2004; Lupia et al 2010] that were reproducible between 
visits. 
 
There is a body of published data that confirms a strong association between 
cigarette smoking, endothelial dysfunction and impaired endogenous fibrinolysis 
[Newby et al 1997b; Newby et al 1999b; Lang et al 2008b; Edirisinghe and Rahman 
2010; Xue et al 2011]. We were interested to see if this vascular and endothelial 
dysfunction could be improved or reversed by SIRT1 activation. There could be 
numerous explanations as to why we failed to achieve improvement with SRT2104 
! 104 
on these parameters in the current study. One possibility is that the SRT2104 
exposure achieved in this study did not lead to adequate or consistent SIRT1 
activation, which would be required to reverse the vascular and endothelial 
dysfunction in these smokers. Unfortunately, there is no current biomarker for SIRT1 
activation or the ability to measure SIRT1 activation directly in humans. Therefore, 
we do not have a good understanding of the pharmacokinetic-pharmacodynamic 
relationship between SRT2104 drug exposure and SIRT1 activation. Although we 
were able to demonstrate improved lipid profiles, it is unclear whether the same 
exposure levels would also lead to improved vascular and endothelial function. There 
are at least 70 known substrates for SIRT1. SRT2104 may differentially deacetylate 
certain substrates in preference to others, depending on the precise interaction 
between SRT2104 and the substrates as well as the level and activity of the 
substrates in a particular disease state. It is also possible that certain abnormalities 
may be reversed more readily than others through SIRT1 activation. While a 28-day 
exposure may be adequate for observing improvement in lipid profiles, longer 
treatment may be required to reverse some of the vascular and endothelial 
abnormalities. The small sample size of our study may also be a potential limitation. 
SRT2104 is the first selective SIRT1 activator to be studied in human clinical trials. 
As the biology of SIRT1 becomes more established and additional data are gathered 
from small exploratory trials such as this one, the optimal approach for developing 
SIRT1 activators and identifying disease states with the greatest therapeutic potential 
will become better defined. 
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In conclusion, we have demonstrated that the oral SIRT1 activator, SRT2104, is safe 
and well tolerated in otherwise healthy cigarette smokers and provides positive 
effects on lipid profiles, but were unable to demonstrate beneficial effects on 
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Background  Arterial stiffness increases with age, and is associated with adverse 
cardiovascular outcome including increased mortality. The effect of the oral small 
molecule SIRT1 activator, SRT2104, on arterial stiffness was examined in otherwise 
healthy cigarette smokers and subjects with type 2 diabetes mellitus. 
Methods  Twenty-four otherwise healthy cigarette smokers and 15 people with 
stable type 2 diabetes were randomised in a double blind, placebo controlled, 
crossover trial and received 28 days of oral SRT2104 (2.0 g/day) or matched placebo. 
Blood pressure was measured using non-invasive oscillatory sphygmomanometry. 
Pulse wave analysis and velocity were measured using applanation tonometry at 
baseline and the end of each treatment period. Due to the small sample size and 
similar trends for both groups, data for the two groups were pooled (post-hoc 
analysis). 
Results  Compared to placebo, treatment with SRT2104 was associated with a 
significant reduction in augmentation pressure (P=0.02) and a trend towards 
improvement in the augmentation index and corrected AIx (P>0.05 for both). 
However, no changes were observed in pulse wave velocity and time to wave 
reflection (P>0.05). Systolic and diastolic blood pressures remained unchanged 
throughout the study. Treatment by cohort interaction was not significant for any of 
the pulse wave parameters, suggesting that the response to SRT2104 in otherwise 
healthy smokers and people with diabetes was consistent. 
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Conclusion  SRT2104 may improve measures of arterial stiffness in otherwise 
healthy cigarette smokers and in subjects with type 2 diabetes. Definitive conclusions 




The enzyme sirtuin belongs to the sirtuin family of nicotinamide adenine 
dinucleotide-dependent histone deacetylases and is highly expressed in the vascular 
endothelium [Edirisinghe and Rahman 2010]. In addition to other characteristics, its 
activation is associated with improved endothelial function                  
[Mattagajasingh et al 2007] and inhibition of atherogenesis [Stein et al 2010]. 
Particular interest has focused on the potential of therapeutic SIRT1 activators to act 
as anti-ageing agents.  
 
Arterial stiffness rises with age and is recognised to be an independent predictor of 
cardiovascular risk [Cockcroft and Wilkinson 2002]. In particular, elevations in pulse 
pressure and aortic stiffness are associated with increased risk of coronary events and 
overall mortality [Vlachopoulos et al 2010]. Indeed, central aortic stiffness is 
associated with the presence of coronary atherosclerosis and ischaemic heart disease 
[McLeod et al 2004].  
 
Cigarette smoking and diabetes mellitus are significant risk factors for the 
development of cardiovascular disease. A wealth of data has established a strong 
correlation between diabetes and cigarette smoke exposure with increased aortic 
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stiffness, endothelial dysfunction and cardiovascular risk [Rehill et al 2006; Binder  
et al 2008; Stehouwer et al 2008; Roos et al 2011]. New pharmacological strategies 
that improve arterial compliance would therefore be highly relevant to these groups 
at increased cardiovascular risk. 
 
The aims of the present study were to assess the effect of the oral SIRT1 activator, 
SRT2104, on measures of arterial compliance in otherwise healthy cigarette smokers 
and patients with type 2 diabetes. It was hypothesised that SIRT1 activation in these 
‘at risk’ groups could lead to an improvement in arterial compliance and therefore 




The study was approved by the Berkshire Research Ethics Committee, received 
Clinical Trial Authorisation from the MHRA, UK, and was conducted at the MHRA 
Phase I accredited Wellcome Trust Clinical Research Facility at the Royal Infirmary 
of Edinburgh and Western General Hospital, UK between June 2010 and September 
2011 (EudraCT #: 2009-016765-28; Clinical trials identifier: NCT01031108). 
Written informed consent was obtained from each volunteer and the study was 






4.3.1   STUDY PARTICIPANTS 
Twenty-four otherwise healthy cigarette smokers and 15 participants with stable 
type 2 diabetes, aged between 18 and 70 years, were eligible for the study. Inclusion 
and exclusion criteria for the study are as outlined in Chapter 2.  
 
4.3.2   STUDY DESIGN 
This was a prospective randomised, double blind, placebo controlled, crossover 
study as described in Chapter 2. Subjects were randomised to receive 2.0 g daily of 
oral SRT2104 or matched placebo for a 28-day period, followed by crossover to the 
alternate study arm for a further 28 days, giving a total dosing duration of 56 days. 
An end of study visit was conducted at Day 70 with a telephone call follow up on 
Day 86. Measures of arterial stiffness were undertaken prior to and at the end of each 
28-day trial period.  
 
All studies were performed in a quiet, temperature controlled (22-25°C) room. 
Participants were fasted and asked to refrain from smoking for 10 hours, and abstain 
from caffeine and alcohol for 24 hours prior to assessment. Subjects remained supine 
for at least 30 minutes before any recordings were commenced. Systolic and diastolic 
blood pressures were recorded using a non-invasive oscillatory sphygmomanometer. 
 
Pulse wave analysis of the radial artery was performed at the wrist using 
micromanometer applanation tonometry and the SphygmoCor™ system in 
accordance with the manufacturer's recommendations as described in Chapter 2. At 
least three independent waveform analyses were obtained from each subject, with 
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measurements only accepted upon meeting SphygmoCor™ quality control criteria. 
The operator performing the analysis was kept constant for each participant 
throughout the study. 
 
4.3.3   BLOOD SAMPLING  
Venous blood samples were collected and analysed at fortnightly intervals to 
measure haematological and biochemical analytes including full blood count, 
coagulation profile, liver and renal function, creatinine kinase, lactate dehydrogenase 
and lipid profile as described in Chapter 2.  
 
4.3.4   DATA ANALYSIS AND STATISTICS 
As described in Chapter 2, data were analysed, where appropriate, using repeated 
measures analysis of covariance on the change from baseline for all parameters. Due 
to the small sample size and similar trends for the two cohorts (otherwise healthy 
cigarette smokers and subjects with type 2 diabetes mellitus) data was pooled       
post-hoc. Unless stated otherwise, values are expressed as mean±SD. Tests for 




4.4.1   BASELINE CHARACTERISTICS 
Participants in the study had a mean age of 45±15 years and were predominantly 
male (68%). Subjects in the type 2 diabetes cohort were older (mean age 58±8 years) 
when compared to the participants in the otherwise healthy smokers group          
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(mean age 38±13 years). All subjects were normotensive with comparable systolic 
and diastolic blood pressures at baseline (Table 4.1). No clinically significant 
changes in haematological or biochemical analytes occurred throughout the study. 
Biochemical measures of renal function (serum urea, creatinine and electrolytes) 
were within normal limits at baseline and remained unchanged with placebo and 
treatment with SRT2104 in both sub-groups (Table 4.2). 
 
4.4.2   BLOOD PRESSURE 
Resting systolic and diastolic blood pressures remained unchanged throughout the 
study with no significant differences between treatment and placebo treatment 
periods.  
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TABLE 4.1   Baseline characteristics of participants who were otherwise 







People with Type 2 
Diabetes  
(n=15) 




















Heart Rate (bpm) 68±1 77±5 
Body Mass Index (kg/m2) 25±4 30±4 
Smoking History 
No. of cigarettes/ day 
No. of pack years 




















1. Antiplatelet agents (%) 
2. Antihypertensive agents 
ARB (%) 
Diuretics (%) 





































































































































   
   
   
   
   

























































































































































































































































































































































4.4.3   PULSE WAVE ANALYSIS AND VELOCITY 
In a combined analysis of otherwise healthy cigarette smokers and participants with 
type 2 diabetes, a reduction in the augmentation pressure was observed in subjects 
receiving SRT2104 compared with placebo (mean change from baseline:     
SRT2104 -1.60 (5.304) versus placebo -0.06 (4.205); P=0.02) and a trend towards 
improvement in the augmentation index (mean change from baseline in AIx: placebo 
-0.64 (8.361) versus SRT2104 -3.47 (9.728); P=0.08) and the corrected AIx  (mean 
change from baseline AIx 75: placebo -2.2- (7.453) versus SRT2104 -4.84 (9.299); 
P=0.07) (Figure 4.1A). Pulse wave velocity and time to wave reflection remained 
unchanged between placebo and treatment arms (P>0.05 for both parameters; Figure 
4.1B). The effects of SRT2104 administration on measures of arterial compliance 
were consistent across the two cohorts. For example, in the SRT2104 arm, mean 
augmentation index at 75 beats/minute was reduced for both healthy smokers and 
participants with type 2 diabetes (-4.97 versus -4.63, respectively). A statistical 















































































































































































































































































































































































































































































































































































































































































4.4.4   TOLERABILITY AND SAFETY 
Subjects in both study groups (healthy cigarette smokers and patients with type 2 
diabetes) tolerated the study medication well. There were no meaningful differences 
in the number of adverse events between active treatment and placebo. All reported 
adverse events were mild in intensity and resolved without any intervention or 
sequelae (Table 4.3). Headaches occurred with nearly equal frequency in the 
treatment (SRT2104) group in both cohorts. Subjects with type 2 diabetes appeared 
to have more frequent gastrointestinal disturbances, such as diarrhoea and nausea in 
comparison to healthy smokers. Elevated liver enzymes (alanine transaminase) 
resulted in withdrawal of one subject in the placebo period (Day 36) of the diabetes 
group. There was only one reported serious adverse event in the study (SRT2104 arm 
of healthy cigarette smokers) of traumatic facial bone fracture that was considered 
unrelated to SRT2104.  
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TABLE 4.3   Summary of treatment emergent adverse events occurring in 
two or more subjects in otherwise healthy cigarette smokers (OHS) and 




Adverse event Number of Events 

































































































































































































































































































This randomised, double blind, placebo controlled, crossover study demonstrated for 
the first time that the oral SIRT1 activator, SRT2104, may improve arterial 
compliance in otherwise healthy cigarette smokers and in people with type 2 diabetes, 
without affecting resting measures of blood pressure.  
 
The assessment of arterial stiffness is increasingly being used in clinical practice as 
an independent measure of cardiovascular risk, including those in high-risk groups 
[Laurent et al 2006]. Ageing is associated with an increase in the stiffness of large 
elastic arteries induced by structural alterations in the vascular media such as an 
increase in collagen and a decrease in elastin content [Weiss and Fontana 2011]. This 
process of biological ageing is accelerated in the presence of conditions such as 
diabetes mellitus and hypertension. Semba et al [2009] and Hoffman et al [2013]  
have demonstrated an association between the presence of advanced glycation end 
products and increased arterial stiffness. Indeed, vascular change induced by 
cigarette smoke is considered to be a model of accelerated vascular ageing. The 
relationship between tobacco exposure [Rehill et al 2006; Binder et al 2008; 
Kubozono et al 2011], diabetes [Stehouwer et al 2008; Roos et al 2011;             
Bruno et al 2012] and increased arterial stiffness is well established.  
 
Calorie restriction can attenuate age-related arterial stiffness in animal models 
through reduced oxidative stress and altered endothelial nitric oxide bioavailability 
[Weiss and Fontana 2011]. Indeed, calorie restriction can extend lifespan in lower 
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organisms and mammals, and improves several metabolic and inflammatory 
parameters [Lane et al 2001; Roth et al 2001; Lane et al 2002; Heilbronn and 
Ravussin 2003; Heilbronn and Ravussin 2005; Heilbronn et al 2006]. SIRT1 has 
been implicated as an important mediator of life span extension mediated by calorie 
restriction [Barzilai et al 1998; Labinskyy et al 2006; Timmers et al 2011]. The 
current hypothesis, therefore, was that activation of SIRT1 may inhibit this process 
of vascular ageing and be associated with improvements in arterial stiffness. 
 
No studies have examined the direct effect of SIRT1 activation on measures of 
arterial compliance. Botden et al [2012] were unable to demonstrate an improvement 
in augmentation index, or central or peripheral blood pressure following treatment 
with red wine polyphenols. In the present study, a 28-day period of treatment with 
the oral SIRT1 activator SRT2104 was associated with a reduction in augmentation 
pressure and trends towards improvement in AIx and corrected AIx. Augmentation 
pressure and index are measures of arterial compliance and wave reflection from 
small to medium sized arteries. As such, they can be influenced by endothelial 
function and a number of other dynamic and functional factors, such as heart rate and 
peripheral circulatory tone [Laurent et al 2006; Stehouwer et al 2008]. Preclinical 
studies have demonstrated improved vascular function with SIRT1 activation 
[Mattagajasingh et al 2007; Ota et al 2007; Csiszar et al 2008; Donato et al 2011], 
and this may explain our observations of improvement in dynamic measures of 




Pulse wave velocity is a more direct measure of arterial stiffness that is determined 
by the structural and physical composition of the arterial wall [Roos et al 2011]. 
Changes in pulse wave velocity are therefore more gradual and less dependent on the 
function of small to medium sized arteries. In the present study, a change in PWV 
was not observed with SRT2104 administration. This is perhaps not surprising given 
the short time period of exposure to SRT2104 (28 days) and the brief period of 
observation. An improvement in pulse wave velocity might be anticipated with a 
longer period of treatment with SRT2104, to allow more favourable structural 
changes in the larger arterial tree. 
 
4.5 STUDY LIMITATIONS 
 
Some limitations of this trial should be considered. Although favourable trends in 
parameters of arterial compliance were observed, some did not achieve statistical 
significance. This may partly be attributed to the trial being designed specifically to 
examine the acute effects of treatment with SRT2104. A longer period of treatment 
may be required for benefits to emerge on variables such as pulse wave velocity, that 
involve structural changes in the arterial wall. Moreover, the sample sizes of the two 
groups examined were small. Two disparate populations were studied in this trial, in 
whom the mechanisms of vascular dysfunction may be very different. Moreover, 
there was a significant inter-subject variability in the mean plasma concentration of 
SRT2104. A higher peak plasma concentration was achieved in otherwise healthy 
cigarette smokers compared to subjects with type 2 diabetes (P <0.05 for mean 
plasma concentration of SRT2104 at 3 hours post dose - otherwise healthy cigarette 
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smokers vs subjects with type 2 diabetes) which may account for some of the 
differences in response seen between the two groups. However, the direction of 
beneficial effects on treatment with SRT2104 was similar between the two groups, 
providing reassurance of a consistency of effect and allowing the post-hoc 
presentation of the results pooled across the two groups. We do acknowledge that 
given the disparate nature of the two groups, the results from this study can only be 




The present study has provided evidence that suggests treatment with the oral SIRT1 
activator, SRT2104, may lead to an improvement in measures of arterial compliance 
in otherwise healthy cigarette smokers and people with type 2 diabetes. The exact 
mechanism of this improved arterial compliance and the effects of prolonged 
treatment with SRT2104 on vascular health remain to be elucidated. Given that 
aortic stiffness and endothelial function are key factors in predicting cardiovascular 
outcomes, identification of novel pharmacological means of improving these 
predictive parameters is important and highly relevant in populations with known 















CHAPTER  5 
 
 
VASCULAR EFFECTS OF UROCORTINS 2 AND 3 
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Vascular effects of urocortins 2 and 3 in healthy volunteers. 








Background  Urocortin 2 and urocortin 3 are endogenous peptides with an emerging 
role in cardiovascular pathophysiology. We assessed their pharmacodynamic profile 
and examined the role of the endothelium in mediating their vasomotor effects in 
vivo in man.  
Methods  Eighteen healthy male volunteers (23±4 years) were recruited into a series 
of randomised, double blind, placebo controlled, crossover studies using bilateral 
forearm venous occlusion plethysmography during intra-arterial urocortin 2          
(3.6-120 pmol/min), urocortin 3 (1.2-36 nmol/min) and substance P (2-8 pmol/min) 
in the presence or absence of inhibitors of cyclooxygenase (aspirin), cytochrome 
P450 metabolites of arachidonic acid (fluconazole) and nitric oxide synthase                    
(L-NG-monomethyl-arginine citrate (L-NMMA)).  
Results  Urocortins 2 and 3 evoked arterial vasodilatation (p<0.0001) without 
tachyphylaxis but with a slow onset and offset of action. Inhibition of nitric oxide 
synthase with L-NMMA reduced vasodilatation to substance P and urocortin 2 
(P≤0.001 for both) but had little effect on urocortin 3 (P>0.05). Neither aspirin nor 
fluconazole affected vasodilatation induced by any of the infusions (P>0.05 for all). 
In the presence of all three inhibitors, urocortin 2- and urocortin 3-induced 
vasodilatation was attenuated (P<0.001 for all) to a greater extent than with             
L-NMMA alone (P≤0.005). 
Conclusion  Urocortins 2 and 3 cause potent and prolonged arterial vasodilatation 
without tachyphylaxis. These vasomotor responses are at least partly mediated by 
endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid. The 
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role of urocortins 2 and 3 remains to be explored in the setting of human heart failure 




Urocortin peptides, especially urocortins 2 and 3, have prominent cardiovascular 
roles and are expressed in the heart. Although related to corticotrophin-releasing 
hormone, they do not appear to have any role in the regulation of the hypothalamic-
pituitary-adrenal axis [Davidson et al 2009a; Davidson and Yellon 2009b]. The 
effects of CRH and the urocortins are mediated via two G protein-coupled receptors: 
CRH-R1 and CRH-R2. Whilst CRH-R1 is predominantly expressed in the brain and 
not in the heart, CRH-R2 is expressed in the myocardium and vascular smooth 
muscle [Wiley and Davenport 2004; Davidson and Yellon 2009b]. It is found in 
human coronary artery microvascular endothelial cells and has been detected in the 
endothelium of a variety of peripheral vascular beds. Urocortin 1 activates both 
receptors whilst urocortins 2 and 3 are potent selective agonists at CRH-R2 but have 
no effect on CRH-R1 [Venkatasubramanian et al 2010]. 
 
The role of urocortins in cardiovascular physiology and pathophysiology, 
particularly heart failure, has become increasingly apparent. Intravenous urocortin 1 
causes marked vasodilatation in mice via CRH-R2 [Bale et al 2000;                     
Coste et al 2000]. Furthermore, mice lacking CRH-R2 receptors are hypertensive, 
suggesting a role for urocortin in the maintenance of basal vascular tone              
[Coste et al 2000]. Systemic administration of urocortin 2 in humans increases 
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cardiac output, heart rate and left ventricular function while decreasing systemic 
vascular resistance and these effects may be amplified in the setting of heart failure 
[Davis et al 2007a; Davis et al 2007b]. Urocortin 3 has not previously been 
administered to humans but, in an ovine model, both urocortins 2 and 3 appeared to 
produce similar cardiovascular effects. [Rademaker et al 2005b;                  
Rademaker et al 2006]. Although urocortins 2 and 3 each activate the same receptor, 
potential differences in their cardiovascular therapeutic utility may arise from their 
differing pharmacokinetic and pharmacodynamic profile  [Davidson et al 2009a]. 
 
The cardiovascular responses of urocortins represent an amalgamation of systemic 
actions. However, their direct in vivo arterial vasomotor effects have never been 
examined in man. Moreover, the role of the endothelium in the mediation of these 
responses is unknown. Therefore, our study aims were to conduct the first 
comparative clinical assessment of local arterial vasomotor effects of urocortins 2 




All studies were approved by the local Research Ethics Committee and carried out in 
accordance with the Declaration of Helsinki. Written informed consent was obtained 






5.3.1   STUDY PARTICIPANTS 
Eighteen healthy non-smoking male volunteers were recruited into a series of 
vascular studies. Participants had no documented previous medical history, were 
taking no regular medication and tested negative in a urinary toxicology screen for 
recreational drugs.  
 
5.3.2   VASCULAR STUDIES 
All studies were conducted using a randomised, double blind, placebo controlled, 
crossover design. They were performed with the patient lying supine, in a quiet, 
temperature controlled room (22-25oC). Volunteers fasted for 4 hours prior to the 
study and refrained from alcohol and caffeine for 24 hours prior to the study. Venous 
cannulae (17-G) were inserted into large subcutaneous veins in the antecubital fossae 
of both arms at the start of the study to facilitate periodic venous sampling. In view 
of the theoretical risk of alterations in body temperature [Telegdy and Adamik 2008] 
and blood glucose concentrations [Li et al 2007] with the first-in-human 
administration of urocortin 3, tympanic temperature (Genius 2 tympanic 
Thermometer, Coviden, Boston, USA) and capillary blood glucose measurements 
(Advantage Accucheck blood glucometer, USA) were performed at baseline and 
after each dose of urocortin 3. Heart rate and blood pressure were monitored at 
regular intervals throughout the study with a semi-automated oscillometric 
sphygmomanometer. 
 
Subjects underwent brachial artery cannulation in the non-dominant forearm with a 
27-standard wire gauge steel needle. Forearm blood flow was measured in the 
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infused and non-infused forearms using bilateral venous occlusion plethysmography 
as described previously [Newby et al 1997b; Newby et al 1999 b]. 
 
5.3.3   PHARMACODYNAMIC STUDY 
Eight healthy volunteers attended on four occasions (Protocol 1) separated by at least 
one week (Figure 5.1A). After an initial infusion of normal saline (0.9%) for 
20 minutes, volunteers received discontinuous (Protocol 1a) or continuous      
(Protocol 1b) incremental intra-arterial doses of urocortin 2 (3.6-120 pmol/min) or 
urocortin 3 (1.2-36 nmol/min) interspersed with saline infusions between doses as 
appropriate.  
 
5.3.4   MECHANISTIC STUDY  
A further 10 healthy volunteers (Protocol 2) attended on each of five occasions to 
receive incremental intra-arterial doses of urocortin 2 (3.6-36 pmol/min), urocortin 3 
(1.2-12 nmol/min) and substance P (2-8 pmol/min; a control endothelium-dependent 
vasodilator that evokes endothelial t-PA release (Figure 5.1B). These infusions were 
administered in the presence of 1) placebo, 2) oral aspirin 600 mg (cyclooxygenase 
inhibition), 3) nitric oxide clamp (nitric oxide synthase inhibition; see below), 4) 
intra-arterial fluconazole (1.2 µmol/min; inhibition of cytochrome P450 metabolites 
of arachidonic acid), and 5) a combination of oral aspirin, intra-arterial fluconazole 












































Figure 5.1.  Schematic representation of study protocols. A) Protocol 1: Incremental intra-arterial 
doses of urocortin 2 (Ucn 2; 3.6-120 pmol/min) and urocortin 3 (Ucn 3; 1.2-36 nmol/min) in the 
presence (Protocol 1a) and absence (Protocol 1b) of saline washout. B) Protocol 2: Incremental 
intra-arterial infusions of Ucn 2 (3.6-36 pmol/min), Ucn 3 (1.2-12 nmol/min) and substance P (subs P; 
2-8 pmol/min) in the presence of 1) saline placebo, 2) oral aspirin, 3) nitric oxide clamp, 4) intra-
arterial fluconazole and 5) combination of oral aspirin, fluconazole and nitric oxide clamp. 
L-NMMA - L-NG-monomethyl-arginine; SNP - sodium nitroprusside. 
!
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The nitric oxide clamp was used to determine the contribution of nitric oxide to 
urocortin-induced vasodilatation. Following baseline saline infusion, the nitric oxide 
synthase inhibitor, (L-NMMA; 8 µmol/min), was infused intra-arterially. To 
compensate for L-NMMA-induced basal vasoconstriction, forearm blood flow was 
returned to baseline using a titrated dose of the exogenous nitric oxide donor sodium 
nitroprusside (SNP; 90-1200 ng/min). Once baseline blood flow had been restored, 
this dose of SNP was co-infused with L-NMMA and continued throughout the study. 
This arrangement allows a constant ‘clamped’ delivery of exogenous nitric oxide 
whilst endogenous nitric oxide synthase activity is abolished. 
 
The order of urocortin 2, urocortin 3 and substance P infusions was randomised 
between subjects, but kept constant for all visits of each individual subject. The order 
of infusion of inhibitors was also randomised in a double blind manner. 
 
5.3.4   VENOUS SAMPLING 
Blood sampling was carried out at baseline for the assessment of full blood count, 
liver and renal function tests, cholesterol and blood glucose levels. Analysis was 
performed by the local clinical biochemistry and haematology reference laboratories.   
 
5.3.5   DATA ANALYSIS AND STATISTICS 
Forearm blood flow data were analysed as described previously [Newby et al 1997b]. 
A normal distribution of the data was demonstrated using D'Agostino and Pearson 
omnibus normality test. All variables are reported as mean±SEM using          
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repeated-measure ANOVA with post-hoc Bonferroni corrections and two-tailed           




5.4.1   STUDY PARTICIPANTS 
All volunteers were young healthy men (23±4 years). Both urocortin 2 and 
urocortin 3 produced marked localised flushing in the infused arm along with facial 
flushing at the highest doses. Volunteers also experienced heightened awareness of 
their heart beat during, and immediately after, the highest dose of urocortin 3          
(36 nmol/min). All symptoms were self-limiting, well tolerated and short-lived. 
Substance P also induced localised flushing of the infused forearm, which was      
self-limiting. There were no clinically significant changes in the standard 
haematological and biochemical analytes including full blood count, blood glucose, 
cholesterol, and renal and hepatic function throughout the study (data on file). 
Capillary blood glucose and body temperature (tympanic) remained unchanged 
during all doses of urocortin 3 (data on file). 
 
Systolic blood pressure and non-infused forearm blood flow remained unchanged at 
all doses with all three peptides across both protocols. However, at the highest 
infused dose of urocortin 3 (36 nmol/min), there was a sinus tachycardia           
(+22±2 beats/min; ANOVA, P<0.0001) with an associated drop in diastolic blood 
pressure (-8.5±0.8 mmHg; ANOVA, P=0.004; Figure 5.2) that was not seen with 


















































































































Figure 5.2.  Haemodynamic responses to intra-arterial infusion of urocortin 2 (Ucn 2;                     
3.6-120 pmol/min) and urocortin 3 (Ucn 3; 1.2-36 nmol/min): At a dose of 36 nmol/min, Ucn 3 
evoked a transient tachycardia associated with a drop in diastolic blood pressure. Open symbols: Ucn 
2; Closed symbols: Ucn 3; Circle: Heart rate; Square: Systolic blood pressure; Triangle: Diastolic 
BP; ***: P<0.0001; **: P=0.004; Dose 1 = 3.6 pmol/min Ucn 2 or 1.2 nmol/min Ucn 3;                       
Dose 2 = 12 pmol/min Ucn 2 or 3.6 nmol/min Ucn 3; Dose 3 = 36 pmol/min Ucn 2 or 12 nmol/min 




5.4.2   PHARMACODYNAMIC EFFECTS OF UROCORTIN 2 AND 3 
Both urocortin 2 and urocortin 3 evoked dose-dependent arterial vasodilatation in the 





Figure 5.3.  Forearm arterial blood flow responses to increasing doses of urocortin 2 (Ucn 2) and 
urocortin 3 (Ucn 3). Circle: infused forearm blood flow; Square: non-infused forearm blood flow. 
P<0.0001 at all doses. 
 
 
Maximal vasodilatation with urocortin 2 was apparent approximately 10 minutes 
after cessation of the 120 pmol/minute infusion (paired Student’s t-test, Ucn 2           
120 pmol/min versus +10 minutes washout; P=0.04) and thereafter the blood flow 



































































































































































































urocortin 3, where the maximum vasodilatory response was immediate (Figure 5.4A). 
The offset of vasodilatation was prolonged with both peptides although urocortin 2 
took longer than urocortin 3 to return to baseline (Figure 5.4A).  
 
The vasodilator effects of both peptides appeared to be reproducible within-day, with 




















Figure 5.4.  Pharmacodynamics of urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3). A) Onset and offset 
of vasodilatory effect of Ucn 2 (left) and Ucn 3 (right) after infusion of highest dose; B) Within-day 
reproducibility of Ucn 2 (left) and Ucn 3 (right) (P=non-significant, 1st Dose response versus 2nd Dose 





























































































































































































































































































5.4.3   ENDOGENOUS FIBRINOLYTIC FACTORS 
Preliminary data showed no effect of urocortin 2 or 3 on endothelial release of t-PA 
and PAI-1.  
 
5.4.4   MECHANISM OF VASODILATATION 
Baseline forearm arterial blood flow was unaffected by oral aspirin or intra-arterial 
fluconazole, and the co-infusion of sodium nitroprusside restored baseline blood 
flow during L-NMMA administration (two-way ANOVA, P>0.05 for all). Inhibition 
of nitric oxide synthase reduced arterial vasodilatation to substance P and urocortin 2 
(two-way ANOVA, P≤0.001 for both) but had no apparent effect on urocortin 3-
induced vasodilatation (two-way ANOVA, P=0.36). Neither inhibition of 
cyclooxygenase with aspirin nor cytochrome P450 metabolites of arachidonic acid 
with fluconazole affected the vasodilatation induced by the urocortins or substance P 
(two-way ANOVA, P>0.05 for all; data on file). In the presence of all three 
inhibitors, substance P, urocortin 2 and urocortin 3-induced vasodilatation was 
further attenuated (two-way ANOVA, P<0.001 for all), but not completely abolished. 
Combined inhibition of cyclooxygenase, nitric oxide synthase and cytochrome P450 
metabolites of arachidonic acid produced a greater reduction in vasodilatation than 




   



































































































































































































































































































































This study represents the first-in-human administration of urocortin 3 and 
demonstrates that both urocortins 2 and 3 directly evoke potent and prolonged 
arterial vasodilatation that is, at least in part, mediated by the endothelium. These 
findings are of direct relevance not only to our understanding of human 
cardiovascular physiology but also inform the development of therapies targeting the 
urocortin system for the treatment of conditions such as heart failure. 
 
The forearm arterial vasodilator effects of urocortin 2 and urocortin 3 are consistent 
with data from in vitro [Huang et al 2002; Sanz et al 2002; Wiley and Davenport 
2004; Chen et al 2005; Smani et al 2010] and preclinical animal studies [Chen et al 
2003; Dieterle et al 2009]. However, in contrast with existing preclinical data, we 
observed a more marked difference in potency between the two peptides. Although 
preclinical studies have suggested urocortin 2 is 10-fold more potent [Hsu and Hsueh 
2001; Fekete and Zorrilla 2007]. Wiley and Davenport [2004] showed equipotency 
of urocortins 2 and 3 in isolated human internal mammary arterial segments. In 
contrast, here we observed that a 300-fold higher dose of urocortin 3 was required to 
evoke comparable vasomotor effects in the human forearm arterial circulation. This 
discrepancy underlines the importance of a direct head-to-head assessment in vivo in 
man, without which the extrapolation of preclinical data may be deceptive.  
 
Urocortins 2 and 3 are specific agonists at the G protein-coupled CRH-R2 receptors, 
mediating their effects through a cascade of intracellular signalling pathways 
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including adenyl cyclase, cAMP [Kageyama et al 2003a; Kageyama et al 2003b], 
and mitogen-activated protein kinases [Brar et al 2000]. Other well characterised 
G protein-coupled receptor (GPCR) agonists such as bradykinin [Witherow et al  
2001; Witherow et al 2003], substance P [Newby et al 1997b] and protease activated 
receptor type 1 activating peptide (SFLLRN) [Gudmundsdottir et al 2006;          
Lang et al 2008b] evoke vasodilatation with rapid onset and offset in the human 
forearm arterial circulation. Unlike these agonists, the maximal vasodilator effect 
evoked by urocortin 2 in this study was apparent approximately 10 minutes 
following completion of the highest dose (Protocol 1a). In addition to a late maximal 
response with urocortin 2, we also observed a prolonged offset. Even at 100 minutes 
post urocortin 2 administration, infused forearm blood flow remained elevated. 
Although not as lengthy as the effect evoked by urocortin 2, urocortin 3-evoked 
vasodilatation was also prolonged and took one hour for blood flow to return to 
baseline after discontinuation of the infusion. This prolonged offset of effect is 
unusual for G protein-coupled receptor agonists, although a similar time course has 
been observed in response to apelin [Japp et al 2008] and vasopressin [Affolter et al  
2003], and is thought to be the result of prolonged receptor occupancy. In vitro 
studies by Hoare et al [2005] have demonstrated differing affinities of urocortin 2 
and 3 to the CRH-R2  receptor determined by the affinity of the extracellular 
domains of the CRH receptors to these agonists.  It remains to be established whether 
urocortin 2 induces receptor transformation, thereby promoting prolonged binding to 
CRH-R2 and a delayed maximal response. However, when assessed in isolation, it is 
clear that the direct vasomotor effects of urocortin 2 and urocortin 3 are more 




The vasodilator effects of both peptides showed good within-day reproducibility 
without evidence of tachyphylaxis. These are important properties especially with 
potential applications in extended or chronic therapies where predictable and 
reproducible pharmacologic and haemodynamic effects are needed. 
 
Several mechanisms have been proposed to explain the mechanistic pathways of 
urocortin-mediated vasorelaxation. Studies to date suggest that the mechanism 
involved may depend on the species or vascular bed in question. In rats, both 
endothelium-dependent [Jain et al 1999; Huang et al 2002] and -independent 
components are implicated [Schilling et al 1998]. Grossini et al demonstrated that 
urocortin 2-mediated vasorelaxation in the coronary arteries of anaesthetised pigs 
was mediated by nitric oxide [Grossini et al  2008]. However, urocortin-mediated 
vasodilatation appeared to be independent of endothelial integrity in isolated human 
coronary and internal mammary artery segments [Wiley and Davenport 2004; Smani 
et al 2010]. In the current study, the nitric oxide clamp appeared to cause modest 
inhibition of urocortin 2-mediated vasodilatation and appeared to be marginally more 
pronounced with urocortin 2 compared to urocortin 3. Inhibition of the cytochrome 
P450 metabolites of arachidonic acid with fluconazole alone did not have an 
appreciable effect on urocortin-mediated vasodilatation, but its addition enhanced the 
inhibitory effect of the nitric oxide clamp. This suggests that endogenous nitric oxide 
and the cytochrome P450 metabolites of arachidonic acid may have a close 
interrelationship and can compensate for one another to maintain vascular tone. A 
similar effect has previously been described for endothelium-derived hyperpolarising 
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factor (EDHF), whereby its relative importance increases in the face of impaired 
nitric oxide bioavailability under conditions of oxidative stress. Whilst urocortin 2 
and urocortin 3-mediated vasodilatation was inhibited by the combination of all three 
inhibitors, it was not abolished and a substantial degree of vasomotor activity 
remained. We cannot exclude a contribution from other endothelial pathways such as 
residual ‘fluconazole insensitive’ EDHF although the results do suggest a substantial 
contribution from direct smooth muscle activation. Whilst the role of the 
endothelium is substantial, a large contribution from endothelium-independent 
vasodilator mechanisms may be seen as an advantage in the potential therapeutic 
applications of CRH-R2 agonism. Arguably, this would allow a more predictable 
response from the manipulation of urocortin (2 or 3) as a therapy for cardiovascular 
conditions, the vast majority of which would be expected to be associated with 
impaired endothelial homeostatic mechanisms but preserved smooth muscle activity.  
 
This study was designed to assess locally active, sub-systemic doses of urocortin 2 
and 3 in the forearm arterial vasculature. Indeed, the forearm venous occlusion 
plethysmography model allows these local effects to be studied at doses         
10 to 100-fold lower than that usually expected or required to elicit a systemic 
response. It would appear, however, that there was a degree of systemic overspill 
associated with the top dose of urocortin 3 tested. The observed decrease in diastolic 
blood pressure and increase in heart rate observed during and after the infusion of the 
top dose of urocortin 3 is notable particularly as it occurred in the absence of any 
change in blood flow in the contralateral non-infused forearm. Usually, in the case of 
systemic overspill, a corresponding change in the ‘control’ non-infused arm would 
!
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be observed [Newby et al 1997a], but this was not the case with the infusion of the 
dose of urocortin 3. We therefore hypothesise that the hypotensive effect observed 
reflects vasodilatation in another more sensitive vascular bed, such as the splanchnic 
circulation, with consequent reflex tachycardia. Absence of a similar haemodynamic 
response to the highest dose of urocortin 2 may be the result of lower, sub-systemic 
doses of the less potent peptide urocortin subtype or, conceivably, a differential in 
the relative sensitivity of the splanchnic and forearm arterial circulation to 
urocortin 2. Systemic doses of up to 100 µg of urocortin 2 have, however, been 
shown to increase heart rate and decrease diastolic blood pressures in healthy adults 
[Davis et al 2007a].  
 
5.6 STUDY LIMITATIONS 
 
The size of our study population was relatively small. However, we have previously 
described the influence of a range of factors on blood flow in the forearm vasculature 
using sample sizes of ≤12 subjects [Newby et al 1997a; Wilkinson and Webb 2001; 
Gudmunsdottir et al 2006; Gudmundsdottir et al 2008; Japp et al  2008;                
Lang et al 2008a; Lang et al 2008b; Lang et al 2008c]. As with most other 
physiological studies, we have not performed multiple testing correction for the data 
obtained. 
 
We studied the changes in forearm blood flow during brief, local intra-brachial 
infusions of urocortins 2 and 3. The apparent differences between urocortin 2 and 3 
!
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observed in our study may reflect, in part, differences in the tissue exposure achieved 
between the two peptides.  
 
We do not as yet know the effects of prolonged infusions of these peptides. 
Moreover, the effects of urocortins 2 and 3 in patients with heart failure remain to be 
explored. Although there is good concordance between the vasomotor responses 
observed in the forearm resistance vessels and other vascular beds              
[Wilkinson and Webb 2001], further studies will be required to explore their 




We have demonstrated that urocortin 2 and urocortin 3 evoke potent prolonged 
arterial vasodilatation and their effects are at least partly dependent upon endothelial 
nitric oxide and cytochrome P450 metabolites of arachidonic acid. These data 
provide important insights into human cardiovascular physiology and they will 
inform the development of further therapies directed towards the urocortin pathway. 
The in vivo role of this endogenous peptide system in patients with heart failure and 
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Background  Urocortin 2 and urocortin 3 may play a role in the pathophysiology of 
heart failure and are emerging as potential therapeutic targets. We assessed the 
vasomotor effects of urocortin 2 and urocortin 3 in patients with heart failure and in 
age- and sex-matched healthy volunteers using an in vivo human forearm arterial 
model. 
Methods  Twelve patients with stable heart failure (NYHA II-IV; 61±2 years) and 
10 age- and sex-matched healthy volunteers (58±2 years) attended once each. 
Bilateral forearm arterial blood flow was measured using forearm venous occlusion 
plethysmography during incremental intra-arterial infusions of urocortin 2            
(3.6-36 pmol/min), urocortin 3 (360-3600 pmol/min) and substance P                      
(2-8 pmol/min).  
Results  Urocortin 2, urocortin 3 and substance P induced dose-dependent forearm 
arterial vasodilatation. There was no difference in the magnitude of forearm arterial 
vasodilatation between the two groups (P>0.05) for all three peptides. At the highest 
dose infused, urocortin 3 induced a transient tachycardia (P<0.05) in both groups 
associated with a drop in diastolic blood pressure in healthy volunteers (P=0.02) 
suggesting systemic spillover from the infused forearm. However, non-infused 
forearm blood flow remained unchanged in both groups (P>0.05). 
Conclusion  The acute forearm arterial vasodilator effects of urocortin 2 and 
urocortin 3 are preserved in patients with heart failure. These findings provide 
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further evidence of the relevance of the urocortin 2 and urocortin 3 in patients with 
heart failure and reinforce the need to further explore this pathway in clinical trials.  
 
6.2      INTRODUCTION 
 
Despite considerable advances in treatment, heart failure continues to carry a poor 
prognosis with high morbidity and mortality. Hence, there remains a major interest in 
the development of novel therapeutic agents for this debilitating condition. The 
recent decades have seen significant advances in therapeutic interventions for 
patients with chronic heart failure. However, the mainstay of treatment in acute heart 
failure involves the use of diuretics, inotropes and vasodilators. There have been 
relatively few recent trials investigating the use of novel agents in acute heart failure 
[Konstam et al 2007; Voors et al 2011; Teerlink et al 2013]. Urocortins are 
endogenous vasoactive peptides that are increasingly recognised to play an important 
cardiovascular homeostatic role and the potential for their manipulation in the 
treatment of heart failure has become the focus of a growing body of research. 
 
We have confirmed that urocortin 2 and 3 are potent arterial vasodilators, the effects 
of which are reproducible and well tolerated in healthy male volunteers 
[Venkatasubramanian et al 2013]. Previous studies in animal models of heart failure 
[Ng et al 2004; Davis et al 2005; Rademaker et al 2005b; Rademaker et al 2006; 
Boonprasert et al 2008; Rademaker et al 2008; Rademaker et al 2009], as well as 
studies in heart failure patients [Davis et al 2007b (urocortin 2)], suggest that there is 
great scope for urocortins as novel biomarkers and as potential therapeutic agents in 
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heart failure. More recently, Wandy Chan et al [2013] have demonstrated beneficial 
haemodynamics of urocortin 2 infusion in acute decompensated heart failure in man. 
Recent studies by Gheorghiade et al [2013] demonstrated increased cardiac output 
and reduced systemic vascular resistance with intravenous administration of         
JNJ-39588146 (a synthetic analogue of human stresscopin) in patients with stable 
heart failure. Human stresscopin is a 40 amino acid peptide, derived from the same 
gene as urocortin 3. The systemic effects of urocortin 3 remain to be elucidated in 
man. Moreover, no clinical study has examined the regional effects of both 
urocortin!2 and 3 (as distinct from the amalgam of systemic effects) in heart failure 
in man, nor has a direct head to head comparison of their effects been made in these 
patients.  
 
With this in mind, we set out to explore the local vasomotor effects of these peptides 














All studies were approved by the local Research Ethics Committee and carried out in 
accordance with the Declaration of Helsinki. Written informed consent was obtained 
from all participants prior to the study. 
 
6.3.1   STUDY PARTICIPANTS 
Twelve patients with stable heart failure (NYHA II-IV) and 10 age- and sex-matched 
healthy volunteers were recruited to attend once each as described in Chapter 2. 
 
6.3.2   VASCULAR STUDIES 
Studies were performed as described in Chapter 2. Forearm blood flow was 
measured in the infused and non-infused forearms using bilateral venous occlusion 
plethysmography as described previously [Newby et al 1997b; Newby et al 1999b].  
 
Subjects attended once each to receive incremental intra-arterial infusions of 
urocortin 2 (3.6-36 pmol/min), urocortin 3 and substance P (substance P;                  
2-8 pmol/min) (Figure 6.1). The order in which urocortin 2, urocortin 3 and 
substance P were infused was randomised. Urocortin 3 was initially infused at a dose 
of 1200-12000 pmol/minute (n=4 patients with heart failure, n=2-matched healthy 
controls). Data analysis from the first 4 patients with heart failure demonstrated a 
significant drop in systolic blood pressure at the highest dose infused in patients with 
heart failure. The protocol was therefore revised leading to reduction in the dose of 
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urocortin 3 to 360-3600 pmol/minute following appropriate approvals. All 
subsequent participants (n=8) thereafter, received the reduced dose of urocortin 3. 
Haemodynamic data from the first 4 patients with heart failure and first 2-matched 
healthy volunteers is therefore presented separately in the results section and not 
included in the main analysis. 
 
 
Figure 6.1.  Schematic representation of study protocol - incremental intra-arterial infusion of 
urocortin 2 (3.6-36 pmol/min), urocortin 3 (360-3600 pmol/min) and substance P (2-8 pmol/min) in 
the presence of a saline washout between peptides. 
Ucn - urocortin; Subst P - substance P. 
 
 
6.3.3   VENOUS SAMPLING 
Baseline blood samples were drawn for assessment of full blood count, renal 
function, blood glucose and cholesterol levels at the start of each study. Analysis was 




6.3.4   DATA ANALYSIS AND STATISTICS 
Data was analysed, where appropriate, by ANOVA with repeated measures, and 
paired and unpaired Student’s t-test as appropriate. Statistical significance was taken 
at the 5% level. All results are expressed as mean±SEM, unless otherwise stated. 
 
6.4     RESULTS 
 
Patients with heart failure were predominantly male. Baseline characteristics of 
patients with heart failure and healthy volunteers are shown in Table 6.1. Patients 
with heart failure were well established on standard heart failure therapy. All patients 
were receiving treatment with an ACE inhibitor or angiotensin receptor blocker. The 
majority of patients were receiving treatment with a beta-blocker. One patient was 


















Mean±SEM or n (%). 
SEM - standard error of the mean; NYHA - New York Heart Association;  ACEi - angiotensin-
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The intra-brachial infusion of all three drugs was well tolerated with no adverse 
events. Intra-brachial infusion of urocortin 2 and 3 produced localised, self-limiting 
forearm flushing and some facial flushing in both groups of participants as noted in 
previous studies [Venkatasubramanian et al  2013].  
 
6.4.1   RESPONSE TO UROCORTIN 3 AT HIGHER INFUSED DOSES (PILOT DATA) 
The first 4 patients with heart failure and the first 2-matched healthy volunteers 
received higher incremental intra-arterial infusion of urocortin 3 at 1200, 3600 and 
12000 pmol/minute, in addition to urocortin 2 and substance  P at the stated doses.  
 
All three peptides (urocortin!2, urocortin 3 and substance P) evoked dose-dependent 
forearm arterial vasodilatation (P<0.05 for all, ANOVA; Figure 6.2A). Urocortin 3 
also produced a drop in systolic blood pressure at the higher doses in patients with 
heart failure (p<0.05). Patients with heart failure were symptomatic with dizziness 
and angina as a result of this fall in systolic blood pressure. As a consequence, the 
dose of urocortin 3 was reduced to 360-3600 pmol/minute for the remaining 
participants in the study. The data from these participants has not been included in 
the main data analysis. Figure 6.2B shows the haemodynamic response to 
urocortin 2, urocortin 3 and substance P in the pilot data group of patients with heart 











































































































































































































































































































































































































































































































Figure 6.2.  B: Changes in systolic, diastolic blood pressure and heart rate to intra-arterial Ucn 2 
(green line) (3.6-36 pmol/min), Ucn 3 (red line) (1200-12000pmol/min) and Sub P (blue line)           
(2-8 pmol/min) in patients with heart failure (n=4) (left top panel) and in age- and sex-matched 
healthy volunteers (n=2) (Right top panel). C:  Changes in systolic pressure during and after intra-
arterial Ucn 3 at the higher doses of 1200-12000 pmol/minute in patients with heart failure. 





6.4.2 MAIN DATA ANALYSIS 
 
Urocortin 2, urocortin 3 and substance P all evoked dose-dependent forearm arterial 
vasodilatation (P<0.0001 for all, ANOVA). There were no differences in forearm 
vasodilatation between the two groups for urocortin 2, urocortin 3 and substance P 
(p=0.63, p=0.44 and p=0.49 respectively). Systolic and diastolic blood pressure and 
heart rate remained unchanged in both groups in response to urocortin2 and 
substance P. At the highest dose, urocortin 3 induced a transient tachycardia in both 
groups (p=0.0009 and p=0.03; healthy volunteers and patients with heart failure 
respectively) accompanied by a drop in diastolic blood pressure (p=0.03) in healthy 
volunteers. Mean systolic and diastolic blood pressures were numerically lower at 
the maximal dose of urocortin 3 in patients with heart failure, but this did not achieve 
statistical significance (p=0.20 and p=0.39 for systolic and diastolic blood pressures 
respectively). Non-infused forearm blood flow remained unchanged throughout the 
study (Figure 6.3). 
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Figure 6.3.  A: Change in absolute forearm arterial blood flow to Urocortin 2 (3.6-36 pmol/min), 
urocortin 3 (360-3600 pmol/min) and substance P (2-8 pmol/min) in patients with heart failure and in 
healthy volunteers. Solid red line: Infused forearm blood flow - patients with heart failure; Broken red 
line: Non-infused forearm blood flow - patients with heart failure; Solid black line: Infused forearm 
blood flow - healthy volunteers; Broken black line: Non-infused forearm blood flow - healthy 
volunteers. B: Non-invasive haemodynamic responses to intra-arterial urocortin 2 (green line), 
urocortin 3 (red line) and substance P (blue line) in patients with heart failure (lower left panel) and 






This study demonstrates that the arterial vasodilator effects of urocortin 2 and 3 are 
preserved in patients with heart failure. We observed a dose-dependent increase in 
forearm arterial blood flow with all three peptides.  
 
Subjects in both groups were appropriately age- and sex-matched. Patients with heart 
failure were well established on standard heart failure therapy. Healthy volunteers 
included participants with no other significant past medical history on no regular 
medications.  
 
Substance P is an endothelium-dependent agonist [Hirooka et al 1992; Newby et al 
1997b; Tagawa et al 1997; Newby et al 1999a; Newby et al 1999b].!Hirooka et al 
[1992] and Takeshita et al [1996] have shown that endothelium-dependent forearm 
arterial vasodilatation mediated by muscarinic receptor (in response to acetylcholine) 
was attenuated in patients with heart failure, but endothelium dependent 
vasodilatation in response to substance P remained preserved. Although the exact 
mechanism behind this difference in response is not clear, it is postulated that part of 
this may be due to reduced endothelium-derived relaxing factor release secondary to 
muscarinic receptor stimulation in patients with heart failure. In keeping with these 
findings, we did not observe a significant difference in the vasomotor responses to 
substance P between groups. This partly may also be explained by the assessment of 
patients who had stable heart failure symptoms who were receiving robust heart 
failure treatment.  
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Impaired endothelial function is a recognised feature and an independent predictor of 
adverse outcome in patients with heart failure [Kubo et al 1991; Nikolic et al 1992; 
Linke et al 2001; de Berrazueta et al 2010; Takishima et al 2012; Yang et al 2015]. 
There is therefore a theoretical concern that urocortin would be less effective in 
patients with heart failure because of this concomitant endothelial dysfunction. 
However, we have been able to demonstrate that urocortin 2 and urocortin 3 evoked 
normal forearm arterial vasodilatory responses in our patients with heart failure. This 
suggests that either endothelial dysfunction does not have a meaningful impact on 
the actions of urocortin or our subjects did not have significant endothelial 
dysfunction. As discussed above, our patients did not demonstrate impaired 
substance P-induced vasodilatation suggesting preserved endothelial function. This 
may reflect that our patients were stable, well treated and receiving optimal medical 
therapy. Whether similar findings would be observed in patients with decompensated 
heart failure remains to be established.!
 
The advantage of the forearm plethysmography technique is the ability to study 
localised, sub-systemic effects of investigational agents at locally active but         
sub-systemic doses. We therefore, expected to observe no major changes in 
haemodynamic parameters in both groups. We did however, notice a dose-related 
tachycardia and drop in diastolic blood pressure in our study with healthy volunteers 
with urocortin 3 [Venkatasubramanian et al 2013]. This change in heart rate and 
diastolic blood pressure at the highest dose of urocortin 3 was attributed to a 
potential systemic spillover, potentially stimulating other vascular beds                  
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(eg. splanchnic), but without appreciable effect on contralateral non-infused forearm 
blood flow. We observed a similar trend in patients with heart failure, but in 
addition, we observed numerically lower systolic blood pressures in patients with 
heart failure during the highest dose of urocortin 3. This was more pronounced at the 
higher infused dose of urocortin 3 in the pilot group. This may be explained by the 
potential lack of compensatory responses to vasodilatation in heart failure leading to 
lower systolic and diastolic blood pressures. Moreover, all patients were receiving 
maximal tolerated doses of beta-blockers, which might explain the relative lack of 
tachycardia in this group. In previous studies, systemic infusion of urocortin 2 in 
patients with heart failure [Davis et al 2007a] produced a drop in both systolic and 
diastolic blood pressures associated with a minimal tachycardia. This was attributed 
to blunted baroreceptor responses in response to the vasodilator effects of urocortin 2 
in patients with heart failure. The lack of a similar trend to fall in blood pressure in 
response to urocortin 2 in heart failure patients in our study may be as a result of 
lower plasma concentrations of urocortin 2 achieved at the doses infused in 
comparison to urocortin 3. !
 
There have been very few recent novel agents to be used in the management of acute 
heart failure. Serelaxin appeared to show some promise in this group of patients. In 
the RELAX-AHF study, intravenous serelaxin infusion was associated with 
dyspnoea relief and improvement in other clinical outcomes in acute heart failure. In 
addition, a significant late (180-day) mortality benefit (both cardiovascular and all 
cause mortality) was observed in the serelaxin group [Teerlink et al 2013]. Serelaxin 
and urocortin both act via G protein-coupled receptors with some overlap in their 
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cardiovascular molecular biology and physiologic effects [Felker et al 2009; 
Venkatasubramanian et al 2010]. Urocortins may therefore hold potential in the 
treatment of acute heart failure.  
 
6.6    STUDY LIMITATIONS 
 
The size of our study population was relatively small. However, the study was 
adequately powered to demonstrate marked changes in forearm arterial blood flow.  
 
The degree of forearm vasodilatation evoked by urocortin 3 appeared to be greater 
than that produced by urocortin 2 in both healthy volunteers and in patients with 
heart failure. This difference may be a result of varying plasma concentrations 
achieved at the doses infused. Plasma assays of urocortin 2 and 3 would help better 
understand the difference in dose-response relationship for the two peptides but are 




Forearm arterial vasodilator effects of urocortin 2 and urocortin 3 are preserved in 
patients with heart failure when compared with age- and sex-matched healthy 
volunteers. Studies to make head-to-head comparisons of the systemic 
haemodynamic effects of both urocortin 2 and urocortin 3 in patients with heart 
failure will be important to inform the clinical development of what appears to be a 




























Cardiovascular disease continues to be a leading cause of mortality worldwide. In the 
United Kingdom, death from cardiovascular disease accounts for more than a quarter of 
all deaths with an estimated cost of £19 billion per year. Heart failure continues to 
remain a major healthcare burden with an estimated 550,000 people living with heart 
failure in the UK. Unsurprisingly, research into novel targets for cardiovascular disease 
and heart failure remains a major focus. This thesis has concentrated upon the effects of 
two such novel hormone systems and their effects on the cardiovascular system in 
health and in disease. The results from this thesis have helped inform the cardiovascular 
effects of these systems and serve as a platform upon which future studies can be based 
upon, in order to successfully translate the findings from bench to bedside.  
 
The first part of the thesis focussed upon the effects of activation of the sirtuin system in 
man. With advancing years, the pathophysiology of ‘diseases of ageing’ and hence, 
novel targets to tackle them, has generated a lot of interest. SRT2104 is a selective small 
molecule activator of the silent information regulator two 1, which has been implicated 
in the beneficial effects of calorie restriction and on longevity in several species. The 
effects of SIRT1 activation in animal models showed promising results on fasting blood 
glucose levels, body weight and triglyceride and plasma lipid concentrations. Previous 
studies with SRT2104 in man had demonstrated that it was safe for use in man. This 
study was therefore undertaken as a Phase 1 clinical trial to examine the in vivo effects 
of SRT2104 on lipid profile, and vascular, endothelial and platelet function in otherwise 
healthy cigarette smokers and in patients with type 2 diabetes mellitus.  
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The second part of the thesis focused upon the in vivo vascular effects of the urocortin 
system using urocortins 2 and 3. For the first time, we demonstrated the direct in vivo 
arterial vasomotor effects of urocortin 2 and 3 in healthy volunteers and in patients with 
stable heart failure. The studies forming part of this thesis represent the ‘first-in-human’ 
administration of urocortin 3. 
 
7.2 SUMMARY OF FINDINGS 
 
7.2.1   CARDIOVASCULAR EFFECTS OF NOVEL SIRT1 ACTIVATOR, SRT2104, IN 
OTHERWISE HEALTHY CIGARETTE SMOKERS 
As a novel potent small molecule activator of silent information regulator two 1, 
SRT2104, has demonstrated significant activity in in vivo mice models of diabetes, 
effectively improving glucose and insulin homeostasis in diet-induced obese mice and 
ob/ob mice. Little is known about its cardiovascular effects in man. Safety and toxicity 
studies with SRT2104 [Hoffman et al 2010] have shown that doses up to 3.0 g/day are 
well tolerated in humans without any dose-related side effects. In keeping with this, we 
observed that once daily administration of SRT2104 for 28 days at a dose of 2.0 g/day 
was safe and well tolerated in otherwise healthy cigarette smokers and in patients with 
type 2 diabetes mellitus. Any reported side effects were mild and resolved without any 
sequelae. As with previous studies with oral SIRT1 activators, we only examined the 
effects over a 28-day dosing period. The effects of prolonged SIRT1 stimulation remain 
to be explored. 
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As part of series of early studies investigating novel SIRT1 activators, we examined the 
pharmacokinetics of SRT2104. Previous Phase 1 trials with SRT2104 have 
demonstrated a substantial food effect in the levels of exposure achieved [Hoffman et al 
2012; Libri et al 2012]. Therefore, in our study, all participants were given a prescribed 
standard meal (breakfast) to ensure improved drug absorption. Despite substantial  
inter-subject variability in exposure, we were able to demonstrate a steady plasma 
concentration of the drug over a 24-hour period with a once a day dosing regime. The 
median time at which maximum plasma concentration was observed (Tmax) on Day 28 
of dosing was 3 hours, which coincided well with vascular study measurements 
performed on those days. The Tmax observed was in keeping with previous 
pharmacokinetic studies with SRT2104 [Hoffman et al 2012; Libri et al 2012].  
 
SRT2104 was identified as a SIRT1 activator in a high throughput screen of a diverse 
library of 290,000 compounds [Milne et al 2007]. SIRT1 activity is increased by 
SRT2104 due to lowering of the Km (Michaelis constant) of its acetylated protein 
substrate, resulting in an approximately 2-fold increase in activity. In our study, we 
have been able to demonstrate that oral dosing with SRT2104 was safe and, at the given 
dose, was able to achieve a steady plasma concentration. However, given that we did 
not directly measure the level of SIRT1 expression, we have been unable to demonstrate 
target engagement of SRT2104. The variability in target engagement at the plasma 
concentrations of SRT2104 achieved may well be a reason for the lack of vascular 
effects seen with the 28-day dosing schedule.  
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In recent years, the focus of basic and epidemiological investigations has shifted to 
factors or mechanisms involved in the early subclinical phases of atherosclerosis. 
Several inflammatory cells and their activation markers play an important role in the 
formation and progression of atherosclerosis [Furman et al 1998; Furman et al 2001; 
Libby 2002]. Inflammation plays a key role in the pathogenesis of atherosclerosis and 
its complications. SIRT1, a key regulator of the inflammatory process, also has a role in 
preventing atherosclerosis through different mechanisms. There is also ex vivo evidence 
to support that SIRT1 plays a role in directly controlling endothelium-dependent 
vasodilatation and eNOS expression [Mattagajasingh et al 2007]. There are no studies 
directly examining the effect of SIRT1 activation on endothelial function in vivo. Based 
on available preclinical data, we hypothesised that activation of SIRT1 through 
SRT2104 would improve endothelial and platelet function in man, and serve to improve 
the cardiovascular risk profile in otherwise healthy cigarette smokers. However we did 
not demonstrate any differences in vascular, endothelial or platelet function with 
SRT2104.  
 
Elevated serum cholesterol is an established risk factor for atherosclerosis and coronary 
heart disease. Despite the lack of effect on direct measures of vascular function, we did 
observe positive and significant improvements in the lipid profile in the otherwise 
healthy cigarette smokers. We observed a 7% mean reduction in serum total cholesterol 
and an 11% mean reduction in LDL cholesterol concentrations. Similar reductions in 
serum total and LDL cholesterol have been demonstrated with previous studies in 
elderly volunteers [Libri et al 2012] and patients with type 2 diabetes mellitus        
[Baksi et al 2014]. The exact mechanism for this reduction is not entirely clear, but a 
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positive regulatory effect on LXR proteins has been postulated. Our findings suggest 
that SIRT1 activation could provide a useful adjunct to lipid-lowering therapies, thereby 
improving cardiovascular risk profiles.  
 
As part of the assessment of vascular function, we then examined the effects of 
SRT2104 on measures of arterial compliance. 
 
7.2.2   EFFECTS OF SRT2104 ON ARTERIAL STIFFNESS IN OTHERWISE HEALTHY 
CIGARETTE SMOKERS AND PATIENTS WITH TYPE 2 DIABETES MELLITUS 
Both endothelial dysfunction and arterial stiffness commonly coexist in patients at 
increased risk of cardiovascular disease. Arterial stiffness is recognised as an 
independent predictor of cardiovascular risk. Calorie restriction can attenuate             
age-related arterial stiffness in animal models. No studies have examined the direct 
effect of SIRT1 activation on measures of arterial compliance. Having established the 
effect on measures of endothelial and platelet function in Chapter 3, we set out to 
examine the effect of SIRT1 activation on measures of arterial compliance.  
 
Chapter 4 presents a combined analysis of treatment with SRT2104 of otherwise 
healthy cigarette smokers and subjects with type 2 diabetes mellitus on measures of 
arterial compliance. Treatment with SRT2104 was associated with a significant 
reduction in augmentation pressure and a trend towards improvement in     
augmentation index and corrected AIx. There were no changes observed in pulse wave 
velocity or time to wave reflection. The lack of change in PWV may result from the 
short duration of exposure to treatment, which may be inadequate to induce structural 
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changes in the arterial wall. The duration of treatment may, however, be adequate to 
improve dynamic measures such as augmentation pressure and index. It would be 
interesting to see whether prolonged administration of SRT2104 renders positive 
changes in all measures of arterial compliance.  
 
In summary, activation of SIRT1 through SRT2104 in healthy cigarette smokers and 
subjects with type 2 diabetes mellitus was safe and well tolerated and was associated 
with an improvement in lipid profile. It did not produce any demonstrable differences in 
vascular, endothelial or platelet functions and had some effect on measures of arterial 
stiffness. 
 
7.2.3   VASCULAR EFFECTS OF UROCORTINS 2 AND 3 IN HEALTHY VOLUNTEERS 
Urocortin 2 and 3 are endogenous vasoactive peptides that belong to the corticotrophin-
releasing hormone family with prominent cardiovascular roles. Urocortin 2 and 3 are 
potent selective agonists at CRH-R2 - a G protein-coupled receptor, which is expressed 
in the myocardium and vascular smooth muscle [Wiley and Davenport 2004;     
Davidson and Yellon 2009]. Recent years have seen an increasing interest, especially 
for urocortin 2, for its role in heart failure.  
 
Ex vivo and animal studies have shown that urocortins are potent vasodilators of 
different arteries from various animal species [Huang et al 2002; Chen et al 2005; 
Smani et al 2007; Smani et al 2010]. The beneficial haemodynamics of urocortin 2 
and 3 have been demonstrated in sheep with heart failure [Rademaker et al 2005b; 
Rademaker et al 2006]. Similar beneficial effects of urocortins have been seen in small 
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human clinical studies of healthy volunteers and patients with heart failure [Davis et al 
2004a; Davis et al 2007; Wandy Chan et al 2013]. However no studies have examined 
the direct in vivo effects of urocortin 2 and 3 on human vasculature or indeed their 
mechanism of action. We therefore set out to examine the effect of in vivo infusions of 
urocortin 2 and 3 on human forearm circulation.  
 
Through a series of studies, using the well-validated technique of forearm venous 
occlusion plethysmography, we were able to demonstrate that both urocortin 2 and 3 
were potent forearm arterial vasodilators. As expected with any vasodilatory peptide, 
we observed localised flushing in the infused forearm at the highest doses of urocortin 2 
and 3. These were, however, self-limiting and well tolerated by all volunteers. 
 
We observed a significant discrepancy in the potency of the two peptides. Preclinical 
data suggest that urocortin 2 is 10-fold more potent than urocortin 3 [Hsu and Hsueh 
2001; Fekete and Zorrilla 2007]. In contrast, we observed that a nearly 300-fold higher 
dose of urocortin 3 was required to evoke comparable arterial effects in the human 
forearm circulation. This discrepancy in potency was observed both in healthy 
volunteers and in later studies with patients with heart failure. Differences in the 
commercial manufacturing process of the two peptides may have contributed to the 
observed discrepancy. The commercially synthesised peptide was further processed and 
filtered, at a local Good Medical Practice recognised unit, into smaller strength vials to 
allow ease of administration. It is therefore possible that this process resulted in loss of 
some peptide activity. Plasma assay of urocortin 2 and 3 at the infused doses would 
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have added useful information of plasma concentrations achieved to explain the 
discrepancy.   
 
Ex vivo and animal data suggests that urocortin 3 has a shorter half-life than urocortin 2 
and has a more rapid onset of maximal activity [Kageyama et al 2003a; Rademaker et al 
2006]. The half-life of urocortin 2 in healthy humans was found to be 10 minutes     
[Davis et al 2007a]. In keeping with preclinical data, the maximal vasodilatory effect of 
urocortin 3 in our study was immediate whereas with urocortin 2, the maximal 
vasodilatory effect was apparent 10 minutes after completion of the highest infused 
dose. In addition to the late maximal response with urocortin 2, we also observed a 
prolonged offset of the vasodilatory effect with urocortin 2 with elevated forearm blood 
flow even at 100 minutes after urocortin 2 administration. Urocortin 3-evoked 
vasodilatation was also prolonged, but shorter than that observed for urocortin 2 with a 
return to baseline blood flow at 60 minutes after urocortin 3 administration. This 
prolonged offset is unusual for G protein-coupled receptor agonists and thought to be 
the result of prolonged receptor occupancy. The vasodilatory effects of both peptides 
were reproducible within-day without any evidence of tachyphylaxis. 
 
Having established that urocortin 2 and 3 are potent vasodilators, we then sought to 
determine the mechanistic pathways of urocortin-mediated vasorelaxation. Use of a 
nitric oxide clamp caused modest inhibition of urocortin 2-mediated vasodilatation. 
This effect appeared to be more pronounced with urocortin 2 compared with urocortin 3. 
There was no appreciable difference in urocortin-mediated vasodilatation with either 
individual inhibition of cyclooxygenase pathway (with aspirin) or cytochrome P450 
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metabolites of arachidonic acid (using fluconazole). However, in combination with the 
nitric oxide clamp, an enhanced inhibitory effect was observed.  We also observed that 
inhibition of nitric oxide and cytochrome P450 metabolites of arachidonic acid in 
combination did not completely abolish urocortin-mediated vasodilatation, which 
suggests that there remains a large contribution from endothelium-independent 
mechanisms. This is in keeping with observed preclinical data in animal and human 
arterial segments [Jain et al 1999; Huang et al 2002; Chen et al 2005; Grossini et al 
2008; Smani et al 2010]. 
 
7.2.4   EFFECT OF UROCORTIN 2 AND 3 ON FOREARM ARTERIAL BLOOD FLOW IN 
PATIENTS WITH HEART FAILURE 
After establishing the local vasomotor effects of urocortin 2 and 3 in healthy volunteers, 
we proceeded to compare the effects of intra-arterial infusion of the two peptides in the 
human forearm circulation in healthy volunteers and patients with heart failure. In 
keeping with the findings in healthy volunteers, we were able to demonstrate that 
urocortin 2 and 3 induced dose-dependent forearm arterial vasodilatation in patients 
with heart failure. However, there was no difference in the magnitude of forearm 
vasodilatation between patients with heart failure and their age- and sex-matched 
healthy controls. This may be explained by the fact that the patients in our study were 
well established on appropriate heart failure therapies or the fact that, as observed in our 
mechanistic study, there is a large endothelium-independent component of        
urocortin-mediated vasodilatation. However, this preservation of vasodilatation suggests 
that urocortin remains a valuable potential agent for the treatment of heart failure. 
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7.3 FUTURE DIRECTIONS 
 
7.3.1   SIRTUINS IN CARDIOVASCULAR AND METABOLIC HEALTH 
Scientific interest in the benefits of sirtuins and SIRT modulators in man is still at its 
relative infancy. Literature to date has identified SIRT1 as the most critical modulator 
of vascular function, with several reported laboratory and animal studies demonstrating 
its prominent role in the regulation of vascular homeostasis and diseases through its 
action at multiple cellular levels. Translating these observed benefits into successful 
clinical trials remains a challenge. In recent years, pharmacological modulation of 
sirtuins to allow development of potent SIRT1 activators has been widely studied. 
Indeed, there have been several in vivo and ex vivo studies and clinical trials designed to 
explore the effects of SIRT1 activation and inhibition through resveratrol and other 
sirtuin modulators and inhibitors [Grozinger et al 2001; Mai et al 2005; Camins et al 
2010; Orecchia et al 2011; Patel et al 2011; Sanchez-Fidalgo et al 2012; Gano et al 
2014]. Summarised below is an overview of sirtuin activators and inhibitors that 
modulate different cellular targets involved in vascular homeostasis and diseases 
(Figure 7.1).  
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Figure 7.1.  An overview of sirtuin activators/inhibitors that modulate different cellular targets involved 
in vascular homeostasis and diseases.  
AMPK - AMP-activated protein kinase; eNOS - endothelial nitric oxide synthase; FOXO - Forkhead box 
O; IL-6 - Interleukin 6; MMP-14 - metalloproteinase14; MnSOD - manganese superoxide dismutase; NF- 
kB - nuclear factor-kappa B; TNF-α - tumor necrosis factor alpha; p53 - tumor protein; UCP - uncoupling 
proteins; SMC - smooth muscle cell; ROS - reactive oxygen species; EPC - endothelial progenitor cells; 
(+) - positively regulated; (−) - negatively regulated; (?) - unknown.  
 
[D’Onofrio et a 2015]. 
 
Very few clinical trials have examined the effect of SIRT1 activation in the prevention 
or treatment of endothelial dysfunction in man. We have been the first to evaluate this. 
Interestingly, although preclinical and animal data suggest that SIRT1 stimulation has 
beneficial effects on eNOS activation, endothelial function and in the maintenance of 
vascular homeostasis, we were unable to demonstrate any significant differences in 
vasomotor or endothelial function.  
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Although SRT2104 is a potent small molecule activator of SIRT1, we did not directly 
measure the change in the level of SIRT1 expression with SRT2104. Correlation of 
plasma concentrations of SRT2104 achieved with measured changes in SIRT1 mRNA 
expression may help understand the relationship between target engagement and 
observed physiological changes.   
 
An important finding in our study was the significant improvement in lipid profile in 
otherwise healthy cigarette smokers. Pharmacological SIRT1 activation lowers plasma 
LDL cholesterol concentrations by inhibiting proprotein convertase subtilisin/kexin 9 
(PCSK9) secretion, thereby increasing hepatic LDL receptor availability and 
subsequently LDL cholesterol clearing [Miranda et al 2015]. It is also postulated that 
SIRT1 activators like SRT2104 could involve a positive regulatory effect on liver X 
receptor proteins. We noticed a 7% reduction in serum total cholesterol with an 11% 
reduction in LDL cholesterol in our study. Although the exact mechanism of this 
reduction is not entirely clear, this lipid-lowering effect makes SIRT1 activation an 
attractive adjunct in the treatment of lipid disorders. It would however be important to 
first establish the efficacy and safety of its long term administration. 
 
The role of SIRT1 activation in metabolic disorders and type 2 diabetes mellitus 
remains a major focus of interest. Animal data have abundantly demonstrated that 
SIRT1 activation leads to improved glucose and insulin homeostasis in ex vivo and 
animal models. Clinical trials to date have however been unable to reproduce this 
improvement in glucose concentrations in human studies. Baksi et al [2014] were 
unable to demonstrate an improvement in glucose or insulin control in patients with 
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type 2 diabetes mellitus following 28 days of treatment with SRT2104, which they 
attributed to a large between-subject variability in the pharmacokinetics of the drug. 
Similar to my own findings with SRT2104, they observed an improvement in the lipid 
profiles. In a small Phase 1 trial in elderly individuals, Libri et al [2012] observed no 
changes in oral glucose tolerance tests, but once again, did see an improvement in lipid 
profile. Results from the diabetic arm of our Phase 1 trial showed no discernible effects 
on vascular, fibrinolytic, lipid or platelet function in patients with type 2 diabetes 
mellitus. An important and significant weight loss in diabetic patients was also observed 
in this trial, the mechanism for which is unclear.  
 
These lead to an exciting and important question – could SIRT1 activation be useful as 
a tool to aid weight loss, lower total and LDL cholesterol and therefore, indirectly, have 
an impact on cardiovascular risk and health? Are these benefits likely to be sustained 
with prolonged administration of SIRT1 activators and does chronic SIRT1 stimulation 
have any deleterious effects? These questions remain unanswered. Table 7.1 lists 
































































































































































































































































































































































































































































































































































































































































































Although SIRT1 is considered the most critical sirtuin for the maintenance of vascular 
homeostasis in preclinical models, the fact that we did not observe any change in 
markers of endothelial function, leads us to question the potential role of other sirtuins 
in cardiovascular health in man. Together with SIRT4 and 5, SIRT3 is localised to the 
mitochondria. Mitochondrial dysfunction plays a central role in several cardiovascular 
diseases such as cardiomyopathy, heart failure, pulmonary hypertension and endothelial 
dysfunction [Wallace 2000; Madamanchi et al 2005]. SIRT3, through its effects on 
mitochondrial function, may play a role in cardiovascular disease states. Similarly, 
SIRT6 has been shown in ex vivo studies to play a role in cardiovascular disease 
including cardiac hypertrophy, heart failure, myocardial hypoxic damage and 
metabolism [Cai et al 2012; Sundaresan et al 2012; Maksin-Matveev et al 2015]. The 
role of these sirtuins remains unexplored in man. 
 
The role of sirtuin activators may hold the key to several important and relevant 
metabolic disease processes in today’s world. However, findings from this thesis, in 
addition to other available literature suggests that at least in the short term, SIRT1 
activation may not necessarily have a direct impact on vascular function, but may 
become an important tool in altering metabolic risk factors for cardiovascular health. 
More information is required through well-designed clinical trials and perhaps more 
potent small molecule activators of SIRT1 to understand the consequences of chronic 





7.3.2   UROCORTIN RECEPTOR ANTAGONISTS 
Urocortins 2 and 3 exert their effects via G protein-coupled CRH-R2 receptors for 
which they are highly specific and potent. CRH-R2 receptors are expressed in the heart, 
vascular smooth muscle cells and intramyocardial blood vessels. In mice, CRH-R2 
receptors may contribute to the maintenance of basal vascular tone. It remains unknown 
whether urocortins and their receptors have a similar role in the maintenance of basal 
vascular tone in humans.  
 
Astressin 2b is a synthetic, highly potent and long lasting antagonist with a greater than 
a 100-fold selectivity for CRH-R2 receptors. Like most antagonist molecules, 
astressin  2b has been used (in animal studies) to characterise the role of CRH-R2 
receptors and to demonstrate that urocortins 2 and 3 act through these receptors. 
Urocortin receptor antagonism is as yet unexplored in humans and as such its role in the 
maintenance of basal arterial vascular tone or indeed its clinical implications, is 
unknown. There is no doubt that understanding the basic mechanism of interaction of 
urocortins with their receptors, through the use of an antagonist, will aid in 
understanding the pharmacology of these peptides. 
 
Given that forearm venous occlusion plethysmography allows examination of local 
vascular effects without the potential of systemic effects, this technique would be best 
suited to study novel peptides like astressin 2b. In fact, as part of my initial work on 
urocortins, we did procure commercially available astressin 2b, but had significant 
problems with the bioactivity and solubility of the peptide to allow safe use in humans. 
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This was therefore abandoned. Perhaps, future preparations of commercially available 
astressin 2b will allow its safe and easy use in human studies.  
 
7.3.3   UROCORTINS IN HEART FAILURE 
Chronic heart failure and acute decompensated heart failure continue to remain a major 
cause of hospitalisation, morbidity and mortality. Despite this, there have been only a 
couple of heart failure drugs with novel mechanisms of action approved for use in the 
United States [Hanigan et al 2016] since 2001 (Figure 7.2). Hence, there remains an 
increasing need for newer therapies for this rather debilitating condition.   
 
There have been more promising new therapies for chronic heart failure than acute 
decompensated heart failure in recent years. Findings from recent trials using LCZ696 
(PARADIGM-HF) [McMurray et al 2014] and ivabradine (SHIFT) [Swedberg et al 
2010] in chronic heart failure have been major landmarks. The result for acute 
decompensated heart failure therapies has been less promising.  
 
Nesiritide, a recombinant brain natriuretic peptide analogue, was the last medication to 
receive Food and Drug Administration approval for the treatment of acute heart failure 
in 2001. Through vasodilatation and reduction in pulmonary capillary wedge pressure, 
nesiritide was thought to improve dyspnoea scores in patients. This drug was later 
withdrawn, as results from the ASCEND-HF trial [Gottlieb et al 2013] showed no 
beneficial clinical outcomes. More recently, early clinical trials with serelaxin 
(RELAX-AHF trial) [Teerlink et al 2013] and omecamtiv mercabil                 
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(ATOMIC-AHF trial) [Teerlink et al 2016] have been more promising, but remain 
under evaluation in ongoing Phase 2 and 3 trials.  
 
The results from my thesis leave no doubt that urocortins 2 and 3 are potent vasodilators 
whose effects remain preserved in patients with heart failure. Also, results from my 
thesis help better understand the mechanism of action and local arterial effects of these 
potent vasodilators and also allows a head to head comparison between urocortin 2 and 
3. In order to translate these results to clinical use, it is vital that the effects observed are 
reproduced in studies with systemic infusions of these peptides. There is already 
published work with systemic infusions of urocortins 1 and 2 in healthy volunteers and 
patients with stable heart failure [Davis et al 2004; Davis et al 2005; Davis et al 2007a;    
Davis et al 2007b]. In acute heart failure, urocortin 2 has been shown to augment 
cardiac output without significant reflex tachycardia [Wandy Chan et al 2013]. This was 
however associated with a transient fall in renal indices concurrent with urocortin 2 
induced reductions in blood pressure.  
 
The effects of urocrotin 3 in man are relatively less well known. Gheorghiade et al have 
recently examined the effects of systemic human stresscopin (JNJ-39588146) in patients 
with stable heart failure with favourable effects on cardiac indices and haemodynamic 
variables [Gheorghiade et al 2013]. Colleagues in my own group have conducted a 
study examining the effects of systemic urocortin 2 and 3 on cardiac index, 
haemodynamic measures and peripheral vascular resistance in healthy volunteers and 
patients with stable heart failure. This study demonstrated that both peptides cause 





















































































































































































   









































































































































































disease. These results are in keeping with that seen in previous studies with systemic 
urocortin 2 infusion in stable heart failure.  
 
Heart failure is associated with an increased neurohormonal activity as evidenced by 
increased central sympathetic activity and increased plasma norepinephrine from 
activated sympathetic fibres [Pepper and Lee 1999]. Studies have shown that muscle 
sympathetic nerve activity (MSNA) is also exaggerated in patients with heart failure 
[Leimbach et al  1986]. Thus, drugs that reduce MSNA may have major benefits in the 
treatment of heart failure. In preclinical models, infusions of urocortin 2 and 3 reduce 
cardiac sympathetic nerve activity in conscious sheep [Charles et al 2010; Charles et al 
2011]. These results were however not reproduced in human MSNA responses to 
urocortin 2 in health or heart failure [Wandy Chan et al 2015. Doi:10.1111/1440-
1681.12449]. 
 
The role of urocortins in heart failure continues to hold promise. Current data available 
have only been through small clinical trials with relatively small numbers of patients 
enrolled. In order to be able to translate these findings into meaningful therapeutic 
options, further work is required. As potent vasodilators, we have seen significant 
reductions in mean arterial pressures and peripheral vascular resistance with these 
peptides. It is possible that this profound vasodilatory effect may in fact serve to be a 
useful antihypertensive treatment in man. However, in the setting of acute heart failure, 
this may prove to be detrimental with reduced renal perfusion. Hence, it is important 
that we continue to carefully examine the effects of prolonged infusions of urocortin 2 
and 3 in patients with heart failure.  
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7.3.4   UROCORTINS AS BIOMARKERS 
In addition to serving as a potential therapeutic tool in the management of heart failure, 
it is possible that urocortins may serve as diagnostic biomarkers in heart failure and 
myocardial ischaemia. To date, there have been a small number of studies that have 
looked at urocortin concentrations in patients with heart failure and their proposed 
utility as biomarkers. Ng et al [2004] showed that plasma urocortin concentrations were 
elevated in patients with heart failure, especially in early stages and that the 
concentrations declined with increasing severity of disease. Contrary to this, several 
other authors [Wright et al 2009; Gruson et al 2010; Tang et al 2010; Yildirim et al 
2014. Doi:10.5152/akd.2014.5793] have demonstrated that urocortin concentrations 
increase as the severity of heart failure increases. These studies suggest that the 
concentrations of urocortin in heart failure correlate well with other heart failure related 
neurohormones but, on their own, urocortins may not serve as a good marker of heart 
failure. However, when used in conjunction with other markers such as the natriuretic 
peptides, urocortins provide additional and independent information. In my thesis, we 
were unable to perform urocortin 2 and 3 assays due to lack of robust commercially 
available assays, but this information will no doubt add to our understanding of the 







7.4  CONCLUDING REMARKS 
 
Findings from my thesis suggest that the sirtuin and urocortin hormone systems may 
hold great promise as potential targets in cardiovascular health. From cardiovascular 
risk factor prevention to heart failure, the two hormone systems do seem to hold their 
place in today’s world of research. Since the initial description of the human sirtuin 
genes in 1999, a great deal of work has been done in the field of sirtuin biology. The 
translation of these findings into effective treatment modalities in man remains an area 
of interest and challenge. With a global increasing burden of heart failure, further work 
is required to examine the potential role of urocortins as a viable, safe treatment option 
in acute decompensated heart failure through larger scale studies. Further work is 
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Commentary
Urocortins in heart failure
Sowmya Venkatasubramanian *, David E. Newby, Ninian N. Lang
Centre for Cardiovascular Science, University of Edinburgh, SU. 305, Chancellor’s Building, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom
1. Introduction
Despite modern advances in the treatment of the causes and
consequences of cardiovascular illness, heart disease remains a
leading cause of death in the western world. In particular, heart
failure continues to carry a poor prognosis with a considerable
burden on the health care system throughout the world: the
estimated direct cost for heart failure in the United States was $30
billion in 2006 [1]. Many novel peptides are emerging as
biomarkers and potential therapeutic tools for this debilitating
condition. Urocortins represent one such group of peptides whose
role in normal cardiovascular physiology and disease states is now
being increasingly recognized. After their initial discovery in 1995
[2], subsequent research has furthered understanding of their
mechanisms, predominantly in pre-clinical models, with expan-
sion of this knowledge into potential therapeutic applications in
humans. This article provides a review of the role of urocortins in
normal cardiovascular physiology and in the pathophysiology of
heart failure.
2. The urocortin–CRH system
Urocortins belong to the corticotrophin-releasing hormone
(CRH) family which includes CRH, fish urotensin I, frog sauvagine,
urocortin 1, urocortin 2 and urocortin 3 [3] (Fig. 1). CRH is
produced in the brain in response to stress, has central effects upon
behaviour, and exerts a variety of peripheral responses. However,
CRH is unlikely to have major effects upon cardiac function as it is
not expressed locally and its plasma concentrations are very low.
In 1995, Vaughan et al. [4] observed urotensin-like immunore-
activity in the Edinger Westphal nucleus and lateral superior olive
regions of the adult rat brain. It was named urocortin (now known
as urocortin 1) to reflect its similarities of structure and biological
properties to urotensin (suckerfish urotensin) and rat CRH. It is
believed to be the second endogenous mammalian ligand for CRH
receptors [5]. Subsequently, two further paralogues of CRH were
identified—urocortin 2 and urocortin 3. Human CRH and urocortin
1 genes have been localized to chromosomes 8 (8q13) and 2 (2p23-
p21), respectively. Urocortin 2 and urocortin 3 have prominent
cardiovascular roles and are expressed in the heart. In contrast to
CRH, the urocortins do not increase corticosterone secretion and do
not appear to have any physiologic role in the regulation of the
hypothalamic–pituitary–adrenal axis [6,7].
2.1. CRH receptors
The effect of CRH and urocortins is mediated via CRH receptors
(CRH-R). These seven transmembrane G-protein coupled receptors
are members of the secretin family [8] and the human CRH-R gene
has been localized to chromosomes 17 (17q12-qter) and 7 (7p21-
p15) [9,10]. Two subtypes of CRH receptors have been identified in
mammals and rodents—CRF-R1 and -R2. Structurally, the two
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subtypes exhibit considerable divergence at the N terminus,
consistent with their distinct pharmacological properties. Further-
more, three splice variants of CRH-R2 have been identified. These
variants differ in the structure of their N-terminal extra-cellular
domain. R2a and R2b have been observed in rodents and in man,
whilst R2g is specific to humans (isolated in the limbic regions of
the human brain) [8]. It is, however, unclear whether the g splice
variant has any specific physiological role. Low homology of the
extra-cellular domains of CRH-R1 and -R2 accounts for differences
in their ligand specificity [8]. Urocortin 1 and CRH both act at CRH-
R1 but the affinity of urocortin 1 for CRH-R2 is more than 10-fold
higher than that of CRH [5]. Whilst urocortin 1 can activate both
receptors, urocortins 2 and 3 are potent and specific agonists at
CRH-R2 [4,11] with little effect at CRH-R1.
3. Biology of urocortins
3.1. Anatomy (tissue distribution of urocortins and CRH receptors)
Immunoreactivity to the urocortins and their receptors has
been demonstrated in the central nervous, digestive, reproductive,
cardiovascular, immune and endocrine systems, suggesting
important roles throughout the body [12]. In the brain, urocortin
1 is most prominent in the Edinger Westphal nucleus and lateral
superior olive. Urocortin 1 mRNA or immunoreactivity has also
been reported in other regions of the brain, such as the cerebellum
and hypothalamus [8], and it appears to be co-localized with
dopamine in the basal ganglia and hypothalamus. Urocortin 1
mRNA is also expressed in vascular smooth muscle cells and in
cardiac myocytes. Urocortin 2 has a similar distribution in the
central nervous system in mouse and rats, but is also seen in high
concentrations in the peripheral tissues including the heart,
adrenals, placenta, stomach, ovary, skin, gastrointestinal tract,
uterine smooth muscle, skeletal muscle and peripheral blood
vessels [8].
The distribution of urocortin 3 is distinct. In the central nervous
system, it is demonstrable in regions of high CRH-R2 expression,
supporting the notion that it is an endogenous ligand [8]. In
humans, urocortin 3 is also seen in peripheral tissues such as
adrenals, heart and kidney—particularly in the distal tubules [13].
CRH-R1 is predominantly found in the central nervous system.
In addition to its central nervous system expression, CRH-R2 is
found in peripheral tissues such as the gut, heart, lymphocytes and
adrenals. In humans, urocortin 1 and CRH-R2a has been identified
in all four chambers of the heart, suggesting that urocortin acts in
an autocrine or paracrine fashion through CRH-Rs [14]. In contrast
to rats where CRH-R2b is the predominant splice variant in the
heart and vascular smooth muscle cells, humans appear to
predominantly express CRH-R2a in these tissues. CRH-R2 has
also been characterized in the human left ventricle and intra-
myocardial blood vessels [15]. In humans, both CRH-R1 and -R2 are
found in the periphery, although their specific role remains to be
fully characterized in human physiology and pathophysiology.
3.2. Biochemistry
3.2.1. Molecular structure
Urocortin is a 40 amino acid-containing neuropeptide, related
to urotensin (63% sequence identity) and CRH (45% sequence
identity) [4]. Rat and human urocortin bear 95% homology to each
other. The precursor protein contains 122 amino acid residues with
an N-terminal methionine and consensus signal peptide sequence,
whilst the carboxy terminus of the precursor contains the C
terminally amidated peptide of urocortin. The CRH analogue
peptides possess an a helical conformation with varying degrees of
amphipathicity. The amphipathic N-terminal helices could play a
crucial role in selectivity of the analogues to CRH-R1, whereas it
may not be as important for CRH-R2 binding [16]. The parent
protein is half the length of urotensin and CRH precursors with
little sequence similarity to either [8]. Urocortin 2 shows moderate
homology with human and rat CRH (34%), urocortin 1 (43%) and
urocortin 3 (37–40%). The half-life of urocortin 1 in healthy
humans and those with stable heart failure is approximately
50 min [17,18]. Urocortin 2 has a shorter half-life of 10 min in
Fig. 1. Amino acid sequences of CRH and its analogue peptides. Sequences shown are that of mammalian CRH and urocortins, amphibian sauvagine and teleost urotensin 1.
Highlighted sequences represent similarity to CRH.
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healthy humans [19]. The exact half-life of urocortin 3 is not yet
known, but it appears to have a more rapid onset and shorter
duration of action [20].
3.2.2. CRH binding protein
Corticotrophin releasing hormone-binding protein (CRH-BP) is
a 37 kDa protein that was first isolated in human plasma in 1989
[21] and binds to both CRH and urocortin 1. Given that the
expression of CRF-BP overlaps that of both CRH and urocortin 1 in
the central nervous system, it has been proposed that the CRH-BP
plays a role in the modulation of the action of urocortin and CRH at
these sites. In humans, CRH-BP has been detected in the brain,
pituitary, liver and placenta [22–24]. In ovine models of heart
failure [25], the half-life of urocortin 1 was markedly prolonged
compared to human models. This has been attributed to the
possible role of CRF-BPs in clearance of urocortin 1 in humans.
However, the exact role of these binding proteins remains to be
fully elucidated in health and disease states.
3.2.3. Intra-cellular signaling pathways
The urocortins bind to G-protein coupled CRH (R1 and R2)
receptors to induce conformational changes in the receptor that
activate intra-cellular signaling pathways (Fig. 2). In most cells,
this involves adenylyl cyclase and cyclic adenosine monopho-
sphate (cAMP). Indeed, Kageyama et al. demonstrated that
urocortin 2 induces vasodilatation in vascular smooth muscle
cells via CRH-R2 in association with increased cAMP accumulation
via activation of adenylate cyclase [26,27]. Mitogen-activated
protein kinases (MAPK) are also implicated in urocortin-mediated
vasodilatation [26] as well as in the cardioprotective role of
urocortin in response to ischemic or hypoxic injury [28]. However,
in some studies, inhibition of the c-AMP or protein kinase A (PKA)
pathway has failed to inhibit the effects of CRH and its related
peptides, suggesting the involvement of other signaling mechan-
isms.
CRH and related agonists can evoke the endothelial release of
nitric oxide via nitric oxide synthase with subsequent accumula-
tion of cyclic guanosine monophosphate (cGMP). This endotheli-
um-dependent mechanism is important in CRH or urocortin-
induced relaxation in placental vasculature [29] and peripheral
arteries, and has been studied in isolated arterial segments such as
the human internal mammary artery graft [30] and in rat coronary
artery [31]. The nitric oxide and cGMP-dependent component of
this vasodilator effect is mediated via activation of calcium-
activated potassium channels in underlying vascular smooth
muscle. Indeed, the vasorelaxant effect of urocortin is blunted in
the presence of L-NAME (NG-nitro-L-arginine methyl ester; a NOS
inhibitor) and ODQ (1H-[1,2,4] oxadiazolo [4,2-a] quinoxalin-1-
one; inhibitor of guanylyl cyclase) [30].
There is increasing evidence that urocortin and CRH-related
peptides play an important role in cell survival mechanisms in a
number of systems. Similar to CRH, urocortin 1 activates the MAPK
extra-cellular signal-related kinases (ERK) 1/2-p42/44 signaling
cascade in in vitro cultures of isolated rat cardiac myocytes, which
is inhibited by blockade of MEK 1/2. This signaling cascade
mediates the cardioprotective function of urocortin in stimulated
hypoxia or ischemia [28]. Urocortins also possess anti-inflamma-
tory properties that appear to be mediated via pro-apoptotic
effects on macrophages via a direct effect on pro-apoptotic Bcl-2
related proteins [32].
3.3. Physiology of urocortins
3.3.1. Cardiovascular actions
The important roles of urocortins in the regulation of normal
cardiovascular physiology are being increasingly recognized.
Fig. 2. Schematic of Urocortin intra-cellular signaling pathway. Urocortins bind to CRH receptors to induce conformational changes in the G protein receptors and activate the
second messenger systems. CRH-BP has a greater affinity to Urocortin 1 and may play a role in its metabolism. Urocortin 1 binds to both CRH-R1 and -R2, whereas Urocortins 2
and 3 are potent, specific CRH-R2 agonists. CRH-BP: corticotrophin releasing hormone-binding protein; CRH-R: corticotrophin releasing hormone receptor; CNS: central
nervous system; ERK 1/2-p42/44: extra-cellular signal-related kinases 1/2-p42/44; c-AMP: cyclic adenosine monophosphate; PKA: protein kinase A; cGMP: cyclic guanosine
monophosphate; NO: nitric oxide; MAPK: mitogen-activated protein kinase.
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Genetically engineered mice lacking CRH-R2 are resistant to
otherwise marked urocortin-evoked changes in cardiac perfor-
mance and blood pressure [33]. Studies, which are largely pre-
clinical, have so far demonstrated a favourable effect of urocortins
on hemodynamic and neurohumoral regulation. Urocortins 1, 2
and 3 produce positive inotropic and lusitropic effects, reduction in
the mean arterial pressure due to decreased peripheral vascular
resistance, and increased coronary perfusion in rodent and ovine
studies.
3.3.1.1. Vascular effects. Central administration of CRH in rats
produces a pressor response, which appears to be mediated
through CRH-R1 receptors [34]. Peripheral administration of CRH
produces a depressor response, which is blocked by a helical CRH
(a non-selective CRH antagonist), and not by antalarmin (selective
CRH-R1 antagonist). As a peptide, CRH has limited access to the
central nervous system. This suggests that the hypotensive effect is
mediated via peripheral CRH-R2 receptors. CRH-R2 may have a
more prominent role in changes in arterial pressure in comparison
to CRH-R1. CRH-R2 may contribute to the maintenance of basal
vascular tone in mice. Indeed, mice deficient in CRH-R2 receptors
are hypertensive with no fall in the mean arterial pressure in
response to exogenously administered urocortin [35]. It remains
unknown whether urocortins and CRH-R have a similar role in the
maintenance of basal vascular tone in humans.
Intravenous administration of CRH produces vasodilatation in
rats and a consequent fall in blood pressure with a reflex increase
in heart rate, although this is not observed in sheep and is seen only
with relatively high doses in higher primates like monkeys and
humans. In anesthetized rats, intravenous injection of human
urocortin 2 reduced basal systemic blood pressure in a dose-
dependent fashion [36]. As demonstrated by Vaughan et al. [4],
urocortin 1 also possesses a potent and long lasting hypotensive
action. Decrease in mean arterial pressure of 18.3 ! 0.7 mm Hg was
observed with urocortin 1 in rats and lasted for almost 2 h. Dieterle
et al. [37] studied the effects of urocortin 2 injection in control and
hypertensive rats. They showed an immediate and sustained
lowering of blood pressure in hypertensive rats with no rise in heart
rate. This effect on the blood pressure was seen for up to 12 h after
intraperitoneal injection of urocortin 2.
Several mechanisms have been postulated for the blood
pressure lowering effects of urocortins. These may include a
direct smooth muscle relaxant effect in combination with an
associated reduction in plasma concentrations of vasoconstrictor
hormones, such as endothelin 1, angiotensin II and arginine
vasopressin (AVP), as seen in animal models of heart failure (see
Section 4.3 on Neurohormonal effects).
Ex vivo studies in the human internal mammary artery [30] and
in the rat coronary artery [31] suggest both endothelium-
dependent and independent components for vasorelaxation. In
isolated rat coronary artery [31], potent vasorelaxant effect of
urocortin 1 was observed with an IC50 of 2.24 nM, in the presence
of an intact endothelium. The endothelium-dependent component
appears to be, at least in part, mediated by nitric oxide via cGMP, as
outlined above. Huang et al. [31] have also shown the role of
activation of barium chloride (BaCl2) sensitive potassium channels
in arterial smooth muscle cells, mediating the endothelial
component of urocortin-induced coronary relaxation. Indeed,
these studies also demonstrate a blunted, but not abolished,
vasorelaxant response to urocortin in endothelium-denuded
arterial segments, further suggesting the role of additional
endothelium-independent mediators. Endothelium-independent
regulation of vascular tone appears to involve calcium (Ca2+)
independent phospholipase A1 and store-operated Ca
2+ entry
Fig. 3. Beneficial effects of urocortins in heart failure. The beneficial effects of urocortins on various systems as seen in animal and human models of heart failure. ACTH:
adrenocorticotrophic hormone; Ucn 1: urocortin 1; LAP: left atrial pressure; BP: blood pressure; PRA: plasma renin activity.
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modulation [38]. Other mechanisms demonstrated in mediating
urocortin-induced vasorelaxation include the MAPK and PKA
pathway [26].
3.3.1.2. Cardiac effects. It is not entirely clear whether urocortins
mediate their protective effects upon cardiac contractility via a
direct effect on cardiac myocytes or via sympathetic stimulation in
response to reduced peripheral resistance. Brar et al. [28] have
demonstrated the presence of a 22 kDa urocortin 1 precursor
protein in neonatal rat cardiac myocytes and release of urocortin
into the supernatant of cardiac myocytes exposed to stimulated
ischemia or hypoxia, suggesting endogenous release of urocortin
from ischemic cardiac myocytes. This may suggest potential direct
and local action of urocortins on cardiac myocytes, mediated via
CRH -R.
To determine whether urocortin induced direct effects on
contractility of cardiac myocytes, Yang et al. [39] observed the
effects of application of 100 nmol/L of urocortin 2 to isolated adult
rabbit ventricular cardiomyocytes. They showed a progressive
enhancement in myocyte contractility with reduction in diastolic
length and concluded that urocortins exert direct positive
inotropic as well as lusitropic effects. These effects were mediated
via activation of CRH-R2 and subsequent stimulation of PKA
activity, leading to augmentation of L-type calcium channel (ICa),
and sarcoplasmic and endoplasmic reticulum Ca2+ ATPase
(SERCA)-mediated Ca2+ uptake into the sarcoplasmic reticulum.
Immediate improvement of left ventricular fractional shorten-
ing and circumferential fibre shortening velocity were noted
following acute injection of urocortin 2 in rats [37]. These
beneficial effects were preserved even at 5 weeks after treatment.
In ovine models, intravenous injection of urocortin 1 causes a
marked dose-dependent increase in cardiac output and contrac-
tility, which is sustained at 24 h post injection [40].
3.3.1.3. Effects in humans. A small number of clinical studies have
carried forward data obtained from animal studies, to look at the
effects of urocortins on cardiovascular and neurohormonal
responses.
In contrast to the favourable hemodynamic responses seen in
normal sheep, infusion of urocortin 1 in healthy humans caused no
change in hemodynamic variables, nor did it affect the plasma
concentrations of humoral factors, such as aldosterone or arginine
vasopressin. The pharmacokinetics of urocortin 1 were similar in
normal humans and in subjects with heart failure: plasma
urocortin 1 half-life of 52 ! 3 min in healthy volunteers and
54 ! 3 min in those with heart failure [18]. Pemberton and colleagues
did not observe any increase in urinary urocortin 1 following its
infusion suggesting that urocortin 1 is not excreted in the kidneys.
Consistent with its predicted cardiovascular profile, urocortin 2
infusion caused a dose-dependent increase in cardiac output with a
decrease in mean arterial and diastolic blood pressure, and systemic
vascular resistance [19]. The effects of systemic urocortin 3 in humans
are yet to be explored. Wiley and Davenport [15] have demonstrated
that urocortin 3, like urocortin 2, causes vasodilatation in isolated
human internal mammary artery segments and that this effect is
mediated via the direct effect of urocortin 3 on the vascular smooth
muscle cells. Although not yet assessed in man, urocortin 3 is likely to
exert cardiovascular effects similar to those evoked by urocortin 2.
3.3.2. Cardioprotective effects—role in ischemia reperfusion injury
Urocortins appear to have a cardioprotective role and indeed,
urocortin expression and peptide release is increased by ischemia
[41].
Urocortin 1 reduces myocyte cell death caused by ischemia
reperfusion injury. This appears to be mediated via several
mechanisms including up-regulation of cardiotrophin 1 expression
[42], stimulation of heat shock protein [43] and natriuretic
peptides, and attenuation of calcium-insensitive phospholipase
A2 gene expression [44]. In vitro secretion of urocortin is also
enhanced by inflammatory cytokines such as interleukin-6,
interleukin-1 and tumour necrosis factor a: factors that are
elevated in patients with heart failure and acute coronary
syndromes [64].
Urocortins 2 and 3 protect neonatal rat cardiac myocytes in vitro
when administered before hypoxia or at the point of reoxygena-
tion. Urocortins 2 and 3 also protect the adult rat heart ex vivo and
acts via the MAPK pathway to reduce the infarct size of a perfused
intact rat heart exposed to regional ischemia [45]. Brar et al. [45]
have demonstrated that urocortin induces ERK 1/2-p42/44
phosphorylation in neonatal rat cardiac myocytes and that
inhibition of MEK 1/2 inhibits its cardioprotective effects.
Nitric oxide is recognized as a key determinant of vascular
health. It acts as a potent vasodilator, inhibits expression of several
pro-inflammatory cytokines and chemokines, and plays a key role
in vascular smooth muscle proliferation, platelet aggregation and
endogenous fibrinolysis [46–48]. Whilst urocortin may act via
nitric oxide to mediate cardiovascular protective effects [46],
studies to date have not yet completely elucidated the effect of
urocortins on the endothelium or nitric oxide.
4. Urocortins and heart failure
Given the potent vasorelaxant and inotropic effects of the
urocortins, interest has grown in their role in the pathophysiology
and potential therapeutic utility in the treatment of heart failure. A
number of studies have demonstrated increased concentrations of
urocortin 1 in cardiac tissue [49,50] and plasma [25,51,52] in
experimental and clinical heart failure. Nishkimi et al. [49]
demonstrated up-regulation of expression of urocortin 1 mRNA
in left ventricular hypertrophy. They also demonstrated increased
urocortin 1 immunoreactivity in the failing heart. This has been
cited as possible evidence that urocortins play a role in the
pathophysiology of cardiac hypertrophy and heart failure (Fig. 3).
4.1. Animal models
Pre-clinical studies of heart failure have previously examined
the roles of urocortins 1 and 2 whilst urocortin 3 remains less well
characterized. The beneficial cardiovascular and neurohumoral
responses of urocortins are preserved, and may be augmented in
the presence of heart failure.
Intravenous infusion of urocortin 1 in an ovine model of heart
failure attenuates the hemodynamic deterioration and harmful
neurohormonal activation associated with heart failure [53]. These
hormones include renin, angiotensin II, aldosterone, endothelin-1,
vasopressin and catecholamines that, along with sympathetic
nervous system activation, combine to exert the hemodynamic
and endocrine hallmarks of heart failure. Furthermore, in this
model, urocortin 1 also protected renal function. The preservation
of cardiac output with urocortin 1 infusion may be partly due to its
inotropic actions, in addition to its coronary arterial vasodilator
effects and improved cardiac bioenergetics. When infused at the
onset of left ventricular pacing, urocortin 1 infusion restricts the
increase in left atrial pressure and attenuates the reduction in
cardiac output. It also has lusitropic and venodilating effects [54].
These results highlight that treatment with urocortin 1 may be
beneficial in the treatment of heart failure initiated early in the
disease. Of note, these favourable hemodynamics persisted during
prolonged (4 day) infusion of urocortin 1.
In keeping with a favourable hemodynamic profile of urocortin
1 in ovine heart failure, urocortin 2 infusion in MLP (muscle
specific LIM protein) deficient mice, a model of dilated cardiomy-
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opathy, caused a dramatic improvement in cardiac output and left
ventricular function, enhanced cardiac contractility and reduced
systolic load [55]. The enhancement in ejection fraction by
urocortin 2 is partly attributed to reduction in arterial load: this
may prove more notable in the failing heart where there is an
afterload mismatch.
Patients with heart failure are likely to receive any new
treatment in conjunction with conventional treatment. Hence it is
important to ensure that any potential new treatment does not
interact with drugs such as ACE inhibitors and b blockers.
Rademaker et al. [56] assessed the combined effects of captopril
with urocortin 2 in sheep with pacing-induced heart failure.
Combined treatment of urocortin 2 with captopril augmented the
decrease in total peripheral resistance by an additional 20%
compared with either agent alone. One of the potential drawbacks
of treatment with ACE inhibitors is its profound hypotensive effect,
which in the presence of heart failure can compromise blood flow
to vital organs, such as the kidneys. When used in combination
with an ACE inhibitor, urocortin 2 evoked an additional decrease in
peripheral resistance without further reduction in the systolic
blood pressure. This makes the combination of these agents an
attractive tool in the management of heart failure. In addition,
combination of urocortin 2 with captopril improved cardiac
performance, decreased peripheral resistance and ventricular
filling pressures in association with reduction in plasma aldoste-
rone and endothelin-1 concentrations. In a murine acute heart
failure model, pre-treatment with a b-adrenergic receptor (AR)
antagonist, did not affect the inotropic or lusitropic actions of
urocortin 2 in vivo indicating that its actions are independent of b-
adrenergic receptors [55].
The effects of combined treatment with urocortin 2 and
furosemide has been studied recently [57]. When this combination
was administered to sheep with pacing-induced heart failure, it
caused increased diuresis, natriuresis and sustained increase in
creatinine excretion and clearance without additional potassium
elimination. Urocortin 2 alone or in combination increased cardiac
output and contractility whilst furosemide had no effect.
Importantly, the combination of the two drugs, produced reversal
of furosemide-induced increase in plasma renin activity (PRA) and
a greater decrease in plasma aldosterone and vasopressin
concentrations. These beneficial effects of Ucn 2 may be mediated
by an increase in cardiac output and consequently improved renal
perfusion. Indeed, improvements in glomerular filtration rate,
urine volume and sodium excretion have been demonstrated in the
ovine model of heart failure [58]. In addition to increased cardiac
output and renal vasodilatation, other postulated mechanisms
include a direct tubular action of Ucn 2 [11] as well as attenuation
of anti-natriuretic and anti-diuretic factors resulting in increased
diuresis and natriuresis [57].
As already noted, the hemodynamic and humoral responses of
urocortin 3 in experimental heart failure are less well studied than
urocortin 1 or 2. In a study of sheep with pacing-induced heart
failure [20], the hemodynamic responses produced by urocortin 3
were similar to that produced by equivalent doses of urocortin 1 or
2. Urocortin 3 caused a marked dose-dependent improvement in
cardiac output and reduction in peripheral resistance and left atrial
pressure. This was associated with a reduction in mean arterial
pressure, beneficial effect on hormonal responses (attenuation of
vasoconstrictor peptide systems) and improved renal function
(dose-dependent increases in urine volume, sodium and creatinine
excretion). The onset and duration of action was much shorter than
that of urocortin 1 or 2.
4.2. Patients with heart failure
Plasma concentrations of urocortins are elevated in patients
with heart failure. Ng et al. [51] found higher plasma urocortin 1
concentrations in men with heart failure as well as in elderly
patients. There appeared to be an inverse relationship between
plasma urocortin concentrations and New York Heart Association
(NYHA) class. In more severe heart failure, as reflected by NYHA
class III or IV and low left ventricular ejection fraction, plasma
urocortin concentrations appeared to be suppressed, suggesting
that up-regulation of the urocortin system in early heart failure
may be cardioprotective. In keeping with this report, more recent
work by Wright et al. [59] has demonstrated elevated concentra-
tions of plasma urocortin 1 in patients with heart failure with
positive relationships to other circulating neurohormones such as
Table 1
Neurohormonal effects of Urocortins in human and ovine models.
Humans Sheep
Healthy Heart failure Healthy Heart failure
Ucn 1 [17] Ucn 2 [19] Ucn 1 [18] Ucn 2 [62] Ucn2 [58] Ucn 3 [20] Ucn1 Ucn 1 [53,63] Ucn 2 [58] Ucn 3 [20]
cAMP = " = = = = #a"b # ##
cGMP " " =
ACTH "" = " " " "" " " ""
Cortisol "" = " = " "" " " ""
GH =
Ghrelin # = = =
LH/FSH/Prolactin =
TSH =
AVP " = = " "" ## " ##
ANP = = # # # ## ##
BNP = = " " ## ## ##
NT–BNP = = = " #
PRA = "" = = = = # ## ##
Aldosterone = " = # = # ## ##
Adrenaline = # = = # # # ## ##
Nor adrenaline = "" = = = = # # #
Endothelin = = = = = = ## ## ##
Adrenomedullin = = = "
Insulin = = =
Angiotensin II ""
Glucose = =
Fields left blank, no available data; (") increase, (#) decrease, (=) no change.
a Suppression of cAMP by Ucn 1 in LV pacing-induced heart failure in sheep—as an acute effect.
b On prolonged exposure to Ucn 1 cAMP levels were substantially increased with a lag between the onset of hemodynamic and hormonal effects.
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brain natriuretic peptide, adrenomedullin and endothelin-1.
However, in contradiction to findings from Ng et al., Wright’s
group noted an inverse relationship of the level of plasma urocortin
1 to left ventricular ejection fraction, with a linear increase in
plasma concentration of urocortin 1 with increasing NYHA class. It
is possible that this difference in results is attributable to
differences in the immunoassay used or potential effect of CRH-
BP on the assay performance. Further research is, however,
required to establish the relationship between urocortin concen-
trations and NYHA class.
Systemic intravenous infusions of urocortins 1 and 2 have been
administered to a small number of patients with heart failure.
Urocortin 1 infusion increased corticotrophin and cortisol, but
produced no changes in hemodynamic, renal or neurohormonal
parameters [18]. Infusion of urocortin 2 [19] evoked an increase in
cardiac output with peripheral vasodilatation and a small increase in
heart rate. Consistent with findings from the ovine model, systolic
blood pressure fell in patients with congestive cardiac failure but not
in control subjects [60]. It has been hypothesised that, in the
presence of heart failure, the urocortin-induced rise in cardiac
output is insufficient to compensate for the pronounced decrease in
systemic vascular resistance [60]. However, this phenomenon may
otherwise be explained by heightened peripheral sensitivity to the
vasodilator effects of urocortin in the presence of heart failure. In
agreement with this suggestion, administration of a CRH-R2
antagonist increases mean arterial blood pressure in sheep with
heart failure but not in those without [61].
Apart from the positive influences on cardiovascular param-
eters when used in treatment in heart failure, urocortins may serve
as potential biomarkers in identification of early heart failure, in
combination with other biomarkers such as brain natriuretic
peptide [59].
4.3. Neurohormonal effects of urocortins in heart failure
As noted above, urocortins cause a pronounced suppression of
vasoconstrictor hormones in animal models of heart failure, which
further supports its potential therapeutic role. However, studies of
urocortins 1 and 2 in humans have only shown modest changes in
neurohormonal activity. It is important to note that in man, infusion
of urocortin 2 in healthy volunteers and in patients with heart failure
does not alter plasma adrenocorticotropic hormone or cortisol
concentrations. Table 1 summarizes the effects of urocortins on
neurohormonal activity in ovine and human experiments.
5. Future of urocortins
There is increasing evidence that urocortins have several
potential uses in management of cardiovascular conditions such as
hypertension, ischemic heart disease and heart failure. The
immediate and sustained blood pressure lowering effects by
urocortin 2 [37] appears to pose a novel and attractive approach for
antihypertensive treatment. The favourable effects on hemody-
namics, renal and neurohumoral mechanisms have generated
much interest in the use of urocortins in heart failure. In particular,
the positive inotropic effect, combined with its ability to reduce
peripheral arterial resistance, favours use in this group of patients.
In humans, studies to date have largely looked at combined
systemic effects of urocortins. Direct arterial and venous effects of
urocortins have not yet been described in man. It has not been
possible to tease out the relative contribution of urocortin-induced
changes in hemodynamic variables on the augmentation of cardiac
output. Further studies are required to look at potential effects of
long-term administration of these peptides.
In the search for novel treatments for heart failure, the focus is
on urocortins 2 and 3. Indeed, urocortin 1 has no hemodynamic
effects in man and also bears the potential to induce unwanted side
effects by activating CRH-R1 and stimulation of the hypothala-
mus–pituitary axis. However, it may have a role as an early
biomarker of heart failure.
The potential application of urocortins in protection from
ischemia reperfusion injury remains of major interest. Evidence
available from pre-clinical models suggests that urocortins may
have a role in protecting against ischemic reperfusion injury and in
limiting infarct size. This has yet to be evaluated in man.
In conclusion, urocortins are emerging as an important group
of peptidic mediators with important roles in human physiology
and pathophysiology. This review provides an overview of their
effects on the cardiovascular system alone. There are several
other potential applications of this group of peptides, including
roles in appetite suppression, in muscle wasting and central
nervous system disorders to name a few. However, their major
effects in the cardiovascular system implicate them as potential
therapeutic targets in a range of processes, particularly heart
failure.
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Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers
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Background-—Urocortin 2 and urocortin 3 are endogenous peptides with an emerging role in cardiovascular pathophysiology. We
assessed their pharmacodynamic profile and examined the role of the endothelium in mediating their vasomotor effects in vivo in
man.
Methods and Results-—Eighteen healthy male volunteers (23!4 years) were recruited into a series of double-blind, randomized
crossover studies using bilateral forearm venous occlusion plethysmography during intra-arterial urocortin 2 (3.6 to 120 pmol/
min), urocortin 3 (1.2 to 36 nmol/min), and substance P (2 to 8 pmol/min) in the presence or absence of inhibitors of
cyclooxygenase (aspirin), cytochrome P450 metabolites of arachidonic acid (fluconazole), and nitric oxide synthase (L-NMMA).
Urocortins 2 and 3 evoked arterial vasodilatation (P<0.0001) without tachyphylaxis but with a slow onset and offset of action.
Inhibition of nitric oxide synthase with L-NMMA reduced vasodilatation to substance P and urocortin 2 (P≤0.001 for both) but had
little effect on urocortin 3 (P>0.05). Neither aspirin nor fluconazole affected vasodilatation induced by any of the infusions (P>0.05
for all). In the presence of all 3 inhibitors, urocortin 2– and urocortin 3–induced vasodilatation was attenuated (P<0.001 for all) to a
greater extent than with L-NMMA alone (P≤0.005).
Conclusions-—Urocortins 2 and 3 cause potent and prolonged arterial vasodilatation without tachyphylaxis. These vasomotor
responses are at least partly mediated by endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid. The role of
urocortins 2 and 3 remains to be explored in the setting of human heart failure, but they have the potential to have major
therapeutic benefits.
Clinical Trial Registration-—http://www.clinicaltrials.gov//. Unique identifier: NCT01096706 and NCT01296607. ( J Am Heart
Assoc. 2013;2:e004267 doi: 10.1161/JAHA.112.004267)
Key Words: forearm plethysmography • nitric oxide • urocortin 2 • urocortin 3 • vasodilatation
U rocortin peptides, especially urocortins 2 and 3, haveprominent cardiovascular roles and are expressed in the
heart. Although related to corticotrophin-releasing hormone
(CRH), they do not appear to have any role in the regulation of
the hypothalamic-pituitary-adrenal axis.1,2 The effects of CRH
and the urocortins are mediated via 2 G-protein-coupled
receptors: CRH-R1 and CRH-R2. Although CRH-R1 is predom-
inantly expressed in the brain and not in the heart, CRH-R2 is
expressed in the myocardium and vascular smooth muscle.2,3
It is found in human coronary artery microvascular endothelial
cells and has been detected in the endothelium of a variety of
peripheral vascular beds. Urocortin 1 activates both recep-
tors, whereas urocortins 2 and 3 are potent selective agonists
at CRH-R2 but have no effect on CRH-R1.4
The role of urocortins in cardiovascular physiology and
pathophysiology, particularly heart failure, has become increas-
ingly apparent. Intravenous urocortin 1 causes marked vaso-
dilatation in mice via CRH-R2.5,6 Furthermore, mice lacking
CRH-R2 receptors are hypertensive, suggesting a role for
urocortin in the maintenance of basal vascular tone.6 Systemic
administration of urocortin 2 in humans increases cardiac
output, heart rate, and left ventricular function while decreasing
systemic vascular resistance, and these effects may be
amplified in the setting of heart failure.7,8 Urocortin 3 has not
previously been administered to humans, but in an ovinemodel,
both urocortin 2 and urocortin 3 appeared to produce similar
cardiovascular effects.9,10 Although urocortin 2 and urocortin 3
each activate the same receptor, potential differences in their
cardiovascular therapeutic utility may arise from their differing
pharmacokinetic and pharmacodynamic profiles.1
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The cardiovascular responses of urocortins represent an
amalgamation of systemic actions. However, their direct in
vivo arterial vasomotor effects have never been examined in
humans. Moreover, the role of the endothelium in the
mediation of these responses is unknown. Therefore, our
study’s aims were to conduct the first comparative clinical
assessment of local arterial vasomotor effects of urocortins 2
and 3 and to determine the role of the endothelium in the
mediation of these effects.
Methods
All studies were approved by the local research ethics
committee and carried out in accordance with the Declaration
of Helsinki. Written informed consent was obtained from all
participants prior to the study.
Study Participants
Eighteen healthy nonsmoking male volunteers were recruited
into the series of vascular studies. Participants had no
documented medical history, were taking no regular medica-
tions, and tested negative in a urinary toxicology screen (Nova
Test, One Step Diagnostic Rapid Test, CA) for recreational
drugs.
Vascular Studies
All studies were conducted using a double-blind, random-
ized, controlled crossover design. They were performed with
the patient lying supine in a quiet, temperature-controlled
room (22°C to 25°C). Volunteers fasted for 4 hours prior to
the study and refrained from alcohol and caffeine for
24 hours prior to the study. Venous cannulae (17G) were
inserted into large subcutaneous veins in the antecubital
fossae of both arms at the start of the study to facilitate
periodic venous sampling. In view of the theoretical risk of
alterations in body temperature11 and blood glucose
concentrations12 with the first-in-human administration of
urocortin 3, tympanic temperature (Genius 2 Tympanic
Thermometer, Coviden, Boston, MA) and capillary blood
glucose (Advantage Accucheck blood glucometer, USA)
measurements were performed at baseline and after each
dose of urocortin 3. Heart rate and blood pressure were
monitored at regular intervals throughout the study with a
semiautomated oscillometric sphygmomanometer (Omron
705IT).
Subjects underwent brachial artery cannulation in the
nondominant forearm with a 27 standard wire-gauge steel
needle. Forearm blood flow was measured in the infused and
noninfused forearms using bilateral venous occlusion pleth-
ysmography as described previously.13,14
Pharmacodynamic Study
Eight healthy volunteers attended on 4 occasions (protocol 1)
separated by at least 1 week (Figure 1A). After an initial
infusion of normal saline (0.9%) for 20 minutes, volunteers
received discontinuous (protocol 1a) or continuous (protocol
1b) incremental intra-arterial doses of urocortin 2 (3.6 to
120 pmol/min; Neurocrine Biosciences, Inc, San Diego, CA)
or urocortin 3 (1.2 to 36 nmol/min; GenScript, NJ)
interspersed with saline infusions between doses as
appropriate.
Mechanistic Study
An additional 10 healthy volunteers (protocol 2) attended on
each of 5 occasions to receive incremental intra-arterial doses
of urocortin 2 (3.6 to 36 pmol/min), urocortin 3 (1.2 to
12 nmol/min), and substance P (2 to 8 pmol/min; a control
endothelium-dependent vasodilator that evokes endothelial
tissue plasminogen activator release; Clinalfa Basic, Bachem
Distribution Services Gmbh, Germany) (Figure 1B). These
infusions were administered in the presence of (1) a placebo,
(2) oral aspirin 600 mg (cyclo-oxygenase inhibition), (3) a
“nitric oxide clamp” (nitric oxide synthase inhibition; see
below), (4) intra-arterial fluconazole (1.2 lmol/min; inhibition
of cytochrome P450 metabolites of arachidonic acid), and
(5) a combination of oral aspirin, intra-arterial fluconazole, and
the nitric oxide (NO) clamp.
The nitric oxide clamp was used to determine the
contribution of nitric oxide to urocortin-induced vasodilata-
tion. Following baseline saline infusion, the nitric oxide
synthase inhibitor L-N(G)-monomethyl arginine citrate
(L-NMMA; 8 lmol/min; Clinalfa Basic, Bachem Distribution
Services Gmbh, Germany) was infused intra-arterially. To
compensate for L-NMMA-induced basal vasoconstriction,
forearm blood flow was returned to baseline using a titrated
dose of the exogenous nitric oxide donor sodium nitroprus-
side (SNP; 90 to 1200 ng/min; Hospira Inc, Lake Forest, IL).
Once baseline blood flow had been restored, this dose of SNP
was coinfused with L-NMMA and continued throughout the
study. This arrangement allows a constant “clamped” delivery
of exogenous nitric oxide while endogenous nitric oxide
synthase activity is abolished.
The order of urocortin 2, urocortin 3, and substance P
infusions was randomized between subjects but kept con-
stant for all visits of each individual subject. The order of
infusion of inhibitors was also randomized in a double-blind
manner.
Venous Sampling
Blood sampling was carried out at baseline for the assess-
ment of full blood count, liver and renal function tests,
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Figure 1. Schematic representation of study protocols. A, Protocol 1—incremental intra-arterial doses of urocortin 2 (Ucn 2; 3.6 to 120 pmol/
min) and urocortin 3 (Ucn 3; 1.2 to 36 nmol/min) in the presence (protocol 1a) and absence (protocol 1b) of saline washout. B, Protocol 2—
incremental intra-arterial infusions of Ucn 2 (3.6 to 36 pmol/min), Ucn 3 (1.2 to 12 nmol/min), and substance P (sub P; 2 to 8 pmol/min) in the
presence of (1) saline placebo, (2) oral aspirin, (3) “nitric oxide” clamp, (4) intra-arterial fluconazole, and (5) a combination of oral aspirin,
fluconazole, and nitric oxide clamp. L-NMMA indicates L-N(G)-monomethyl arginine citrate.
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cholesterol, and blood glucose levels. Analysis was performed
by the local clinical biochemistry and hematology reference
laboratories.
Data Analysis and Statistics
Forearm blood flow data were analyzed as described previ-
ously.13 A normal distribution of the data was demonstrated
using the D’Agostino & Pearson omnibus normality test.
All variables are reported as mean!SEM using repeated-
measures analysis of variance (ANOVA) with post hoc
Bonferroni corrections and a 2-tailed Student t test as
appropriate (Graph-Pad Prism, GraphPad Software, San Diego,
CA). Significance was taken as 2-sided P<0.05.
Results
Study Participants
All volunteers were young healthy men (23!4 years). Both
urocortin 2 and urocortin 3 produced marked localized
flushing in the infused arm along with facial flushing at the
highest doses. Volunteers also experienced heightened
awareness of their heartbeat during and immediately after
the highest dose of urocortin 3 (36 nmol/min). All symptoms
were self-limiting, well tolerated, and short-lived. Substance P
also induced localized flushing of the infused forearm, which
was self-limiting. There were no clinically significant changes
in the standard hematological and biochemical analytes
including full blood count, blood glucose, cholesterol, and
renal and hepatic function throughout the study (data on file).
Capillary blood glucose and body temperature (tympanic)
remained unchanged during all doses of urocortin 3 (data on
file).
Systolic blood pressure and noninfused forearm blood flow
remained unchanged at all doses with all 3 peptides across
both protocols. However, at the highest infused dose of
urocortin 3 (36 nmol/min), there was a sinus tachycardia
(+22!2 beats/min; ANOVA, P<0.0001) with an associated
drop in diastolic blood pressure ("8.5!0.8 mm Hg; ANOVA
P=0.004; Figure 2) that was not seen with either substance P
or urocortin 2 infusions.
Pharmacodynamic Effects of Urocortins 2 and 3
Both urocortin 2 and urocortin 3 evoked dose-dependent
arterial vasodilatation in the infused arm (2-way ANOVA,
P<0.0001) (Figure 3).
Maximal vasodilatation with urocortin 2 was apparent
#10 minutes after cessation of the 120 pmol/min infusion
(paired Student t test, Ucn 2 120 pmol/min versus +10-
minute washout; P=0.04), and thereafter the blood flow
gradually returned toward baseline. This was in contrast to the
effect seen with urocortin 3, for which the maximum
vasodilatory response was immediate (Figure 4A). The offset
of vasodilatation was prolonged with both peptides, although
urocortin 2 took longer than urocortin 3 to return to baseline
(Figure 4A).
The vasodilator effects of both peptides appeared to be
reproducible within a day, with no evidence of tachyphylaxis
(2-way ANOVA, P>0.05 for all; Figure 4B).
Endogenous Fibrinolytic Factors
Preliminary data showed no effect of urocortin 2 or urocortin
3 on endothelial release of tissue plasminogen activator and
plasminogen activator inhibitor-1 (data on file).
Mechanism of Vasodilatation
Baseline forearm arterial blood flow was unaffected by oral
aspirin or intra-arterial fluconazole, and the coinfusion of SNP
restored baseline blood flow during L-NMMA administration
(2-way ANOVA, P>0.05 for all). Inhibition of nitric oxide
synthase reduced arterial vasodilatation to substance P and
urocortin 2 (2-way ANOVA, P≤0.001 for both) but had no
Figure 2. Hemodynamic responses to intra-arterial infusion of
urocortin 2 (Ucn 2; 3.6 to 120 pmol/min) and urocortin 3 (Ucn 3; 1.2
to 36 nmol/min). At a dose of 36 nmol/min, Ucn 3 evoked transient
tachycardia associated with a drop in diastolic blood pressure. Open
symbols, Ucn 2; closed symbols, Ucn 3; circle, heart rate; square,
systolic blood pressure (BP); triangle, diastolic BP; ***P<0.0001;
**P=0.004; dose 1=3.6 pmol/min Ucn 2 or 1.2 nmol/min Ucn 3;
dose 2=12 pmol/min Ucn 2 or 3.6 nmol/min Ucn 3; dose 3=36
pmol/min Ucn 2 or 12 nmol/min Ucn 3; dose 4=120 pmol/min
Ucn 2 or 36 nmol/min Ucn 3; bpm indicates beats per minute.
DOI: 10.1161/JAHA.112.004267 Journal of the American Heart Association 4
Urocortins 2 and 3 in Healthy Volunteers Venkatasubramanian et al
 by guest on April 13, 2016http://jaha.ahajournals.org/Downloaded from 
apparent effect on urocortin 3–induced vasodilatation (2-way
ANOVA, P=0.36). Neither inhibition of cyclo-oxygenase with
aspirin nor cytochrome P450 metabolites of arachidonic acid
with fluconazole affected the vasodilatation induced by the
urocortins or substance P (2-way ANOVA, P>0.05 for all; data
on file). In the presence of all 3 inhibitors, substance P–,
urocortin 2–, and urocortin 3–induced vasodilatation was
further attenuated (2-way ANOVA, P<0.001 for all) but
not completely abolished. Combined inhibition of cyclo-
oxygenase, nitric oxide synthase, and cytochrome P450
metabolites of arachidonic acid produced a greater reduction
in vasodilatation than the nitric oxide clamp alone (2-way
ANOVA, P≤0.005 for urocortins 2 and 3; Figure 5).
Discussion
This study represents the first administration in humans of
urocortin 3 and demonstrates that both urocortin 2 and
urocortin 3 directly evoke potent and prolonged arterial
vasodilatation that is, at least in part, mediated by the
endothelium. These findings are of direct relevance not only
to our understanding of human cardiovascular physiology but
also inform the development of therapies targeting the
urocortin system for the treatment of conditions such as
heart failure.
The forearm arterial vasodilator effects of urocortin 2 and
urocortin 3 are consistent with data from in vitro3,15–18 and
preclinical19,20 animal studies. However, in contrast with
existing preclinical data, we observed a more marked
difference in potency between the 2 peptides. Although
preclinical studies have suggested urocortin 2 is 10-fold more
potent,21,22 Wiley et al3 showed equipotency of urocortins 2
and 3 in isolated human internal mammary arterial segments.
In contrast, here we observed that a 300-fold-higher dose of
urocortin 3 was required to evoke comparable vasomotor
effects in human forearm arterial circulation. This discrepancy
underlines the importance of a direct head-to-head assess-
ment in vivo in humans, without which the extrapolation of
preclinical data may be deceptive.
Urocortins 2 and 3 are specific agonists at the
G-protein-coupled CRH-R2 receptors, mediating their effects
through a cascade of intracellular signaling pathways includ-
ing adenyl cyclase, cyclic adenosine monophosphate,23,24 and
mitogen-activated protein kinases.25 Other well-characterized
G-protein-coupled receptor agonists such as bradykinin,26,27
substance P,28 and protease activated receptor type 1
activating peptide29,30 evoke vasodilatation with rapid onset
and offset in human forearm arterial circulation. Unlike these
agonists, the maximal vasodilator effect evoked by urocortin 2
in this study was apparent !10 minutes following completion
of the highest dose (protocol 1a). In addition to a late maximal
response with urocortin 2, we also observed a prolonged
offset. Even 100 minutes post–urocortin 2 administration,
infused forearm blood flow remained elevated. Although
not as lengthy as the effect evoked by urocortin 2, urocortin
3–evoked vasodilatation was also prolonged and took 1 hour
for blood flow to return to baseline after discontinuation of the
infusion. This prolonged offset of effect is unusual for
G-protein-coupled receptor agonists, although a similar time
course has been observed in response to apelin31 and
vasopressin,32 and is thought to be the result of prolonged
receptor occupancy. In vitro studies by Hoare et al33 have
demonstrated differing affinities of urocortin 2 and urocortin 3
to the CRF-R2 receptor determined by the affinity of the
Figure 3. Forearm arterial blood flow responses to increasing doses of urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3). Circle, infused forearm blood
flow; square, noninfused forearm blood flow. P<0.0001 at all doses.
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extracellular domains of the CRF receptors to these agonists.
It remains to be established whether urocortin 2 induces
receptor transformation, thereby promoting prolonged binding
to CRH-R2 and a delayed maximal response. However, when
assessed in isolation, it is clear that the direct vasomotor
effects of urocortin 2 and urocortin 3 are more prolonged than
previously reported.
The vasodilator effects of both peptides showed good
within-day reproducibility without evidence of tachyphylaxis.
These are important properties, especially for potential
applications in extended or chronic therapies in which
predictable and reproducible pharmacologic and hemodynam-
ic effects are needed.
Several mechanisms have been proposed to explain the
mechanistic pathways of urocortin-mediated vasorelaxation.
Studies to date have suggested that the mechanism involved
may depend on the species or vascular bed in question. In
rats, both endothelium-dependent17,34 and -independent
components were implicated.35 Grossini et al36 demonstrated
that urocortin 2–mediated vasorelaxation in the coronary
arteries of anaesthetized pigs was mediated by nitric oxide.
However, urocortin-mediated vasodilatation appeared to be
independent of endothelial integrity in isolated human coro-
nary and internal mammary artery segments.3,16 In the
current study, the NO clamp appeared to cause modest
inhibition of urocortin 2–mediated vasodilatation and
Figure 4. Pharmacodynamics of urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3). A, Onset and offset of vasodilatory effect of Ucn 2 (left) and Ucn 3
(right) after infusion of highest dose. B, Within-day reproducibility of Ucn 2 (left) and Ucn 3 (right); P=nonsignificant, first dose response vs second
dose response; Ucn 2 and Ucn 3. Closed circle: first dose response; open circle, second dose response.
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appeared to be marginally more pronounced with urocortin 2
compared with urocortin 3. Inhibition of cytochrome P450
metabolites of arachidonic acid with fluconazole alone did not
have an appreciable effect on urocortin-mediated vasodilata-
tion, but its addition enhanced the inhibitory effect of the NO
clamp. This suggests that endogenous nitric oxide and
cytochrome P450 metabolites of arachidonic acid may have
a close interrelationship and can compensate for one another
to maintain vascular tone. A similar effect has previously been
described for endothelium-derived hyperpolarizing factor
(EDHF), whereby its relative importance increases in the face
of impaired NO bioavailability under conditions of oxidative
stress. Although urocortin 2– and urocortin 3–mediated
vasodilatation was inhibited by the combination of all 3
inhibitors, it was not abolished, and a substantial degree of
vasomotor activity remained. We cannot exclude a contribu-
tion from other endothelial pathways such as residual
“fluconazole-insensitive” EDHF, although the results do sug-
gest a substantial contribution from direct smooth muscle
activation. Although the role of the endothelium is substantial,
a large contribution from endothelium-independent vasodila-
tor mechanisms may be seen as an advantage in the potential
therapeutic applications of CRH-R2 agonism. Arguably, this
would allow a more predictable response from the manipu-
lation of urocortin (2 or 3) as a therapy for cardiovascular
conditions, the vast majority of which would be expected to
be associated with impaired endothelial homeostatic mech-
anisms but preserved smooth muscle activity.
This study was designed to assess locally active, subsys-
temic doses of urocortins 2 and 3 in forearm arterial
vasculature. Indeed, the forearm venous occlusion plethys-
mography model allows these local effects to be studied at
doses 10- to 100-fold lower than that usually expected or
required to elicit a systemic response. It would appear,
however, that there was a degree of systemic overspill
associated with the top dose of urocortin 3 tested. The
observed decrease in diastolic blood pressure and increase in
heart rate observed during and after the infusion of the top
dose of urocortin 3 is notable, particularly as it occurred in the
absence of any change in blood flow in the contralateral
noninfused forearm. Usually, in the case of systemic overspill,
a corresponding change in the “control” noninfused arm
would be observed,28 but this was not the case with the
infusion of the dose of urocortin 3. We therefore hypothesize
that the hypotensive effect observed reflects vasodilatation in
another, more sensitive vascular bed, such as splanchnic
circulation, with consequent reflex tachycardia. Absence of a
similar hemodynamic response to the highest dose of
urocortin 2 may be the result of lower subsystemic doses of
the less potent peptide urocortin subtype or, conceivably, a
differential in the relative sensitivity of splanchnic and forearm
arterial circulation to urocortin 2. However, systemic doses up
to 100 lg of urocortin 2 have been shown to increase heart
rate and decrease diastolic blood pressures in healthy adults.7
Study Limitations
The size of our study population was relatively small.
However, we have previously described the influence of a
range of factors on blood flow in forearm vasculature using
sample sizes of ≤12 subjects28–31,37–39 As with most other
physiological studies, we have not performed multiple testing
correction for the data obtained.
We studied the changes in forearm blood flow during brief
local intrabrachial infusions of urocortins 2 and 3. The
apparent differences between urocortin 2 and urocortin 3
observed in our study may reflect, in part, differences
between the 2 peptides in the tissue exposure achieved.
Figure 5. Vasomotor effects of inhibition of endothelial nitric oxide synthase, cycloxygenase, and cytochrome P450 metabolites of arachidonic
acid on urocortin 2–, urocortin 3–, and substance P–mediated vasodilatation. Open circle, placebo; closed circle, nitric oxide clamp; closed
triangle, combined aspirin (600 mg), nitric oxide clamp, and fluconazole (1.2 lmol/min).
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We do not as yet know the effects of prolonged infusions
of these peptides. Moreover, the effects of urocortins 2 and 3
in patients with heart failure remain to be explored. Although
there is good concordance between the vasomotor responses
observed in the forearm resistance vessels and other vascular
beds,40 further studies will be required to explore their
systemic effects in health and disease in humans.
Conclusions
We have demonstrated that urocortin 2 and urocortin 3 evoke
potent prolonged arterial vasodilatation and that their effects
are at least partly dependent on endothelial nitric oxide and
cytochrome P450 metabolites of arachidonic acid. These data
provide important insights into human cardiovascular physi-
ology, and they will inform the development of further
therapies directed toward the urocortin pathway. The in vivo
role of this endogenous peptide system in patients with heart
failure and the role of CRH-R2 in human health and disease
remain to be explored.
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Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in
Otherwise Healthy Cigarette Smokers
Sowmya Venkatasubramanian, MD; Radzi Mohd Noh, MD; Shruti Daga, MD, PhD; Jeremy P. Langrish, MD, PhD; Nikhil V. Joshi, MD, PhD;
Nicholas L. Mills, MD, PhD; Ethan Hoffmann; Eric W. Jacobson, MD; George P. Vlasuk, PhD; Brian R. Waterhouse, MS; Ninian N. Lang, MD,
PhD; David E. Newby, PhD, MD
Background-—We examined the effect of the oral SIRT1 activator SRT2104 on cardiovascular function in otherwise healthy
cigarette smokers.
Methods and Results-—Twenty-four otherwise healthy cigarette smokers participated in a randomized double-blind, placebo-
controlled crossover trial and received 28 days of oral SRT2104 (2.0 g/day) or matched placebo. Plasma SRT2104 concentrations,
serum lipid profile, plasma fibrinolytic factors, and markers of platelet and monocyte activation were measured at baseline and at
the end of each treatment period together with an assessment of forearm blood flow during intra-arterial bradykinin, acetylcholine,
and sodium nitroprusside infusions. Three hours postdose, mean plasma SRT2104 concentration was 1328!748 ng/mL after 28
days of active treatment. Compared with placebo, serum lipid profile improved during SRT2104 administration, with reductions in
serum total cholesterol ("11.6!20 versus 6!21 mg/dL), low-density lipoprotein cholesterol ("10!17 versus 3!21 mg/dL), and
triglyceride ("39.8!77 versus 13.3!57 mg/dL) concentrations (P<0.05 for all). All vasodilators produced a dose-dependent
increase in blood flow (P<0.0001) that was similar during each treatment period (P>0.05 for all). No significant differences in
fibrinolytic or blood flow parameters were observed between placebo and SRT2014.
Conclusions-—SRT2104 appears to be safe and well tolerated and associated with an improved lipid profile without demonstrable
differences in vascular or platelet function in otherwise healthy cigarette smokers.
Clinical Trial Registration-—http://www.clinicaltrials.gov. Unique identifier: NCT01031108. ( J Am Heart Assoc. 2013;2:
e000042 doi: 10.1161/JAHA.113.000042)
Key Words: cigarette smokers • endothelium • forearm plethysmography • platelet activation • SIRT1 • sirtuins • vascular
O riginally identified in yeast, sirtuins represent a class ofhighly conserved nicotinamide adenine dinucleotide
(NAD)–dependent histone deacetylases that have 7 identified
members in mammalian species.1,2 They have been impli-
cated in the beneficial effects of calorie restriction on
longevity in several species and are promising drug targets
for a variety of diseases of aging.3 Sirtuin (silent mating type
information regulation 2 homolog) 1 (SIRT1) is the best-known
member of this class of proteins and is expressed broadly in
multiple tissues and highly expressed in the vascular endo-
thelium.4 SIRT1 inhibition is associated with vascular dys-
function and arterial thrombosis5 as well as alterations in
fibrinolysis.6 Conversely, SIRT1 activation is associated with
improved endothelial function,7 enhanced lipid metabolism,8
and inhibition of atherogenesis.9
Smoking tobacco remains one of the most important and
consistent modifiable risk factors for coronary heart disease
and is associated with an up to 7-fold increased risk of
nonfatal myocardial infarction.10 It is associated with both
accelerated atherosclerosis11 and a propensity for acute
coronary thrombosis.12,13 This is mediated through a variety
of mechanisms including alterations in vascular, endothelial,
fibrinolytic, and platelet function.14–17 The precise cellular
mechanism for these effects is as yet unknown, but cigarette
smoke is associated with oxidative stress, endothelial nitric
oxide synthase acetylation, and increased endothelial cell
senescence that has been attributed to reduced SIRT1 levels.4
To date, there have been few clinical studies to assess the
effect of SIRT1 activation in vivo in humans. Therefore, the
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aim of the present study was to examine the in vivo effects of
a novel oral SIRT1 activator, SRT2104, on the lipid profile and
vascular, endothelial, and platelet function in otherwise
healthy cigarette smokers. We hypothesized that SIRT1
activation could improve the cardiovascular risk profile and
reverse or improve the vascular and endothelial dysfunction
associated with cigarette smoking.
Methods
The studywas approved by the Research Ethics Committee, was
given Clinical Trial Authorization by the Medicines and Health-
care products Regulatory Authority (MHRA), and carried out at
theMHRA Phase 1 accredited Wellcome Trust Clinical Research
Facility at the Royal Infirmary of Edinburgh, United Kingdom,
between June 2010 and September 2011. Written informed
consent was obtained from each volunteer, and the study was
carried out in accordance with the Declaration of Helsinki.
Study Participants
Twenty-four otherwise healthy male and female volunteers
aged between 18 and 70 years who smoked ≥10 cigarettes
daily for at least 1 year were eligible for the study. Exclusion
criteria included the presence of significant comorbidities,
chronic illness, renal or liver impairment, history of gastroin-
testinal diseases or surgeries influencing drug absorption,
history of alcoholism, history of neoplastic disease within the
last 5 years, a positive urinary test for recreational drugs,
pregnancy, and participation in other clinical trials or blood
donation within the last 3 months. Eligibility of participants
including absence of relevant medical history was confirmed
through a standardized form completed by the registered
general practitioners after informed consent. Tests for
pregnancy (serum human chorionic gonadotrophin [HCG]
concentrations at screening and urinary HCG concentrations
at study visits) were conducted on all female participants of
child-bearing potential.
Study Design
This was a prospective double-blind, randomized, placebo-
controlled crossover study (1:1 SRT2104:placebo). Subjects
were randomized to receive 2.0 g daily of oral SRT2104 or
matched placebo (Sirtris Pharmaceuticals Inc) for a 28-day
period, followed by crossover to the alternate study arm for
another 28 days, giving a total dosing duration of 56 days. An
end-of-study visit was conducted on day 70, with a phone call
follow-up on day 86. Assessment of drug safety, tolerability,
and efficacy on vascular function was carried out at baseline
and during and at the end of each treatment period (Figure 1).
Vascular Studies
Vascular studies were undertaken before and at the end of
each 28-day trial period. All studies were performed with the
patient lying supine in a quiet temperature-controlled (22°C to
25°C) room. Participants were fasted and asked to refrain
from smoking for 10 hours before the study and to avoid
caffeine and alcohol for 24 hours before the study. Venous
Figure 1. Study design: schematic representation of study design. PK indicates pharmacokinetic; SCR, screening.
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cannulas (17G) were inserted into large subcutaneous veins in
the antecubital fossae of both arms at the start of the study to
facilitate periodic venous sampling. Supine heart rate and
blood pressure were monitored at intervals throughout the
study using a semiautomated noninvasive oscillometric
sphygmomanometer (Omron 705 IT).
Forearm Venous Occlusion Plethysmography
Forearm blood flow was measured in the infused and
noninfused forearms using forearm venous occlusion plethys-
mography as described previously.17 Subjects underwent
brachial artery cannulation in the nondominant forearm with
a 27 standard-wire-gauge steel needle. After a 20-minute
baseline infusion with 0.9% saline, incremental intra-arterial
doses of bradykinin (American Peptide Co) at 100, 300, and
1000 pmol/min (an endothelium-dependent vasodilator that
evokes tissue plasminogen activator [t-PA] release); acetyl-
choline (Chem. Pharm Fabrik GmBH) at 5, 10, and 20 lg/min
(an endothelium-dependent vasodilator that does not evoke
t-PA release); and sodium nitroprusside (Hospira Inc) at 2, 4,
and 8 lg/min (an endothelium-independent vasodilator that
does not evoke t-PA release) were infused for 6 minutes at
each dose, with a 30-minute 0.9% saline washout infusion
between drugs. The order of drugs was randomized between
subjects but kept constant for each subject across the 3 visits.
Blood Sampling
Paired venous blood samples were obtained from each
forearm before and during the infusion of intra-arterial
bradykinin. Samples were collected into acidified buffered
citrate (Stabilyte; Trinity Biotech Plc) and citrate (BD Vacu-
tainer; BD UK Ltd) for determination of t-PA and plasminogen-
activator inhibitor type 1 (PAI-1) concentrations, respectively.
Samples were placed on ice before centrifuging at 2000g for
30 minutes at 4°C. Platelet-free plasma was decanted and
stored at !80°C before further analysis. Venous blood
samples were collected into EDTA at the beginning and end
of the vascular study to determine hematocrit.
Plasma t-PA antigen and activity (t-PA Combi Actibind t-PA
ELISA kit; Technoclone, Vienna, Austria) and PAI-1 antigen and
activity (Elitest PAI-1 Antigen and Zymutest PAI-1 Activity;
Hyphen Biomed) concentrations were determined by enzyme-
linked immunosorbent assays (ELISAs).
Platelet and Monocyte Activation
Flow-cytometric measurements of platelet–monocyte
aggregation (PMA) and platelet surface expression of
P-selectin and monocyte CD11b expression (Mac-1/CD11b)
were performed at baseline and at the end of each treatment
period as described previously.16,18,19 Briefly, peripheral
venous blood was drawn from a large antecubital vein and
anticoagulated with the direct thrombin inhibitor D-phenylal-
anine-L-arginine chloromethyl ketone (75 lmol/L PPACK;
Cambridge Biosciences) and immunolabeled within 5 minutes
of phlebotomy for subsequent flow cytometric analysis.
Directly conjugated monoclonal antibodies were obtained
from DakoCytomation and Serotec. Samples were stained
with the following conjugated monoclonal antibodies:
phycoerythrin (PE)–conjugated CD14, PE-conjugated CD62p,
PE-conjugated CD11b, fluorescein isothiocyanate (FITC)–
conjugated 42a, and FITC-conjugated CD14 and appropriate
control isotypes. Once stained, samples were incubated for
20 minutes at room temperature before being fixed with
FACS-Lyse (Becton-Dickinson). All samples were analyzed
using a FACS Calibur flow cytometer using CellQuestPro
software (Becton-Dickinson).
Venous blood was collected in citrate at baseline and after
each dosing period to assess plasma-soluble CD40 ligand
(sCD40L) concentrations. Blood was centrifuged at 1500g for
15 minutes at 4°C, and plasma was decanted and stored at
!80°C for further analysis by ELISA (Bender Medsystems).
Safety and Pharmacokinetic Analyses
Venous blood samples were collected biweekly to measure
hematological and biochemical analytes including full blood
count, coagulation profile, liver and renal function, creatine
phosphokinase, lactate dehydrogenase, lipid profile°C and
free fatty acids. Analyses were conducted by the regional
clinical hematology and biochemistry reference laboratories
using an automated hematology analyzer (XE2100, Sysmex
Corporation and ACL TOP, Instrumentation Laboratory), an
automated chemistry analyzer using colorimetric, kinetic and
enzymatic ultraviolet and color assays (AU2700/AU640
analyzers, Beckman & Coulter), ion-selective electrodes
(sodium, potassium, and chloride assays) and 2-point and
multiple-point rate assays (Ortho Clinical Vitros 250 analyzer).
Venous blood samples were taken into prelabeled heparin-
ized sodium tubes for pharmacokinetic assessment of plasma
SRT2104 concentrations (Simbec Laboratories Limited). Serial
blood samples were collected on days 1, 28, and 56
immediately before (0 minutes) and 15, 30, 60, 120, 180,
240, 480, 720 and 1440 minutes following study medication.
Plasma was separated by centrifugation of whole blood at
1500g at 4°C for 15 minutes, and decanted and stored at
!80°C until analyzed.
Methodology of SRT2104 Analysis
Plasma concentrations of SRT2104 were measured using
liquid chromatography with tandem mass spectrometry
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detection in positive ion mode. High-pressure liquid chroma-
tography was performed using Betasil silica–100 columns
using a Phenomenex C18 guard column.22
Data Analysis and Statistics
Plethysmographic datawere analyzed asdescribed previously.21
Estimated net release of t-PA and PAI-1 antigen and activity was
defined as the product of forearm plasma flow (based on blood
flow and hematocrit) and the difference in plasma antigen (or
activity) concentrations between the 2 forearms. On the basis of
previous power calculations,20 a sample size of 20 gives 80%
power to detect a change in net t-PA antigen release of 27.0 ng/
100 mL of tissue per minute, assuming a standard deviation of
40.0 and a 2-sided P<0.05 (paired t test). To account for a 20%
dropout rate, we recruited 24 subjects.
Fibrinolysis and forearm blood flow data were analyzed
using a linear mixed-model repeated-measures analysis of
covariance. Treatment differences were investigated in a
model adjusting for period, treatment by period, vasodilator
dose, treatment by vasodilator dose, and vasodilator dose by
period using SAS for UNIX (version 9.1.3 or higher; SAS
Institute). Values for these parameters are expressed as model
adjusted (least square means) and 95% confidence intervals.
Between-day reproducibility of forearm venous occlusion
plethysmography data was assessed using the Bland–Altman
method, and coefficient of reproducibility was determined for
95% confidence intervals using the Student t distribution. All
other values are expressed as mean!SD.
Results
Study Participants
Volunteers had a mean age of 38!13 years (median,
37 years) and relatively equal sex distribution (58% male)
and were normotensive without any significant coexisting
medical conditions. Volunteers had a body mass index of
25!4 kg/m2 and a mean cigarette consumption of 17!6
cigarettes per day over 21!14 years. The mean urinary
cotinine concentration at screening was 1352!950 ng/mL.
All 24 volunteers completed all study visits. Before drug
administration, 1 subject was withdrawn from the study
because of problems with venous access and was replaced.
Pharmacokinetics, Tolerability, and Safety
Three hours postdose, mean plasma SRT2104 concentration
was 1328!748 ng/mL after 28 days of active treatment
(Figure 2). The median plasma SRT2104 concentration after
28 days of treatment was 366 ng/mL (IQR, 940 ng/mL). The
median time at which the maximum plasma concentration
was observed (Tmax) on day 28 of dosing was 3.05 hours,
which coincided well with study measurements performed on
those days (2 to 4 hours postdose). The geometric mean area
under the curve (AUC0-s) was 6412 h " ng/mL. Consistent
with previous observations,22 there was substantial intersub-
ject variability in exposure during this study.
All subjects tolerated study medication well. Commonly
reported side effects included headache (25%) and rhinitis,
nasopharyngitis, and respiratory tract symptoms (17%)
(Table 1). The reported adverse events were mild in intensity
and resolved without any intervention or sequelae. There were
no meaningful differences in the number of events between
active treatment and placebo. There was only 1 reported
serious adverse event in the study (SRT2104 arm): a traumatic
facial bone fracture that was considered unrelated to SRT2104.
Blood pressure and heart rate remained unchanged
throughout the study. There were no effects on cardiac rhythm
or the 12-lead electrocardiogram, and specifically there were
no effects on the corrected or uncorrected QT intervals. There
were no clinically significant adverse effects involving any of
the clinical hematological or biochemical analytes.
Lipid Profile
Treatment with SRT2104 had a favorable effect on the lipid
profile. A statistically significant period effect was observed in
the analysis of total and low-density lipoprotein (LDL)
cholesterol concentrations. Baseline values were higher in
subjects receiving placebo in the first period. Regardless of
treatment arm, the level of change from baseline was greater
in period 2 for total and LDL cholesterol and less in period 2
for triglycerides. Adjusted summaries combined over period
are presented in Table 2. There was a reduction in total and
LDL cholesterol as well as triglyceride concentrations. There
Figure 2. Pharmacokinetics: mean plasma concentration–time
curve following oral dosing of SRT2104 on day 1 (closed circles)
and day 28 (open circles). Data presented as mean!SD.
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Table 1. List of Adverse and Serious Adverse Events
System Symptom (AE/SAE)
Number of Events
Placebo (n=24) SRT2104 (n=24)
Any event — 18 18
Nervous system disorders Headache 4 6
Paresthesia 0 2
Hypoesthesia 1 2
Carpal tunnel syndrome 0 1
Presyncope 1 1
Burning sensation 0 1
Sciatica 0 1
Respiratory, thoracic, and mediastinal disorders Oropharyngeal pain 1 2
Rhinorrhea 0 1
Gastrointestinal disorders Flatulence 1 0
Mouth ulceration 0 1
Abdominal pain upper 1 0
Hemorrhoids 1 0
Reproductive system and breast disorders Dysmenorrhea 3 1
Musculoskeletal and connective tissue disorders Back pain 2 0
Musculoskeletal chest pain 1 0
Musculoskeletal pain 1 0
Myalgia 0 1
Investigational Blood bilirubin increased 1 1
Creatinine phosphokinase increased 1 0
LDH increased 1 0
AST increased 1 0
General disorders and administration site conditions Influenza-like illness 1 0
Fatigue 1 0
Catheter site pain 0 1
Catheter site rash 1 0
Catheter site–related reaction 1 0
Catheter site swelling 1 0
Edema peripheral 0 1
Pyrexia 0 1
Swelling 0 1
Infections and infestations Nasopharyngitis 0 1
Rhinitis 2 2
Upper respiratory tract infection 1 0
Oral herpes 0 1
Respiratory tract infection 0 1
Injury, poisoning, and procedural complications Contusion 1 0
Excoriation 1 1
Arthropod bite 1 0
Facial bones fracture* 0 1
Laceration 1 0
Continued
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was no effect on high-density lipoprotein concentrations, and
the 7% fall in total cholesterol was attributable to the 11% fall
in LDL cholesterol concentrations.
Vasomotor Function
Noninfused forearm blood flow remained unchanged through-
out all assessment periods, as were the predose measure-
ments of blood flow in the infused arm between visits
(P>0.05). There was a dose-dependent increase in the infused
forearm blood flow with all 3 agonists (acetylcholine,
bradykinin, and sodium nitroprusside) in the presence of
either SRT2104 or placebo (P<0.0001 for all 3 agonists;
Figure 3). There were no significant differences in response
to either endothelium-dependent or -independent vasodilators
in the presence of SRT2104 compared with placebo (brady-
kinin, P=0.1169; acetylcholine, P=0.1683; sodium nitroprus-
side, P=0.9039: placebo versus SRT2104). There were no
differences in forearm vasodilatation between the baseline
and placebo visits of the study for all 3 agonists (P=0.5649,
P=0.4009, and P=0.2908 for bradykinin, acetylcholine, and
sodium nitroprusside, respectively), confirming the good
reproducibility of the measurements (Table 3).
Endogenous Fibrinolysis and Monocyte and
Platelet Activation
There was a dose-dependent increase in bradykinin-evoked
net t-PA antigen and activity release (P<0.0001 for both) in
the infused arm that was unaffected by SRT2104 (P=0.3691
and P=0.1377, placebo versus SRT2104, for net t-PA antigen
and activity, respectively; Table 4). Plasma plasminogen
activator inhibitor-1 (PAI-1) activity decreased with time
during all study visits (P<0.05), consistent with its circadian
variation and t-PA release. Plasma PAI-1 antigen and activity
concentrations were similar in both treatment arms
(P=0.8877 and P=0.6635, placebo versus SRT2104, for
plasma PAI antigen and activity, respectively).
SRT2104 had no effect on markers of in vivo platelet or
monocyte activation (Figure 4).
Discussion
In this randomized, double-blind, placebo-controlled crossover
trial of otherwise healthy cigarette smokers, we have
demonstrated that oral SRT2104 is safe and well tolerated




Placebo (n=24) SRT2104 (n=24)
Skin and subcutaneous tissue Rash 1 0
Metabolism and nutrition disorders Decreased appetite 0 1
Vascular disorders Phlebitis 0 1
Eye disorders Eye pain 1 0
Vision blurred 0 1
Ear and labyrinthine disorders Motion sickness 0 1
Surgical and medical procedures Vasectomy 1 0
*Serious Adverse Event.
AE indicates adverse event; SAE, serious adverse event; LDH, lactate dehydrogenase; AST, aspartate aminotransferase.
Table 2. Effect of SRT2104 on Serum Lipid Concentrations
Placebo (n=22) SRT2104 (n=20)
Total cholesterol (mean!SD), mg/dL
Baseline 174!54 176!50
Day 28/56 180!51 164!47
Change from baseline 6!21 "12!20*
HDL cholesterol, mg/dL
Baseline 46!11 47!10
Day 28/56 50!13 51!16
Change from baseline 3!7 4!7
LDL cholesterol, mg/dL
Baseline 99!41 99!37
Day 28/56 102!37 88!34
Change from baseline 3!21 "10!17*
Triglycerides, mg/dL
Baseline 133!110 140!114
Day 28/56 146!149 100!67
Change from baseline 13!57 "40!77*
*P<0.05.
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein.
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treatment with SRT2104 was associated with an 11% mean
reduction in serum LDL cholesterol concentrations, but
without demonstrable differences in vasomotor function,
endothelial function, or platelet activation assessments
compared with placebo. The favorable effects on lipid profile
suggest that SIRT1 activation may have a beneficial role in
Figure 3. Effect of bradykinin (100, 300, 1000 pmol/min), acetylcholine (5, 10, 20 lg/min), and sodium nitroprusside (2, 4, 8 lg/min) on
absolute forearm blood flow. Blue, placebo; red, SRT2104; closed circle, infused forearm blood flow; open circle, noninfused forearm blood flow.
Data presented as mean!95% confidence interval.
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patients at risk of developing or with established cardiovas-
cular disease.
Elevated serum cholesterol is an established risk factor
for atherosclerosis and coronary heart disease. In general,
coronary heart disease risk is reduced by 2% to 3% for each
1% decrease in total cholesterol concentrations.23 We
observed a 7% mean reduction in serum total cholesterol
and an 11% mean reduction in LDL cholesterol concentra-
tions without affecting serum high-density lipoprotein cho-
lesterol concentrations. The mechanism of this lipid-lowering
effect is not entirely clear but is consistent with observa-
tions associated with SIRT1 activation in animals. Resvera-
trol (3,5,4′-trihydroxy-trans-stilbene) is a naturally occurring
polyphenolic compound that is believed to confer health
benefits through SIRT1 activation.24 Resveratrol has been
found to lower plasma triglycerides and cholesterol
accumulation in guinea pigs25 and to suppress atherogenic
lesion formation in apolipoprotein E–deficient mice.26
Indeed, SRT2104 also lowers triglyceride levels in preclinical
murine models of dyslipidemia, diabetes, and obesity as well
as improving insulin sensitivity and metabolic function in
these animals.27 One mechanism whereby SIRT1 activators
such as SRT2104 could improve lipid profiles may involve a
positive regulatory effect on liver X receptor proteins (LXRs),
nuclear receptors involved in cholesterol and lipid homeo-
stasis. Nuclear receptor LXR is a substrate for SIRT1. Li
and colleagues have shown that SIRT1 deacetylates and
positively regulates this receptor, potentially altering cho-
lesterol transport and metabolism.28 Although the exact
mechanism of the improved lipid profiles seen with SIRT1
activation remains to be determined, our findings would
suggest that SIRT1 activation could provide a therapeutic
adjunct to current lipid-lowering strategies, leading to
improvements in cardiovascular disease pathophysiology
and thus clinical outcomes.
There are currently no published data directly examining
the effects of SIRT1 activation on vasomotor function or
endogenous fibrinolysis in vivo in humans. Despite the several
beneficial effects of SIRT1 activation on endothelial function
observed in preclinical in vitro studies,6,7,29–31 we were unable
to demonstrate improvements in vascular, endothelial, or
platelet function in these otherwise healthy smokers. Why
was this?
Did we use appropriate and sufficiently sensitive
techniques? Forearm venous occlusion plethysmography is a
well-established technique that has been used extensively
over the years to study human vascular physiology and has
been considered a gold standard in the assessment of
vascular function in health and disease.32 Using endothelium-
dependent (bradykinin and acetylcholine) and -independent
(sodium nitroprusside) vasodilators, we observed a dose-
dependent increase in forearm arterial vasodilatation with all
3 agonists. Our results are comparable with those reported in
previously published studies17,33–35 in otherwise healthy
cigarette smokers including impaired t-PA release.15,36,37
Moreover, our data had low variance and were highly
reproducible when we compared the baseline responses with
those obtained during placebo administration. Similarly, flow
cytometric analysis is considered a sensitive gold standard for
measurement of in vivo platelet activation. We have previously
shown that in patients with peripheral arterial disease,
measurements of platelet–monocyte aggregates are
reproducible and consistently reflect other markers of platelet
and monocyte activation.38 In the present study, we again
report comparable levels of platelet–monocyte aggrega-
tion19,39 that were reproducible between visits.
There is a body of published data that confirms a strong
association between cigarette smoking, endothelial dysfunc-
tion, and impaired endogenous fibrinolysis.4,14,17,21,40 We
were interested to see if this vascular and endothelial
dysfunction could be improved or reversed by SIRT1 activa-
tion. There could be numerous explanations why we failed to
achieve improvement with SRT2104 in these parameters in
the current study. One possibility is that the SRT2104
exposure achieved in this study did not lead to adequate or
consistent SIRT1 activation, which would be required to
reverse the vascular and endothelial dysfunction in these
smokers. Unfortunately, there is no current biomarker for
SIRT1 activation or the ability to measure SIRT1 activation
directly in humans. Therefore, we do not have a good
understanding of the pharmacokinetic-pharmacodynamic
relationship between SRT2104 drug exposure and SIRT1
activation. Although we were able to demonstrate improved
lipid profiles, it is unclear whether the same exposure levels
Table 3. Between-Day Repeatability of Forearm Blood Flow
Drug Dose
Mean of Differences
in Forearm Blood Flow





















Between-day reproducibility (baseline vs placebo visit) in absolute forearm blood flow for
bradykinin (100, 300, 1000 pmol/min), acetylcholine (5, 10, 20 lg/min), and sodium
nitroprusside (2, 4, 8 lg/min).
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would also lead to improved vascular and endothelial function.
There are at least 70 known substrates for SIRT1. SRT2104
may differentially deacetylate certain substrates in preference
to others, depending on the precise interaction between
SRT2104 and the substrates as well as the level and activity
of the substrates in a particular disease state. It is also
possible that certain abnormalities may be reversed more
readily than others through SIRT1 activation. Although a 28-
day exposure may be adequate for observing improvement in
lipid profiles, longer treatment may be required to reverse
some of the vascular and endothelial abnormalities. The small
sample size of our study may also be a potential limitation.
SRT2104 is the first selective SIRT1 activator to be studied in
human clinical trials. As the biology of SIRT1 becomes more
established and additional data are gathered from small
exploratory trials such as this one, the optimal approach for
developing SIRT1 activators and identifying disease states
with the greatest therapeutic potential will become better
defined.
In conclusion, we have demonstrated that the oral SIRT1
activator SRT2104 is safe and well tolerated in otherwise
healthy cigarette smokers and provides positive effects on
lipid profiles, but were unable to demonstrate beneficial
effects on vascular, endothelial, or platelet function compared
with placebo.
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Objective: Arterial stiffness increases with age, and is
associated with adverse cardiovascular outcome
including increased mortality. The effect of the oral
small molecule SIRT1 activator, SRT2104, on arterial
stiffness was examined in otherwise healthy cigarette
smokers and participants with type 2 diabetes mellitus.
Methods: 24 otherwise healthy cigarette smokers and
15 people with stable type 2 diabetes were randomised
in a double-blind placebo-controlled crossover trial and
received 28 days of oral SRT2104 (2.0 g/day) or
matched placebo. Blood pressure was measured using
non-invasive oscillatory sphygmomanometry. Pulse
wave analysis and velocity were measured using
applanation tonometry at baseline and the end of each
treatment period. Owing to the small sample size and
similar trends for both groups, data for the two groups
were pooled (post hoc analysis).
Results: Compared to placebo, treatment with
SRT2104 was associated with a significant reduction in
augmentation pressure (p=0.0273) and a trend towards
improvement in the augmentation index and corrected
augmentation index (p>0.05 for both). However, no
changes were observed in pulse wave velocity and time
to wave reflection (p>0.05). Systolic and diastolic blood
pressures remained unchanged throughout the study.
Treatment by cohort interaction was not significant for
any of the pulse wave parameters, suggesting that the
response to SRT2104 in otherwise healthy smokers and
people with diabetes was consistent.
Conclusions: SRT2104 may improve measures of
arterial stiffness in otherwise healthy cigarette smokers
and in participants with type 2 diabetes. Definitive
conclusions are not possible given the small sample
size and exploratory nature of this analysis.
Trial registration number: NCT01031108.
INTRODUCTION
The enzyme sirtuin (silent mating-type infor-
mation regulation 2 homologue) 1 (SIRT1)
belongs to the sirtuin family of nicotinamide
adenine dinucleotide-dependent histone dea-
cetylases and is highly expressed in the vascu-
lar endothelium.1 In addition to other
characteristics, its activation is associated with
improved endothelial function2 and inhib-
ition of atherogenesis.3 Particular interest has
been focused on the potential of therapeutic
SIRT1 activators to act as anti-ageing agents.
Arterial stiffness rises with age and is recog-
nised to be an independent predictor of
KEY QUESTIONS
What is already known about this subject?
▸ Among the seven known sirtuins, SIRT1 has
been identified as the most critical modulator of
vascular function. Animal and laboratory studies
have amply demonstrated its prominent role in
the regulation of vascular homeostasis and dis-
eases. However, little is known about their direct
vascular effects in man.
What does this study add?
▸ The present study has provided evidence that
suggests treatment with the oral SIRT1 activator,
SRT2104, may lead to an improvement in mea-
sures of arterial compliance in otherwise healthy
cigarette smokers and people with type 2 dia-
betes. The exact mechanism of this improved
arterial compliance and the effects of prolonged
treatment with SRT2104 on vascular health
remain to be elucidated.
How might this impact on clinical practice?
▸ Given that aortic stiffness and endothelial function
are key factors in predicting cardiovascular out-
comes, identification of novel pharmacological
means of improving these predictive parameters is
important and highly relevant in populations with
known cardiovascular risk factors.
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cardiovascular risk.4 In particular, elevations in pulse
pressure and aortic stiffness are associated with
increased risk of coronary events and overall mortality.5
Indeed, central aortic stiffness is associated with the
presence of coronary atherosclerosis and ischaemic
heart disease.6
Cigarette smoking and diabetes mellitus are significant
risk factors for the development of cardiovascular
disease. A wealth of data has established a strong correl-
ation between diabetes and cigarette smoke exposure
with increased aortic stiffness, endothelial dysfunction
and cardiovascular risk.7–10 New pharmacological strat-
egies that improve arterial compliance would therefore
be highly relevant to these groups at increased cardiovas-
cular risk.
The aims of the present study were to assess the effect
of the oral SIRT1 activator, SRT2104, on measures of
arterial compliance in otherwise healthy cigarette
smokers and patients with type 2 diabetes. It was
hypothesised that SIRT1 activation in these ‘at risk’
groups could lead to an improvement in arterial compli-
ance and therefore reduce their cardiovascular risk.
METHODS
The study was approved by the Berkshire Research
Ethics Committee, received Clinical Trial Authorisation
from the Medicines and Healthcare products Regulatory
Agency (MHRA, UK), and was conducted at the MHRA
phase I accredited Wellcome Trust Clinical Research
Facility at the Royal Infirmary of Edinburgh, UK
between June 2010 and September 2011 (EudraCT #:
2009-016765-28; Clinical trials identifier: NCT01031108).
Written informed consent was obtained from each vol-
unteer and the study was carried out in accordance with
the declaration of Helsinki.
Study participants
Twenty-four otherwise healthy cigarette smokers and 15
participants with stable type 2 diabetes, aged between 18
and 70 years, were eligible for the study. Healthy cigar-
ette smokers were required to have smoked ≥10 cigar-
ettes daily for at least 1 year. Participants with type 2
diabetes were non-smokers and were selected on the
basis of having a diagnosis of type 2 diabetes mellitus for
at least 6 months prior to inclusion in the study, with no
change in medications having been made for at least the
preceding 3 months, a fasting blood glucose
≤13.9 mmol/L (250 mg/dL) and diabetes control and
complications trial-aligned HbA1c<9% (75 mmol/mol)
on screening. Exclusion criteria included the presence
of significant comorbidities, chronic illness, renal or
liver impairment, history of gastrointestinal diseases or
previous surgical procedures that would influence drug
absorption, history of alcoholism, history of neoplastic
disease within the last 5 years, a positive urinary test for
recreational drugs, pregnancy and participation in other
clinical trials or blood donation within the last
3 months. Patients with type 2 diabetes mellitus on ACE
inhibitors, antiplatelet or anticoagulant therapies were
excluded from the study. Tests for pregnancy (serum
human chorionic gonadotropin (HCG) concentrations
at screening and urinary HCG concentrations at study
visits) were conducted on all female participants of
childbearing potential.
Study design
This was a prospective double-blind randomised
placebo-controlled cross-over study. Participants were
randomised to receive 2.0 g daily of oral SRT2104 or
matched placebo (Sirtris, a GSK company,
Massachusetts, USA) for a 28-day period, followed by
cross-over to the alternate study arm for a further
28 days, giving a total dosing duration of 56 days. An end
of study visit was conducted at day 70 with a telephone
call follow-up on day 86. Measures of arterial stiffness
were undertaken prior to and at the end of each 28-day
trial period. Figure 1 outlines participant enrolment,
intervention allocation, follow-up and data analysis for
both groups.
All studies were performed in a quiet temperature
controlled (22–25°C) room. Participants were fasted and
asked to refrain from smoking for 10 h, and abstain
from caffeine and alcohol for 24 h prior to assessment.
Participants remained supine for at least 30 min before
any recordings were started. Systolic and diastolic blood
pressures were recorded using a non-invasive oscillatory
sphygmomanometer (Omron705 IT, Omron Healthcare
Europe, the Netherlands).
Pulse wave analysis of the radial artery was performed
at the wrist using micromanometer applanation tonome-
try (Millar Instruments, Texas, USA) and the
SphygmoCor system (AtCor Medical, Sydney, Australia)
in accordance with the manufacturer’s recommenda-
tions. Briefly, pulse wave analysis derives an aortic pulse
pressure waveform from the radial artery wave via a
mathematical transfer function. The arterial pressure
waveform is a composite of the forward pressure wave
created by ventricular contraction and a reflected wave
generated by peripheral vascular resistance.11 The aug-
mentation pressure is the pressure difference between
the second and first systolic peaks. The augmentation
index, augmentation pressure as a percentage of the
pulse pressure, is a measure of systemic arterial stiffness
and wave reflection. Corrected augmentation index
represents the augmentation index corrected for heart
rate.12 The time to wave reflection declines with increas-
ing arterial stiffness, and provides a surrogate measure
of aortic pulse wave velocity.13 At least three independ-
ent waveform analyses were obtained from each partici-
pant, with measurements only accepted on meeting
SphygmoCor quality control criteria. Pulse wave velocity
was calculated by measuring the time for the pulse wave
to travel between the carotid and femoral arteries. The
operator performing the analysis was kept constant for
each participant throughout the study.
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Blood sampling
Venous blood samples were collected at fortnightly inter-
vals to measure haematological and biochemical analytes
including full blood count, coagulation profile, liver and
renal function, creatine kinase, lactate dehydrogenase
and lipid profile. Analyses were conducted by the regional
clinical haematology and biochemistry reference lab-
oratories using an automated haematology analyser
(XE2100, Sysmex Corporation ( Japan) and ACL TOP,
Instrumentation Laboratory), an automated chemistry ana-
lyser using colorimetric, kinetic and enzymatic ultraviolet
and colour assays (AU2700/AU640 analysers, Beckman
and Coulter), ion selective electrodes (sodium, potassium
and chloride assays) and two point and multiple point rate
assays (Ortho Clinical Vitros 250 analyser, USA).
Data analysis and statistics
Data were analysed, where appropriate, using repeated
measure analysis of covariance on the change from
baseline for all parameters. Initially, analyses were con-
ducted separately on cohorts. As a result of the small
sample size and similar trends for the two cohorts, these
data were pooled post hoc. Treatment differences were
investigated in a model adjusting for baseline, period,
treatment by period and treatment by cohort using SAS
for UNIX (V.9.1.3 or higher) (SAS Institute, Cary, North
Carolina, USA). Unless stated otherwise, values are
expressed as mean±SD. Tests for treatment effect were
two-sided with a significance level of 0.05.
RESULTS
Baseline characteristics
Participants in the study had a mean age of 45±15 years
and were predominantly male (68%). Participants in the
type 2 diabetes cohort were older (mean age 58±8 years)
when compared with the participants in the otherwise
healthy smokers group (mean age 38±13 years). All par-
ticipants were normotensive with comparable systolic
Figure 1 Consolidated Standards of Reporting Trials flow diagram representing participant enrolment, intervention allocation,
follow-up and data analysis. (A) Recruitment of otherwise healthy cigarette smokers; (B) participants with type 2 diabetes
mellitus.
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and diastolic blood pressures at baseline (table 1). No
clinically significant changes in haematological or bio-
chemical analytes occurred throughout the study.
Biochemical measures of renal function (serum urea,
creatinine and electrolytes) were within normal limits at
baseline and remained unchanged with placebo and
treatment with SRT2104 in both subgroups (table 2).
Blood pressure
Resting systolic and diastolic blood pressures remained
unchanged throughout the study with no significant dif-
ferences between treatment and placebo treatment
periods.
Pulse wave analysis and velocity
In a combined analysis of otherwise healthy cigarette
smokers and participants with type 2 diabetes, a reduc-
tion in the augmentation pressure was observed in parti-
cipants receiving SRT2104 compared with placebo
(mean change from baseline: SRT2104−1.60 (5.304) vs
placebo−0.06 (4.205); p=0.0273) and a trend towards
improvement in the augmentation index (mean change
from baseline in AIx: placebo–0.64 (8.361) vs SRT2104
−3.47 (9.728); p=0.0813) and the corrected augmenta-
tion index (mean change from baseline AIx75: placebo
−2.2−(7.453) vs SRT2104−4.84 (9.299); p=0.0747)
(figure 2A). Pulse wave velocity and time to wave reflec-
tion remained unchanged between placebo and treat-
ment arms (p>0.05 for both parameters; figure 2B). The
effects of SRT2104 administration on measures of arter-
ial compliance were consistent across the two cohorts.
For example, in the SRT2104 arm, mean augmentation
index at 75 bpm was reduced for healthy smokers and
participants with type 2 diabetes (−4.97 vs −4.63,
respectively). Measures of arterial compliance and stiff-
ness for the individual cohorts have been presented in
the online supplementary table S1. A statistical inter-
action between cohort and treatment was not observed
(p>0.05 for all variables tested).
Tolerability and safety
Participants in both study groups (healthy cigarette
smokers and patients with type 2 diabetes) tolerated the
study medication well. There were no meaningful
Figure 1 Continued
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differences in the number of adverse events between
active treatment and placebo. All reported adverse
events were mild in intensity and resolved without any
intervention or sequelae (table 3). Headaches occurred
with nearly equal frequency in the treatment (SRT2104)
group in both cohorts. Participants with type 2 diabetes
appeared to have more frequent gastrointestinal distur-
bances, such as diarrhoea and nausea in comparison
with healthy smokers. Elevated liver enzymes (alanine
transaminase) resulted in withdrawal of one participant
in the placebo period (day 36) of the diabetes group.
There was only one reported serious adverse event in
the study (SRT2104 arm of healthy cigarette smokers) of
traumatic facial bone fracture that was considered unre-
lated to SRT2104.
DISCUSSION
This randomised double-blinded cross-over study
demonstrated for the first time that the oral SIRT1 acti-
vator, SRT2104, may improve arterial compliance in
otherwise healthy cigarette smokers and in people with
type 2 diabetes, without affecting resting measures of
blood pressure.
The assessment of arterial stiffness is increasingly
being used in clinical practice as an independent
measure of cardiovascular risk, including those in high-
risk groups.14 Ageing is associated with an increase in
the stiffness of large elastic arteries induced by structural
alterations in the vascular media such as an increase in
collagen and a decrease in elastin content.15 This
process of biological ageing is accelerated in the pres-
ence of conditions such as diabetes mellitus and hyper-
tension. Semba et al16 and Hofmann et al17 have
demonstrated an association between the presence of
advanced glycation end products and increased arterial
stiffness. Indeed, vascular change induced by cigarette
smoke is considered to be a model of accelerated vascu-
lar ageing. The relationship between tobacco expos-
ure,9 10 18 diabetes7 8 19 20 and increased arterial
stiffness is well established.
Calorie restriction can attenuate age-related arterial
stiffness in animal models through reduced oxidative
stress and altered endothelial nitric oxide bioavailabil-
ity.15 Indeed, calorie restriction can extend lifespan in
lower organisms and mammals, and improves several
metabolic and inflammatory parameters.21–26 SIRT1 has
been implicated as an important mediator of lifespan




People with type 2
diabetes (n=15)
Mean age (years) 38±13 58±8
Sex
Male 14 (58) 13 (87)
Female 10 (42) 2 (13)
Baseline blood pressure (mm Hg)
Systolic 129±6 133±7
Diastolic 77±2 80±3
Heart rate (bpm) 68±1 77±5
Body mass index (kg/m2) 25±4 30±4
Smoking history
Number of cigarettes/day 17±6 –
Number of pack years 16 –
Urinary cotinine concentration (ng/mL) 1352±950 –
Glycaemic profile
Baseline blood glucose (mg/dL) 85±0 144±2
HbA1c (%) – 7.4±0.8
Concomitant medications
Antiplatelet agents – 5 (33%)
Antihypertensive agents – 3 (20%)
ARB – 2 (13%)
Diuretics – 10 (67%)
Lipid lowering agents – 13 (86%)
Hypolycaemic agents – 4 (27%)
Biguanide – 2 (13%)
Sulfonamide – 1 (6%)
Thiazolidine – 2 (13%)
Insulin
Others
Values expressed as mean±SD.
ARB, angiotensin receptor blocker; HbA1c, haemoglobin A1c.
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extension mediated by calorie restriction.27–29 The
current hypothesis, therefore, was that activation of
SIRT1 may inhibit this process of vascular ageing and be
associated with improvements in arterial stiffness.
No studies have examined the direct effect of SIRT1
activation on measures of arterial compliance. Botden
et al30 were unable to demonstrate an improvement in
augmentation index or central or peripheral blood
Table 2 Changes in biochemical measures of renal function in otherwise healthy cigarette smokers and participants with
type 2 diabetes mellitus administered placebo and SRT2104
Otherwise healthy cigarette smokers









Day 1 Day 28 Day 1 Day 28 Day 1 Day 28 Day 1 Day 28
Serum urea (mg/dL) 17±3 14±3 11±3 14±3 17±3 17±3 17±6 14±3
Serum creatinine (mg/dL) 0.8±0.1 0.8±0.1 0.7±0.1 0.8±0.1 0.8±0.1 0.8±0.1 0.9±0.1 0.9±0.1
Electrolytes
Sodium (mmol/L) 140±2 140±2 140±2 140±1 139±1 139±3 138±2 139±3
Potassium (mmol/L) 4.0±0.4 4.0±0.4 4.0±0.4 4.0±0.2 4.0±0.3 4.0±0.3 4.0±0.2 4.0±0.4
Chloride (mmol/L) 109±3 107±3 108±3 107±2 104±4 104±3 103±2 104±2
Values expressed as mean±SD.
Figure 2 Effect of treatment with SRT2104 on measures of arterial compliance in otherwise healthy cigarette smokers and
participants with type 2 diabetes mellitus–change from baseline. (A) Pulse wave analysis—augmentation index, corrected
augmentation index, augmentation pressure and time to wave reflection. (B) pulse wave velocity. Solid column: placebo; checked
column: SRT2104. (C) baseline parameters of measures of arterial compliance-combined data.
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pressure following treatment with red wine polyphenols.
In the present study, a 28-day period of treatment with
the oral SIRT1 activator SRT2104 was associated with a
reduction in augmentation pressure and trends towards
improvement in augmentation index and corrected aug-
mentation index. Augmentation pressure and index are
measures of arterial compliance and wave reflection
from small to medium sized arteries. As such, they can
be influenced by endothelial function and a number of
other dynamic and functional factors, such as heart rate
and peripheral circulatory tone.7 14 Preclinical studies
have demonstrated improved vascular function with
SIRT1 activation,2 31–33 and this may explain our obser-
vations of improvement in dynamic measures of arterial
stiffness following short-term administration of SRT2104.
Pulse wave velocity is a more direct measure of arterial
stiffness that is determined by the structural and physical
composition of the arterial wall.8 Changes in pulse wave
velocity are therefore more gradual and less dependent
on the function of small to medium sized arteries. In













Any event 18 18 11 14
Nervous system disorders Any event 6 (25%) 11 (46%) 1 (7%) 7 (47%)
Headache 4 6 1 5
Paraesthesia 0 2 0 1
Hypoaesthesia 1 2 0 0
Presyncope 1 1 0 0
Respiratory, thoracic and
mediastinal disorders
Any event 1 (4%) 3 (13%) 0 3 (20%)
Oropharyngeal pain 1 2 0 0
Rhinorrhoea 0 1 0 1
Gastrointestinal disorders Any event 3 (13%) 1 (4%) 4 (29%) 8 (53%)
Diarrhoea 0 0 2 4
Nausea 0 0 1 2
Abdominal pain upper 1 0 0 1
Dyspepsia 0 0 0 2
Reproductive system and breast
disorders
Any event 3 (13%) 1 (4%) 0 0
Dysmenorrhea 3 1 0 0
Musculoskeletal and connective
tissue disorders
Any event 4 (17%) 1 (4%) 0 2 (13%)
Back pain 2 0 0 0
Investigational Any event 2 (8%) 1 (4%) 1 (7%) 1 (7)
Blood bilirubin increased 1 1 0 0
Alanine amino transferase
increased
0 0 1 0
Abnormal liver function
test
0 0 0 1
General disorders and
administration site conditions
Any event 4 (17%) 4 (17%) 2 (14%) 3 (20%)
Influenza like illness 1 0 0 1
Fatigue 1 0 1 1
Infections and infestations Any event 3 (13%) 5 (21%) 3 (21%) 1 (7%)
Nasopharyngitis 0 1 3 0
Rhinitis 2 2 0 0
Upper respiratory tract
infection
1 0 0 1
Injury, poisoning and procedural
complications
Any event 4 (17%) 2 (8%) 3 (21%) 1 (7%)
Contusion 1 0 1 0
Excoriation 1 1 0 0
Skin and subcutaneous tissue Any event 1 (4%) 0 1 (7%) 3 (20%)
Pruritus 0 0 0 2
Metabolism and nutrition disorders Any event 0 1 (4%) 2 (14%) 2 (13%)
Hypoglycaemia 0 0 1 2
Vascular disorders Any event 0 1 (4%) 0 2 (13%)
Flushing 0 0 0 2
OHS, otherwise healthy cigarette smokers; T2DM, type 2 diabetes mellitus.
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the present study, a change in pulse wave velocity was
not observed with SRT2104 administration. This is
perhaps not surprising given the short-time period of
exposure to SRT2104 (28 days) and the brief period of
observation. An improvement in pulse wave velocity
might be anticipated with a longer period of treatment
with SRT2104, to allow more favourable structural
changes in the larger arterial tree.
STUDY LIMITATIONS
Some limitations of this trial should be considered.
Although favourable trends in parameters of arterial
compliance were observed, some did not achieve statis-
tical significance. This may partly be attributed to the
trial being designed specifically to examine the acute
effects of treatment with SRT2104. A longer period of
treatment may be required for benefits to emerge on
variables such as pulse wave velocity that involve struc-
tural changes in the arterial wall. Moreover, the sample
sizes of the two groups examined were small. Two dispar-
ate populations were studied in this trial, in whom the
mechanisms of vascular dysfunction may be very differ-
ent. However, the direction of beneficial effects on treat-
ment with SRT2104 was similar between the two groups,
providing reassurance of a consistency of effect and
allowing the post hoc presentation of the results pooled
across the two groups.
Conclusion
The present study has provided evidence that suggests
treatment with the oral SIRT1 activator, SRT2104, may
lead to an improvement in measures of arterial compli-
ance in otherwise healthy cigarette smokers and people
with type 2 diabetes. The exact mechanism of this
improved arterial compliance and the effects of pro-
longed treatment with SRT2104 on vascular health
remain to be elucidated. Given that aortic stiffness and
endothelial function are key factors in predicting cardio-
vascular outcomes, identification of novel pharmaco-
logical means of improving these predictive parameters
is important and highly relevant in populations with
known cardiovascular risk factors.
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AIMS
Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and are emerging therapeutic targets. We
aimed to examine the local and systemic cardiovascular effects of urocortin 2 and urocortin 3 in healthy subjects and patients with
heart failure.
METHODS
Patients with heart failure (n = 8) and age and gender-matched healthy subjects (n = 8) underwent bilateral forearm arterial blood
flow measurement using forearm venous occlusion plethysmography during intra-arterial infusions of urocortin 2 (3.6–
36 pmol min!1), urocortin 3 (360–3600 pmol min!1) and substance P (2–8 pmol min!1). Heart failure patients (n = 9) and healthy
subjects (n = 7) underwent non-invasive impedance cardiography during incremental intravenous infusions of sodium nitro-
prusside (573–5730 pmol kg!1 min!1 ), urocortin 2 (36–360 pmol min!1 ), urocortin 3 (1.2–12 nmol min!1) and saline placebo.
RESULTS
Urocortin 2, urocortin 3 and substance P induced dose-dependent forearm arterial vasodilatation in both groups (P < 0.05 for
both) with no difference in magnitude of vasodilatation between patients and healthy subjects. During systemic intravenous in-
fusions, urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and peripheral vascular resistance
index in both groups (P < 0.01 for all). Urocortin 2 produced similar responses to urocortin 3, although increases in cardiac index
and heart rate were only significant in heart failure (P < 0.05) and healthy subjects (P < 0.001), respectively.
CONCLUSION
Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance and increase cardiac output in both health and
disease. These data provide further evidence to suggest that urocortins 2 and 3 continue to hold promise for the treatment of
heart failure.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Urocortins 2 and 3 are emerging therapies for treating heart failure.
• Urocortins 2 and 3 reduce peripheral vascular resistance and increase cardiac output in both health and disease.
WHAT THIS STUDY ADDS
• This is the first direct head-to-head comparison of urocortin 2 and urocortin 3 in man.
• These data provide further evidence that urocortin 2 and urocortin 3 hold major potential for the treatment of heart
failure.
Introduction
There are almost sixmillion people living with heart failure in
the USA. This comes at an annual cost to the US economy of
over $30 billion [1]. Despite many evidence-based therapies
for patients with chronic heart failure, treatments for acute
heart failure are limited, less well developed and have not
been shown to improve clinical outcomes. Indeed the use of
inotropic agents has been associated with harm [2–4]. How-
ever, the tentative but promising improvements in clinical
outcome seen with serelaxin in the recent RELAX-AHF study
[5] has renewed enthusiasm for the assessment of novel vaso-
active mediators in this important patient group.
The urocortins are an endogenous peptidic hormone
group comprising urocortin 1, urocortin 2 and urocortin 3
with vasodilator, inotropic and lusitropic effects [6].
Urocortins 2 and 3 counteract many of the effects of
corticotrophin-releasing hormone (CRH) [7–10] and act on
the CRH-receptor 2 (CRH-R2), a G-protein coupled receptor
that is expressed abundantly in the heart and peripheral vas-
culature [11, 12]. Urocortin 2 causes vasodilatation in healthy
volunteers, augments cardiac output and reduces vascular re-
sistance in healthy humans, patients with acute decompen-
sated, and also chronic stable, heart failure [13–16].
A recombinant acetate salt of urocortin 3 (JNJ-39 588 146
[recombinant stresscopin]), improved cardiac output whilst
reducing vascular resistance in amulticentre study of patients
with chronic stable heart failure [17]. We recently demon-
strated that urocortins 2 and 3 increase forearm blood flow
in young healthy volunteers [15]. To date, no clinical study
has separated the regional from systemic effects of urocortins
2 and 3 in heart failure or conducted a direct head to head
comparison of their effects.
We aimed to evaluate and compare the local and systemic
cardiovascular effects of urocortins 2 and 3 in patients with
heart failure and healthy subjects by assessing (i) local fore-
arm arterial blood flow using venous occlusion plethysmog-
raphy and (ii) cardiac output and vascular resistance using
thoracic bioimpedance cardiography. We hypothesized that
urocortins 2 and 3 would cause vasodilatation, reduced pe-
ripheral vascular resistance and increased cardiac output in
both healthy subjects and patients with heart failure.
Methods
Both studies were approved by the local research ethics com-
mittee (South East Scotland REC 01) and carried out in accor-
dance with the Declaration of Helsinki. The registered clinical
trials on UKCRN were ID 10749 and 13002.
Written informed consent was obtained from all partici-
pants prior to the study.
Study participants
Patients with heart failure were eligible if they were aged 18–
80 years, New York Heart Association (NYHA) symptom
class II–III and had echocardiographically confirmed left
ventricular ejection fraction <35% with left ventricular
end diastolic diameter > 5.5 cm. Patients were required to
be receiving maximally tolerated doses of angiotensin-
converting enzyme inhibitor and β-adrenoceptor blocker
therapies for at least 3 months. Healthy subjects had no sig-
nificant previous medical history and were on no regular
medications. Exclusion criteria for both groups included
systolic blood pressure > 190 mmHg or <90 mmHg, haemo-
dynamically significant valvular heart disease and other
severe or significant co-morbidities including bleeding
diathesis, renal or hepatic failure, anaemia or recent
infective/inflammatory conditions. Women of child bearing
potential were also excluded.
Protocol A: local vascular study
This was a randomized study (Figure 1A) of eight patients
with heart failure and eight age and gender-matched healthy
subjects. Subjects attended once each to receive incremental
intra-arterial infusions of urocortin 2 (3.6, 12, 36 pmolmin!1,
molecular weight 4450.3 g mol!1), urocortin 3 (360, 1200,
3600 pmol min!1, molecular weight 4137.9 g mol!1) and
substance P (2, 4, 8 pmol min!1 [control endothelium-
dependent vasodilator]) for 6 min at each dose with a
30 min washout period between agents.
Forearm venous occlusion plethysmography studies were
performed with the subject lying supine, in a quiet,
temperature-controlled room (22–25°C). Participants fasted
for 4 h prior to the study and refrained from alcohol and caf-
feine for 24 h prior to the study. Venous cannulae (17G) were
inserted into large subcutaneous veins in the antecubital fos-
sae of both arms at the start of the study to facilitate periodic
venous sampling. Heart rate and blood pressure were moni-
tored at regular intervals throughout the study with a semi-
automated oscillometric sphygmomanometer (Omron
705IT). Participants underwent brachial artery cannulation
of the non-dominant forearm with a 27 standard wire-gauge
steel needle for agent infusion. Forearm blood flow was mea-
sured in the infused and non-infused forearms using bilateral
venous occlusion plethysmography as described previously
[18, 19].
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Protocol B: systemic study
This was a randomized, double-blind, placebo controlled
crossover study (Figure 1B). Three patients with heart failure
and three volunteers participants were involved in both stud-
ies. Patients with heart failure (n = 9) and healthy subjects
(n = 7) were recruited. Participants had venous cannulae
inserted into both antecubital fossae and attended on two oc-
casions, receiving intravenous infusions of saline (placebo) or
SNP (573, 1909, 5730 pmol kg!1 min!1) followed by either
urocortin 2 (36, 108, 360 pmol min!1) or urocortin 3 (1.2,
3.6, 12 nmol min!1). On the second visit, participants re-
ceived the two remaining agents not administered on visit
1. Each agent was given in three ascending doses for 10 min
at each dose. A 1 h saline washout was given between agents
and a further 30min of saline washout was administered after
the cessation of the second agent.
Haemodynamic monitoring. Haemodynamic measurements
were recorded throughout the study. Cardiac output, blood
pressure and stroke volume were recorded using non-
invasive thoracic impedance cardiography (NCCOM3-R7,
BioMed, CA, USA or Cardioscreen 1000, Medis, Germany)
and oscillometric sphygmomanometry (Omron HEM-
705CP, Omron, Matsusaka, Japan). Values were indexed to
body surface area where appropriate and peripheral
vascular resistance index was calculated using recorded
measurements (PVRI = MAP/CI).
Safety. Study stopping criteria were in place to ensure
participant safety. Criteria included a drop in diastolic blood
pressure of >25 mmHg, fall in heart rate below
50 beats min!1 or rise above 120 beats min!1, at the request
of the participant, attending nurse or the attending
physician.
Venous sampling. Baseline blood samples were drawn for
assessment of full blood count, renal function, glucose and
cholesterol concentrations at the start of each study. The
local clinical biochemistry and haematology reference
laboratories performed analysis.
Data analysis and statistics. Data were collected in a double-
blind fashion for both studies. Data were analyzed, where
appropriate, by analysis of variance (ANOVA, one way and
two way with repeated measures where appropriate). All
results in figures are expressed as mean ± SEM. All statistical
analysis was performed with GraphPad Prism, version 6
(GraphPad Software, San Diego, CA, USA). Statistical
significance was taken as two-sided P < 0.05.
Figure 1
A) Schematic representation of study protocol A – vascular study and B) schematic representation of study protocol B – systemic study. A) forearm
blood flow. B) systemic haemodynamic responses
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Results
Patients with heart failure and healthy subjects recruited
were predominantly male and middle-aged. Heart failure
patients had greater BMI compared with healthy subjects.
Participant characteristics are shown in Table 1. Patients with
heart failure were receiving maintenance heart failure ther-
apy. Patients and volunteers were age and gender-matched
in protocol A and age matched alone in protocol B. Three pa-
tients with heart failure and three volunteer participants were
recruited to both studies.
Protocol A – vascular study
The intra-brachial infusion of all three drugs was well
tolerated with no adverse effects. Intra-brachial infusion of
urocortin 2 and 3 produced localized, self-limiting forearm
flushing and some facial flushing in both groups of partici-
pants as noted in previous studies [15].
Urocortin 2, urocortin 3 and substance P all evoked dose-
dependent forearm arterial vasodilatation in both participant
groups (mean changes across the three doses [95% CI] from
baseline as follows: urocortin 2 +60% [9–111] P < 0.05,
+72% [21–123] P < 0.01; urocortin 3 +167% [100–237]
P < 0.0001, +151% [82–219] P < 0.0001; substance P +227%
[130–326] P < 0.0001, +155% [57–253] P < 0.001 for healthy
controls and heart failure patients, respectively; Figure 2A).
There were no significant differences in changes in forearm
blood flow between heart failure patients and healthy
subjects (urocortin 2 +12% [!40 to 63%] P = 0.84, urocortin
3 !18% [!86 to +50%], P = 0.80; substance P !72%
[!170 ! +26%] P + 0.19).
Blood pressure and heart rate remained unchanged in
both groups in response to urocortin 2 and substance P. At
the highest dose, urocortin 3 induced a transient tachycardia
compared with baseline in both groups (heart failure
+14.9 beats min!1 [20.9 to 8.9], healthy volunteers
+21.3 mmHg [27.3 to 15.3] both P < 0.0001) that was accom-
panied by a drop in systolic (!17.4 mmHg [!7.9 to !26.9],
P < 0.0001) and diastolic blood pressure in patients with
heart failure (!8.4 mmHg [!3.5 to !13.3], P < 0.001) and a
drop in diastolic blood pressure alone in healthy subjects
(!12.4 mmHg [!7.5 to !17.3], P < 0.0001, Figure 2B).
Non-infused forearm blood flow remained unchanged
throughout the study (data not shown).
Protocol B – systemic study
Participants displayed hypotension at the higher doses of
SNP initially administered in the study (17.2 nmol
kg!1 min!1), frequently reaching study stopping criteria. A
dose reduction to SNP (maximum dose of 5730 pmol-
kg!1 min!1) was made after two healthy subjects completed
the study. For the urocortins, hypotension reaching study
stopping criteria was met in one heart failure patient for
urocortin 2 and two heart failure patients and one healthy
subject for urocortin 3. Participants described dose-
dependent symptoms of tachycardia and a warm sensation
with both urocortins, but there were no significant adverse
events attributable to either urocortin 2 or urocortin 3. Full
blood count and serum biochemistry was unchanged
between the two study visits (Table 1).
Urocortin 2 had no significant effect on cardiac index in
healthy subjects and heart rate in heart failure patients when
compared with saline placebo (P > 0.05 for both, see Figure 3
Table 1
Participant characteristics for protocol A and B
Protocol A Protocol B
Heart failure




patients (n = 9)
Healthy subjects
(n = 7)
Age (years) 55.5 [52.25–67] 57 [53–65.75] P = 0.84 58 [50–66.5] 58 [45–66] P = 0.56
BMI 30 ± 5.4 25.1 ± 2.3 P = 0.03 32.2 ± 4.3 25.9 ± 1.9 P = 0.003
Gender 5 M, 3F 5 M, 3F 7 M, 2F 4 M, 3F
ACEi/ARB 8 (100) n/a 9 (100) n/a
BB 6 (75) n/a 7 (78) n/a
MRA 5 (63) n/a 8 (89) n/a
Digoxin 1 (13) n/a 4 (44) n/a
Loop diuretic 6 (75) n/a 6 (67) n/a
Haemoglobin
(visit 1 vs visit 2, g l!1)
n/a n/a 136.0 ± 14.46 vs
133.0 ± 14.96
(P > 0.99)
143.7 ± 7.111 vs
135.3 ± 8.524
(P > 0.99)
Creatinine (visit 1 vs
visit 2, μmol l!1)
n/a n/a 109.8 ± 39.66 vs
116.3 ± 74.95
(P > 0.99)
75.29 ± 8.635 vs
72.67 ± 7.840
(P > 0.99)
n (%), mean ± SD, median [interquartile range]
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and Table 2 for results). Otherwise urocortin 2 and urocortin
3 increased cardiac index and heart rate and reduced mean
arterial pressure and peripheral vascular resistance index in
both patients with heart failure and healthy subjects
(P < 0.05 for all). There was no effect of either urocortin 2 or
urocortin 3 on stroke volume (P > 0.05 for both).
At the doses used, urocortin 3 caused greater mean in-
creases than urocortin 2 in cardiac index (+13.4 [+4.1 to
+22.6], P < 0.01) and heart rate (+11.0 [+2.9 to +19.2],
P < 0.01) and greater mean reductions in mean arterial
pressure (+4.4 [0.0 to +8.7], P < 0.05) and peripheral vascular
resistance index (+11.2 [2.2 to +20.1], P < 0.01) in patients
with heart failure. No such haemodynamic differences
existed between urocortin 2 and urocortin 3 in healthy
subjects. No haemodynamic differences existed between
participant groups for both urocortin 2 and urocortin 3
(P > 0.05 for all). Following cessation of the intravenous
infusions, haemodynamic variables returned to baseline after
40–60 min (for example, cardiac index, Figure 4). Over the
infusion and washout period, urocortin 3 again caused a
greater increase in cardiac output (P < 0.0001) than urocortin
2 in patients with heart failure but not in healthy subjects
(P = 0.48).
Discussion
For the first time, we report the local vascular and systemic
effects of urocortins in both patients with heart failure and
healthy subjects. We demonstrate that both urocortin 2
and urocortin 3 increase cardiac index and reduce periph-
eral vascular resistance and their parenteral administration
is feasible, safe and well tolerated. We conclude this haemo-
dynamic profile suggests that urocortins 2 and 3 hold major
potential for the treatment of acute heart failure.
Forearm venous occlusion plethysmography combined
with intra-arterial cannulation allows the assessment of local,
sub-systemic vasomotor effects of peptides without exerting a
systemic response. This is particularly useful in the study of
novel compounds, such as urocortin 2 and urocortin 3. We
have previously demonstrated that urocortin 2 and 3 cause
vasodilatation in healthy subjects and that is in part medi-
ated by endothelium-dependent factors such as nitric oxide
and endothelium derived hyperpolarizing factor [15]. Im-
paired endothelial function is a recognized feature and an in-
dependent predictor of adverse outcome in patients with
heart failure [20–24]. There is therefore a theoretical concern
that urocortin would be less effective in patients with heart
failure because of this concomitant endothelial dysfunction.
However, we demonstrate that urocortin 2 and urocortin 3
evoked normal forearm arterial vasodilatory responses in
our patients with heart failure. This suggests that either
endothelial dysfunction does not have a meaningful impact
on the actions of urocortin or our subjects did not have
significant endothelial dysfunction. Interestingly, our pa-
tients did not demonstrate impaired substance P induced
vasodilatation suggesting preserved endothelial function.
This may reflect that the patients studied had stable heart
Figure 2
Haemodynamic responses during local administration of urocortin 2, urocortin 3 and substance P (protocol A). A) Percentage change in forearm
arterial blood flow to urocortin 2 (3.6–36 pmol min!1), urocortin 3 (360–3600 pmol min!1) and substance P (2–8 pmol min!1) in patients with
heart failure (red) and in healthy subjects (black). B) Non-invasive systemic hemodynamic responses to intra-arterial urocortin 2 (red), urocortin 3
(blue) and substance P (green) in healthy subjects (A) and patients with heart failure (B). (**** = P,0.0001,** = P < 0.01, * = P < 0.05)
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failure symptoms and were well-treated and receiving opti-
mal medical therapy. Whether similar findings would be ob-
served in patients with decompensated heart failure remains
to be established.
During local intra-arterial infusions of the urocortins, we
were not anticipating observing any major changes in
haemodynamic variables in either group. However, we found
dose-related increases in heart rate and falls in diastolic blood
pressure, especially with urocortin 3 in healthy subjects. This
suggests that at the doses used here, we had systemic spill
over of urocortin such that we achieved vasoactive blood
concentrations outwith the forearm. The doses where
systemic systemic spill over was seen helped guide the dosing
regime used in protocol B. We have seen systemic spill over
previously with other compounds such as substance P [25]
and this is heralded by systemic flushing and rises in the
contralateral non-infused forearm blood flow. However, here
we observed no change in contralateral non-infused forearm
Figure 3
Changes in haemodynamic responses from baseline following systemic infusion (protocol B). Haemodynamic responses to infusions of urocortin
2, urocortin 3 and SNP in healthy subjects (black) and patients with heart failure (red) at doses 1–3 (D1–D3). * represents significant differences
from saline placebo (not shown) across the three doses (see Table 2). ^ represents significant differences between participant groups.
(****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; ^^P < 0.01)
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blood flow although subjects did develop some skin flushing.
This suggests that other vascular beds, such as the dermal and
splanchnic circulation, are more sensitive to the actions of
the urocortins than the forearm circulation. The increase in
heart rate at the highest dose of urocortin 3 was less
pronounced in patients with heart failure and this was likely
due to concomitant β-adrenoceptor blocker therapy. Further-
more the associated lower systolic and diastolic blood
pressures in this group may be explained by a relative lack
of compensatory tachycardia response to vasodilatation in
these patients.
During systemic intravenous infusions, we observed in-
creases in cardiac output with both urocortins. This increase
in cardiac output is likely to occur in response to the systemic
vasodilatation induced by the urocortins. Although there was
no change in stroke volume for either urocortin, this is not a
direct measurement of inotropy and we cannot exclude a
direct inotropic effect of urocortin on the heart, as previously
seen with urocortin 2 in rodents [26]. At the doses we admin-
istered, urocortin 3 exerted more marked haemodynamic
effects than urocortin 2 in patients but not healthy subjects.
This may reflect the differences in doses we employed, but
may also reflect important differences between these two
agents. This needs further exploration to determine which
urocortin subtype is themost promising for clinical therapeu-
tic development.
Differences in biological effects between the urocortins
can be explained by the structural differences that exist
between the two agents, generating conformational changes
in the G protein coupled receptor, in turn altering secondary
messenger systems that are responsible for creating the
biological effects seen. However it may not be this simple
and there may be other systems involved. Promising preclin-
ical studies suggest a role for the urocortins in the inhibition
Table 2
Results of systemic infusion of urocortin 2 and 3
Urocortin 2 Urocortin 3 SNP
Healthy volunteers
Cardiac index +11.9 [!3.1, +26.9] P = 0.17 +25.4 [+9.8, +41.0]*** +21.7 [+5.5, +37.8]**
Heart rate +17.2 [+7.2, +27.1]*** +25.0 [+14.7, +35.4]**** +29.0 [+18.4, +39.8]****
MAP !8.0 [!2.6, !13.5]** !10.8 [!5.1, !16.4]**** !13.0 [!7.2, !18.8]****
SV !3.7 [!13.8, +6.4] P = 0.77 !6.3 [!16.9, +4.2] P = 0.40 !6.8 [!17.4, +3.9] P = 0.35
PVRI !17.6 [!3.5, !31.7]** !23.1 [!8.4, !37.8]*** !22.1 [!6.9, !37.3]**
Heart failure
Cardiac index +10.1 [+1.0, +19.3]* +23.5 [+14.3, +32.7]**** +14.2 [+3.8, +24.7]**
Heart rate +7.1 [!0.8, +15.0] P = 0.1 +18.1 [+10.0 , +26.3]**** +7.4 [!1.8, +16.6] P = 0.16
MAP !4.8 [!0.5, !9.0]* !9.1 [!4.8, !13.5]**** !13.6 [!8.7, !18.5]****
SV +2.7 [!2.4, +7.8] P = 0.51 +4.3 [!0.9, +9.5] P = 0.14 +0.7 [!4.8, +6.3] P = 0.99
PVRI !14.0 [!5.3, !22.7]*** !25.2 [!16.2, !34.2]**** !22.1 [!12.2, !32.0]****
Mean difference [95% CI] of each agent with saline placebo across the three administered doses. * represents significant differences from
placebo. ( ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05).
Figure 4
Duration of haemodynamic response (min) to intravenous urocortin 2 and urocortin 3 (protocol B). Effects of urocortin 2 (red) and urocortin 3
(blue) last 40–60min after cessation of dose 3 (D3) before returning to baseline. At the doses used, urocortin 3 caused a greater increase in cardiac
output compared with urocortin 2 in patients with heart failure (P < 0.0001) but not healthy subjects (P = 0.48)
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of cardiac sympathetic nerve activity [SNA] [27, 28], often
overactive in patients with heart failure. Although Ucn2 has
been reported to increase skeletal muscle SNA in humans
[29], this should not necessarily be seen as a discrepant find-
ing as SNA responses typically are regionally differentiated.
Increases in heart rate have not been reported in recent
studies with urocortin 2/stresscopin [16, 17]. However higher
doses of urocortin 2 [14], comparable with the doses we have
used here, saw similar increases in heart rate.
There may be concern regarding the clinical use of a heart
failure therapy that is both positively chronotropic and ino-
tropic. This combination of effects might predispose to in-
creased myocardial oxygen consumption and potential
arrhythmia, particularly in patients with coronary artery dis-
ease. We observed no episodes of arrhythmia or adverse ef-
fects in our study and, indeed, urocortin 2 has been shown
to have anti-arrhythmic effects that would be hugely benefi-
cial in treating this group of patients [30, 31]. However, our
infusions were brief and adverse effects may be seen with lon-
ger infusions or in those patients with decompensated heart
failure. In addition, avoidance of significant hypotension re-
mains an important consideration, especially in patients
with already low perfusion pressure or renal impairment. Re-
sults from our study suggest that dose titration during admin-
istration may be needed to optimize cardiac output and
vasodilatory responses, whilst avoiding the unwanted effects
of significant tachycardia or hypotension.
Study limitations
This study included only patients with stable heart failure
who were prescribed evidence-based heart failure therapy
that may have affected the response of these agents. However,
there was no evidence of diminished effect with concomitant
medical therapy in patients with heart failure. We did not
include patients with acute decompensated heart failure but
we did compare with healthy control subjects, not used in a
similar sized study with urocortin 2 [14]. Although our results
cannot be extrapolated to the setting of acute heart failure,
there appears to be no reason why the beneficial effects seen
in this study cannot be replicated in the acute heart failure
setting provided an appropriate, controlled dosing regime is
used. Furthermore studies using urocortin 2, and derivatives
thereof, in the acute setting have already been carried out
successfully. There does however remain a clear need for
urocortin 3 to be trialled in this group of patients.
We observed increases in cardiac index in protocol B but
it should be reinforced that this study was not designed to
compare the relative contributions of chonotropy, inotropy
and vasodilatation to the changes in cardiac index we
recorded. Invasive studies would be required for this.
Furthermore, the molar concentrations of urocortin 2 and
urocortin 3 at each dose were different and differences in
efficacy may reflect the differences in dose used and not true
differences in potency.
Finally although there was no change in stroke volume for
either agent, we did not conduct invasive haemodynamic
monitoring which would be required for assessment of true
inotropy and also useful for assessment of pulmonary
capillary wedge pressure (PCWP). Surprisingly two recent
studies did not detect a statistically significant reduction in
PCWP in patients with heart failure with either urocortin
2/stresscopin [16, 17]. However a clear trend toward a reduc-
tion in PCWP was seen in both studies.
In conclusion, we demonstrate that both urocortin 2 and
urocortin 3 increase cardiac index and reduce peripheral vas-
cular resistance. Their parenteral administration was feasible,
safe and well tolerated. We conclude that these data provide
further evidence suggesting urocortin 2 and urocortin 3 con-
tinue to hold promise for the treatment of heart failure.
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